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NOMENCLATURE OF VIRAL POLYPEPTIDES 
To indicate viral proteins and (precursor) polyproteins a generally 
accepted nomenclature is used (1,2). 
Each polypeptide is designated by its apparent molecular weight in 
thousands, taken from gel filtration in б M guanidine hydrochloride 
for polypeptides below MW 30,000 and Polyacrylamide gel electro­
phoresis in the presence of sodium dodecyl sulfate (SDS-PAGE) for 
polypeptides above MW 30,000. (Breaking this rule, sometimes SDS-
PAGE results are also used to indicate apparent molecular weights 
of the smaller viral proteins). 
The number indicating the apparent molecular weight of the poly­
peptide is preceded by a "p" for protein, "gp" for glycoprotein, 
and "pp" for phosphoprotein or by "P" for polyprotein, "gP" for 
glycosylated polyprotein, "Pr" for precursor polyprotein, "gPr" 
for glycosylated precursor polyprotein and "pPr" for phosphorylated 
precursor polyprotein. 
Additional information about the structural role of a viral protein 
can be added in parentheses, e.g. (E) indicates an envelope protein, 
(c) a core protein and (Ν) a ribonucleoprotein. (Note: parentheses 
are often omitted). In practice the use of these additions is 
restricted to the murine leukemia virus envelope proteins p15E and 
p12E, to discriminate them from the unrelated core proteins ρ 15 
and ρ 12. 
(Precursor) polyproteins are identified further by a superscript 
indicating the gene (gag, pol, enν or onc/src) from which they 
originate. 
A proposed nomenclature (3) that uses the subgene order of each 
viral protein for its designation (e.g. ρ 15 = gag-a, ρ 12 = gag-b, 
etc.) is not (yet) adopted by most authors. 
Examples: 
ρ 15 : viral core protein of 15,000 apparent 
molecular weight 
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ρ 15(E) or ρ15Ε : viral envelope protein of 15,000 apparent 
molecular weight 
gp70 : viral envelope glycoprotein of 70,000 
apparent molecular weight 
дР О
9 3 9
 : glycosylated gag polyprotein of 80,000 
apparent molecular weight (containing 
viral core proteins ρ 15, ρ 12, рЗО and pio) 
gPrB2 : glycosylated env precursor polyprotein of 
82,000 apparent molecular weight (containing 
viral envelope proteins gp70 and p15E) 
рРгб5 or Ргб5 : phosphorylated gag precursor polyprotein 
of 65,000 apparent molecular weight 
1. August, J.T., O.P. Bolognesi, E. Fleissner, R.V. Gilden, and 
R.C. Nowinski. 1974. Virol. 60 : 595-601. 
2. Janjoom, G.A., V.L. NG, and R.B. Arlinghaus. 1978. J. Virol. 
25 : 408-412. 
3. Stephenson, J.R., R.K. Reynolds, S.G. Devare, and F.H. 
Reynolds. 1977. J. Biol. Chem. 252 : 7818-7825. 
Note: In chapters 5 and 7 we introduce a similar but not identical 
nomenclature for still unidentified virus-related translation 
products: a number indicating apparent molecular weight in thousands 
preceded by "tp" for translation £roduct. 
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INTRODUCTION AND PERSPECTIVE 
The murine leukemia viruses belong to the RNA tumor virus group 
(generic name: Oncovirinae; see chapter 2.1.). These viruses are 
widespread among vertebrates. In 1970 Temin et al. ( 1) and 
Baltimore (2) simultaneously and independently discovered a unique 
feature of these viruses: they contain an enzyme, called reverse 
transcriptase or RNA-dependent DNA polymerase, that is able to 
transcribe RNA into DNA. This discovery not only led to some 
theoretical discussions about Crick's "central dogma" (э). 
More importantly, a main tool came available for the construction 
and analysis of genetic recombinants that contain eukaryotic genes 
integrated in prokaryotic vehicles (e.g. 4,5). The discovery of 
reverse transcriptase also greatly stimulated further research of 
the architecture, the replication and the gene expression of RNA 
tumor viruses, and, of course, of the mechanism by which they 
induce tumors. Particularly their role in the etiology of cancer 
in humans has been the subject of intensive research (6). Temin 
and Baltimore received the Nobel price in 1975. 
In the past decade most details about the composition and structure 
of the RNA tumor viruses and about their replication and gene 
expression have been elucidated. These subjects are discussed in 
the sections 2, 3 and 4 of chapter 2. The work on the gene expres­
sion of RNA tumor viruses was placed in an ordered frame by 
Baltimore (7) who in 1973 defined four genes on the non-defective 
RNA tumor virus genome: a gene encoding the viral core proteins, 
a gene encoding the viral envelope proteins, a gene coding for 
reverse transcriptase, and a gene responsible for the transforming 
and tumorigenic properties of the virus. The prototype virus for 
this gene classification was the Rous avian sarcoma virus (ASV). 
This virus rapidly induces sarcomas in chickens and transforms 
fibroblasts in vitro. On the other hand, avian leukosis viruses 
and murine leukemia viruses only induce tumors in haemopoietic 
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tissues after a delayed period of time and are nat able to transform 
fibroblasts. The idea grew that these viruses lack a separate gene 
for oncogenesis. 
Earlier work in this field from this laboratory primarily dealt 
with the biosynthetic pathway of viral structural proteins in 
murine leukemia virus—infected cells on the one hand and with the 
virus-specific RNAs in these cells on the other (8,9,10). The 
translation products of virion RNA have also been studied (11). It 
was found that infected cells contain different size-classes of 
virus—specific mRNAs. In this thesis (chapters 3, 4, 5) experiments 
are described that show that each of these size—classes directs 
the synthesis of different virion constituents. Core proteins and 
reverse transcriptase are synthesized on genome-length mRNA, where-
as the envelcpe proteins are made on a subgenone-size mRNA, 
comprising about half of the genome. A still smaller mRNA directed 
the synthesis of cellular proteins that in some way are encap-
sidated by the virions. 
These results were obtained by translating size-fractionated mRNA 
from murine leukemia virus-infected cells in oocytes of the African 
clawed frog Xenopus laevis. These oocytes are large enough for 
injection by simple technical means and have a major advantage 
compared to cell-free translation systems in that all cellular 
processes are continuing apparently unimpaired. The oocyte system 
has been reviewed recently by an other thesis from this laboratory 
(12). 
Since it was known from the literature that the subgenomic mRNA 
directing the synthesis of murine leukemia virus envelope proteins 
arises from genome—length RNA in the nucleus of the infected cell 
(see chapter 2.4.4,5), we reasoned that injection of genome-length 
RNA from the virus itself, from the cytoplasm or from the nucleus 
of the infected cell into the nuclei of Xenopus oocytes possibly 
night also lead to the formation of a subgenomic mRNA that supports 
the synthesis of viral envelope proteins. These experiments are 
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described in chapter 7. Similar experiments, described in the 
literature, using an other, highly sensitive system, did have 
success, but we were unable to reach the same result with the 
oocyte system. Possible reasons are discussed. 
About the mechanism by which RNA tumor viruses induce tumors much 
less is known. Only the sarcoma-induction by avian sarcoma viruses 
is rather well-documented. Despite all efforts, involvement of RNA 
tumor viruses in the etiology of human cancer could not be 
demonstrated convincingly ( 6). 
As to leukemia induction by leukemia viruses, the importance of 
recombination by these viruses with endogenous viral sequences was 
recognized. These recombinations seem to occur rather frequently 
and not only with more or less related viral sequences. Probably 
they occur at random with at least part of the host genome. The 
vast majority of these recombinations presumably are dead ends, 
but in rare cases some viral sequences are replaced by host 
sequences, either virus-related or not, which transfer a new 
biological property to the newly formed variant. With the aid of 
appropriate in vitro selection techniques ( 13) these variants may 
prove to be a general tool for cloning of cellular genes ( 14). 
Variants that acquire (extra) tumorigenic properties will be 
positively selected by the organism. As a consequence of the 
replacement of viral by поп-viral sequences the virus becomes 
replication-defective. Examples of this kind of RNA tumor viruses 
are the avian acute leukemia viruses and the mammalian sarcoma 
viruses. ASV, the prototype RNA tumor virus, as a non-defective 
sarcomagenic virus in fact appears to be an exceptional member of 
the RNA tumor virus group! 
Recombinant viruses are discussed in chapter 2.4.5. 
A still rather undeveloped field in RNA tumor virology is the 
immunological defense of the organism against the virus and the 
virus-induced tumors. In this respect a major role may be played 
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by the virus—related cell surface antigens that are present on 
infected, and in some cases, uninfected cells. 
Chapter 2.7. deals with the present knowledge of these antigens. 
One example of the virus-related cell surface antigens is the 
Moloney cell surface antigen (MUSA) that is related to a tumor-
specific transplantation antigen induced on mouse cells by Moloney 
murine leukemia virus. The nature of this antigen was the subject 
of a number of studies but has been unknown for a long time. In 
chapter 6 of this thesis it is shown that MCSA is a product of the 
envelope gene of a defective virus that is not related to the 
Moloney strain of murine leukemia viruses. 
It is not difficult to foresee that in the near future many 
puzzling aspects in RNA as well as DNA tumor virology will be 
solved. The combination of the recombinant DNA technique and 
sophisticated sequence techniques will reveal many data on gene 
structure and expression both of viruses and of cells. Molecular 
biology and immunology alike will profit from the newly developed 
hybridoma technique for the generation of monoclonal antibodies. 
For this reason, the prospects for a better understanding of 
oncogenesis and the role of immunological mechanisms in the defense 
against cancer seem very favourable at the moment. 
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RNA TUMOR VIRUSES - A SURVEY 
In this outline emphasis will be laid on the description of murine 
leukemia viruses. However, attention will be paid to other types of 
murine RNA tumor viruses and to RNA tumor viruses of other species, 
especially of birds, whenever applicable. 
This survey is meant to indicate the scientific frame in which the 
experimental work reported in this thesis fits. Therefore, rather 
than giving another review of the (murine) RNA tumor viruses, I 
decided to refer quite often to some recent reviews that give a 
complete account of the vast amount of original papers. This 
enabled me to concentrate on the newest findings not yet covered by 
published reviews in this rapidly expanding field. 
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2.1. MAIN CHARACTERISTICS AND CLASSIFICATION 
Taxonomically RNA tumor viruses (Oncnvirinael form the main sub­
family of the virus family called Retroviridae (82). 
Retrovirus particles have a diameter of about 100 nm. They consist 
of a lipoprotein envelope with glycoprotein protrusions ("spikes") 
enclosing an icosahedral protein cors shell within which there is 
a helical nucleocapsid. Recently a thin layer, the inner coat, has 
been detected just beneath the viral envelope (30,196). The most 
characteristic biochemical feature of the family is the occurence 
of the enzyme RNA-dependent DNA polymerase (reverse transcriptase) 
within the virion (82,312). The RNA content of a virus particle is 
about 1 Іо, protein 60-70 %, lipid 20-30 ^  and carbohydrate 2 % 
(ЗІ2). The viral genome is a single stranded RNA molecule with a 
molecular weight of about 3 χ 10 which is present in the nucleo­
capsid as a dimer (24θ) complexed with iflNA (307; cf. section 
2.2.5.). 
A confusing array of taxonomie devices has been developed to 
classify the RNA tumor viruses. 
1. Morphology. On the basis of their morphology RNA tumor viruses 
can be classified as type A, type B, type С or type D viruses (55, 
312). 
Type A viruses are virus-like particles with a toroidal nucleoid. 
They are believed to be precursors of B-type and C-type viruses. 
Cells releasing B—type particles contain A—type particles, 
enclosed by a core membrane, in their cytoplasm. The A-type 
particles move from the endoplasmatic reticulum to the cell 
surface, from which they bud, acquiring an outer membrane with 
regularly arranged spikes. The toroidal nucleoid is then converted 
into the spherical and eccentrically located nucleoid of the 
mature B-type particle. The C-type particles develop quite 
differently. Their nucleocapsids first appear as crescent-shaped 
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structures immediately below the cell surface and as the virion 
buds from the cell surface the nucleoid matures into a complete 
toroid surrounded by an inner core shell and an outer envelope 
membrane. Because of the toroidal nucleoid these particles are 
also classified as A-type particles. They further develop into the 
mature C-type particles with their spherical, centrally placed 
nucleoid. 
Finally, D—type viruses have a larger diameter than B— or C-type 
particles and have pleomorphic nucleoids. 
The most prominent representative of the B-type viruses is the 
mouse mammary tumor virus (MuMTV). The Mason-Pfizer monkey virus 
(МРМ ; an endogenous virus of the langur monkey) is one of the 
few known D-type viruses. C-type viruses have been isolated from 
reptiles, birds and mammals. Especially from chickens and mice a 
number of C—type virus isolates have been well characterized. 
2. Transmission (312). Exogenous RNA tumor viruses persist by 
horizontal or epigenetic spread f e.g. through the milk) among 
members of a susceptible species. Endogenous viruses spread by 
vertical transmission of the viral genome, integrated as provirus 
in the host genome, through the gametes from parent to offspring. 
3. Species of origin. RNA tumor viruses are commonly identified 
according to the species from which they have been first isolated. 
Occasionally virus strains were isolated from what appeared to be 
a secondary host (21,22,182,312). For murine endogenous viruses 
even the particular mouse strain they are isolated from is used 
for their classification. 
4. Pathogenicity (108,312). RNA tumor viruses can be named or 
grouped after the kind of neoplasia they induce. Carcinoma viruses 
cause malignant tumors of epithelial origin. Sarcoma viruses 
cause solid connective tissue tumors. A number of different tumors 
of the haemopoietic and retículo—endothelial systems can be 
induced by RNA tumor viruses. These tumors can either be leukemic, 
with highly elevated levels of white blood cells (e.g. lymphatic 
leukemia, erythroblastosis) or aleukemic, with a solid tumor in 
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various compartments of the retículo—endothelial system (в.я. 
lymphosarcoma, thymoma). 
Generally a clonal isolate causes only one kind of tumor. Some 
transforming RNA tumor viruses, however, like the murine sarcoma 
viruses, are replication—deficient and need non-defective leukemia 
viruses for their replication (326). So-called pseudotypes are 
formed: the helper virus supplies the necessary structural and non­
structural proteins not coded for by the sarcoma viral genome (326). 
Finally, absence of any known pathogenicity is also found for some 
RNA "tumor" viruses that in all other respects are closely related 
to pathogenic RNA tumor viruses. 
5. Host range (312). Differences in host range form the basis of 
the sub-division of avian viruses in seven main subgroups (A to G). 
Murine leukemia viruses are grouped in ecotropic (only infectious 
for mouse cells), xenotropic (not infectious for mouse cells, but 
infectious for cells of several other species) and amphotropic 
viruses (infectious both for mouse cells and for cells of other 
species). 
Eco- and amphotropic viruses can be N-tropic (1000 or more times 
preferential growth in cells carrying the so-called Fv-1 
haplotype, typically represented by the NIH-Swiss cell line), B-
tropic (preferential growth in cells with a Fv-1 haplotype; 
e.g. BALB/c cells) or NB-tropic (growth in both types of cells). 
The Fv-1 gene and other host genes (among them genes coding for 
receptors on the cell membrane that recognize viral envelope 
glycoproteins) determining the host range of RNA tumor viruses, 
are the subject of extensive research (26,97,122,291). 
6. Antigenicity (6,298,312). Three major forms of antigenicity 
are associated with RNA tumor viruses. Type-specific antigens 
identify each particular strain of virus. Group-specific antigens 
are shared by related viruses from a single species and inter­
species antigens are the (few) antigens that viruses from dif­
ferent species have in common. These three classes of antigenic 
specificity are present in different proportions on all viral 
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proteins. By competitive radioimmunoassays (RIA) one can group the 
viruses according to the antigenic relatedness of each of their 
structural (39,123,124,182,294,296,303,304) or non-structural (106, 
219) proteins. 
Rather soon it was recognized (312) that the main type-specific 
antigen of avian viruses, present on the viral envelope glyco-
protein, could be used as a serologically detectable marker for 
the avian subgroup classification. Together with other evidence 
(312) this has led to the conclusions that the host range of avian 
tumor viruses was determined by the envelope glycoprotein. 
The very recent development of monoclonal antibodies against viral 
proteins (184,302) provides a new tool for a more detailed serolo-
gical classification of the RNA tumor viruses. 
7. Biochemical approaches. The isolation of all viral constituents 
of the virus particle to apparent purity and the rapid progress 
in technology (itself having been stimulated by the intensive 
study of RNA tumor viruses all over the world) enabled the use of 
biochemical characterization as an aid for grouping of viruses. 
Tryptic peptide mapping of viral proteins (68), RNAse-finger-
printing of viral RNA (340), molecular hybridization with viral 
RNA or proviral DNA (20,21,22,23,34,182), analysis of in vitro 
reverse transcription products (114), all these biochemical 
methods have been used for classification of RNA tumor viruses. 
Biochemical analyses have also led to the recognition of molecular 
differences that coincide with macroscopic differences. For 
instance, by protein analysis (SDS-polyacrylamide gel electro-
phoresis, peptide mapping; 96,126) as well as by RNA analysis 
(fingerprinting, partial sequence elucidation; 73,247,276) it was 
found that the recognition site for the restrictive action of 
the Fv-1 locus determining N/B tropism of ecotropic mouse viruses 
was situated on the core protein p30, while the broader host 
range (eco-, xeno—, amphotropism) of mouse viruses appeared to be 
determined by the envelope glycoprotein gp70 (12,69,313). 
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2.2. АНСНГГЕСТиПЕ AND COMPOSITION OF THE VIRION 
Most proteins found in the virion are virus-specific and coded for 
by the viral genome. To the structural components of the virus 
also belong carbohydrates and lipids. These components are derived 
from the infected cell. In addition to the viral reverse transcrip­
tase a number of cellular enzymatic activities have been found 
associated with the virion [312]. Several species of RNA can be 
isolated from the virion. Apart from the high molecular weight 
RNA (35S), these are cellular RNAs with no apparent role in virus 
replication, with the exception of a particular tRNA species which 
plays an important role in reverse transcription of the viral 
genome (cf. section 2.3.). 
A schematic structure of the virion is drawn in Fig. 1. An enumera­
tion of the properties of structural and non-structural virus-
specific proteins is presented in table 1. A detailed discussion, 
also covering the viral genome, is given below. 
2.2.1. VIRAL ENVELOPE 
The envelope of retroviruses is derived from the plasma membrane 
of the host cell. Therefore, the viral envelope proteins at the 
budding sites of the host cell should be arranged in a similar 
configuration as in the virion. As a result, one may expect to 
find some cellular plasma membrane constituents in the viral en­
velope. For instance, a specific histocompatibility antigen and 
the viral envelope glycoprotein of Friend erythroleukernia virus 
were reported to be topographically linked on the surface of cells 
transformed by this virus and virions produced by these cells con­
tained the same antigen (36). The viral envelope, however, main­
ly consists of three virus-coded proteins. In the murine leukemia 
virus these proteins are a glycoprotein of 70,000 molecular weight, 
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gp70, a поп-glycosylated protein, ρΙΞΕ, with an apparent molecular 
weight of 15,GOD-IB,000,and a specific degradation product of p15E 
with a molecular weight of 12,000-14,000, p12E (67,142, 196,29θ). 
It should be noted here that similar proteins of different viruses 
may differ in their molecular weights to a small extent. 
The glycoprotein gp70 is the most exposed protein of the virus. It 
forms the major target for virus neutralizing antibodies (134,141, 
290). It contains the main type-specific antigenic determinant (6), 
it is responsible for host range restriction of the virus (cf. sec­
tion 2.1.) and it is required for entry of the virus into a host 
cell (25,58,194,235). 
The carbohydrate moiety of the molecule has no or little antigenic 
activity (29). The protein backbone of the glycoprotein has a 
molecular weight of about 45,000 (187,349). 
The glycoproteins form the "knobs" of the spikes on the virion. 
The "stalks" are presumably formed by p15E and p12E (30,195,196). 
The gp70 and p15E/p12E molecules are rather stably associated and 
partly coupled by covalent disulfide linkages (172,229,230,305,346; 
H.P.J. Bloemers, personal communication). 
One spike is composed of four to six gp70-p15E/p12E subunits (231, 
305). The relevance of the proteolytic degradation of pISE into 
ρ 12E is not clear. This degradation takes place after the release 
of the virion from the cell (H.P.J. Bloemers, personal communica­
tion) . 
2.2.2. INNER COAT 
The composition of the inner coat remains to be established. 
Bolognesi and coworkers suggest that the viral low molecular weight 
phosphoprotein is a likely candidate for the formation of this 
substructure (30,195,196). This protein, pp12, has a molecular 
weight of 12,000 in rodent viruses, but the protein with similar 
antigenic and biochemical properties has a molecular weight of 
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Figure 1. Murine leukemia virus. 
Diagrammatic illustration of virion structure and composition. 
26 
15,000 (pp15) in some viruses of primate origin. The idea of 
Bolognesi et al. for the location of pp12 in the inner coat is 
mainly based on their observation that pp12 could neither be found 
in purified cores of Friend murine leukemia virus (F-MuLV) nor on 
the virus surface (30, 196). These results are opposed to those of 
others (216), who detected all four non—envelope structural pro­
teins, including pp15, of the primate virus 40-114 in the viral 
core particle. Moreover, viral core particles and virions contained 
these proteins in the same relative amounts. This discrepancy could 
be explained by a difference in the viral core isolation procedure, 
giving rise to the cosegregation of the inner coat with the viral 
core in the latter case. There are indications that the hydrophobic 
viral protein of 15,000 molecular weight, p15, is rather closely 
associated with the viral envelope. First, isolated viral envelopes 
contained 40 °^ of the amount of ρ 15 present in the intact virion 
(322). Second, the p15 molecule exhibits typical properties of a 
membrane protein (13). And, finally, it could be labeled by 
lactoperoxidase iodination of the intact virion although virus 
could not be neutralized nor lysed by anti-p15 antibodies (13). 
These results suggest a localisation of ρ 15 just below the virus 
surface and perhaps ρ 15 is the protein that forms the inner coat. 
2.2.3. CORE SHELL 
The primary constituent of the core shell is the protein p30 
(30,000 molecular weight), the major protein species of the virion. 
It has strong group—specific and interspecies antigenic deter­
minants (6,196). As discussed before (cf. section 2.1.) this 
protein determines Ν/Β tropism of murine eco- and amphotropic 
viruses. The actual localization of pp12 is not known, but most 
evidence points to a core-associated place for this phosphoprotein. 
A remarkable feature of this protein is its ability to bind spe­
cifically to the homologous genomic RNA, with less than 15 mole-
Table 1. 
Structural and non—structural protein components of murine leukemia virus. 
Viral 
protein 
gp70 
p15E(c) 
p12E(c) 
p15 
рріг 
рЗО 
p1D 
p75 
(a) 
10 
г 
13 
13 
7 
ЬО 
4 
1 
Structural 
component 
"knob" of 
spike 
"stalk" of 
spike 
inner coaf 
core asso­
ciated'' 
core shell 
nucleo-
protein 
reverse 
transcriptase 
Virion 
structure 
envelope 
inner coat 
core 
exterior 
ribonucleo-
prntein-
complex 
Molecular 
weight 
70,000 
15,000-
18,000 
12,000-
14,000 
15,000 
12,000 
30,000 
7,00O-
10,000 
70,000-
60,000 
Isoelectric 
point 
4.5 - 6.2 
4.4 - 4.6 
6. 1 - .З 
4.1 _ 5.Э 
6.2 - B.O 
Э.1 -11,6 
n.t.(d) 
Antigenic 
detprmlnants 
t,g,(i.s.) 
g.i.s. 
t.g.i.s. 
(t),g.i.s. 
B.ti.s.) 
g.i.s. 
Other properties 
Glycosylated, determines virus penetration 
and is target for hunoral response against 
virus infection 
Non-glycosylated, hydrophobic 
Hydrophobic 
Hydrophilic, phosphorylated; binds to 
homologous RNA 
Major viral core protein 
Highly basic, binds to RNA and DNA 
RNA-dependent DMA polymerase 
a] Estimate of weight percentage of total virion protein represented by each protein. 
b) t = type—specific, g - grouf>-specific, and i.s. = inter species. Minor determinants are in parentheses. 
сJ In the literature discrimination between p15E and pl2E is not always made. 
d) n.t. - not tested. 
Data are compiled from the litprature cited in the text. 
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cules per molecule of RNA (263,264). This binding depends on the 
extent of phosphorylation of pp12: only molecules with a low lev/el 
of phosphorylation bind strongly to the viral RNA (265). 
2.2.4. RIBDNUCLEOPROTEIN COMPLEX 
The viral genome is embedded in a nucleocapsid structure that con­
tains the basic protein ρ 10 (7,000-10,000 molecular weight) as its 
structural component. This protein can bind RNA and DNA with a 
marked preference for single-stranded nucleic acid molecules (57, 
258). Maximally one ρ 10 molecule per 70 nucleotides can be bound 
to 35S viral RNA (25B). 
The viral reverse transcriptase is also present in the nucleocapsid, 
in an amount of about 20-70 molecules per virion ( 196). The enzyme 
is able to complex with p30 molecules (9,205) as well as with tRNA 
(307). A marked difference exists in the binding of avian and mam­
malian reverse transcriptase to tRNA. Avian reverse transcriptase 
binds specifically to the primer-tfìNA (218,307; cf. next section), 
murine reverse transcriptase, however, can bind to all tRNA spe-
cies of different origin (221,307). A number of reviews have been 
published (106,257,308,333) on this 70,000-80,000 molecular weight 
enzyme that reversely transcribes the viral genomic RNA into pro-
viral DNA. 
2.2.5. VIRAL RNA 
The viral genome is present in the virion as an RNA complex with 
a sedimentation coefficient of about 50-70S . On heat dissociation 
several loosely associated 4S and 55 RNAs, two RNA molecules of 
30-405 (3.0-3.5 χ 10 molecular weight) and two strongly bound 
tRNA molecules are released (240,307,312). The two 35S RNA mole­
cules are identical (15,307) and linked to each other in the 50-
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70S complex at their 5' termini by hydrogen bonding between anti-
parallel palindromic sequences (18,19,112,280). The 3' end of the 
35S genome is polyadenylated (about 200 residues; 18,159). The 5' 
end possesses the typical cap structure m7G5'pppS'NmpNp (31,93,248) 
and methylated adenosines are found at specific internal sites of 
the RNA (31,61,93). These features are typical for eukaryotic mes­
senger RNAs and, in fact, the viral genome can serve as a messenger 
far the synthesis of virus-specific polypeptides (cf. sections 2.3. 
and 2.4.). The viral genome is terminally redundant (45,47,112,261, 
301,340). The length of this redundancy is about 16 nucleotides for 
avian sarcoma virus (ASV) (26) and 60 nucleotides for murine leu­
kemia virus (MuLV) (45). The redundancy is not lost in genetic 
crosses with strains of ASV possessing different terminal redun­
dancies (340) and it may play an important role during the reverse 
transcription process (cf. section 2.3.). To each 35S RNA molecule 
one primer-tRNA molecule of cellular origin is bound (307). In ASV 
Trp 
this was shown to be tRNA , while in rodent viruses it is 
tRNA (307). Other tRNA species have been implicated for primate 
viruses (ЗО7), Primer—tRNA molecules are rather stably bound by 
base pairing with their 3' ends (residues 2-17 for ASV (53) and 
residues 2-20 for MuLV (226) ) to the genomic RNA. 
This complex is more stable than the dimer linkage between the 35S 
RNA molecules in the 70S complex (307). The bound tRNA molecule 
serves as a primer for DNA synthesis during reverse transcription 
(307; cf. section 2.3.). When this reaction is carried out in an 
in vitro endogenous system (i.e. a system with whole virions) so-
called strong-stop DNA is preferentially made under certain limit­
ing conditions (81). This is a single-stranded DNA molecule with 
a discrete, short length. With ASV strong-stop DNA has a length 
of 101 nucleotides, with MuLV the length is about 135 bases (307). 
The strong-stop DNA of ASV is sequenced (112,280). Hybridization 
experiments and direct comparison of the strong-stop DNA sequence 
with the sequence of 5' terminal RNA oligonucleotides (45,112,280, 
307) has led to the conclusion that the strong-stop DNA is a copy 
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of the 5' end of the genorre (not including the ultimate mTGS'p). 
This result locates the primer binding-site of the ASV genome at 
residue 104—119 (numbered from the 5' terminus of the viral RNA). 
In analogy, the primer binding-site of the MuLV genome would be at 
residues 138-156. With the sequence of the strong-stop DNA and the 
Trp 
sequence of the 3' end of tHNA now the first 119 ribonucleotides 
of the ASV genomic RNA are known (112,280]. This sequence shows 
some remarkable features. There is a region complementary to the 
3' end of eukaryotic IBS ribosomal RNA at positions 63-69 of the 
viral RNA and an AUG codon at positions 83-85, suggesting the pres-
ence of a ribosome binding-site (279) and an initiation site for 
translation in this part of the genome. Furthermore, the presence 
of a primer-tRNA binding-site directly downstream of this region 
(see above) led to speculations on a regulatory role for the primer-
tRNA on the dual function of the genomic RNA: when tRNA is bound, 
the RNA would be available for reverse transcription and not for 
translation and vice versa (cf. sections 2.3. and 2.4.). 
In vitro ribosome binding experiments, however, showed that the 
main ribosome binding-site of the genome was situated between 
residues 9 and 53 (56). 
Pr76 is the product of the 5' terminal gene of the genome (67; 
-, Met 
cf. section 2.4.). It was shown by formylmethionyl-tRNA labeling 
that Pr76 is a primary translation product (56,217). The se-
quence of the first N—terminal amino acids of this polyprotein has 
been elucidated recently (56,217) and, rather surprisingly, one 
had to conclude that this sequence is not encoded by the first 119 
nucleotides of the ASV genome. Apparently, the synthesis of the 
product of the 5' terminal gene of ASV is initiated more downstream 
on the genome. The recent availability of proviral DNA in large 
amounts obtained by molecular cloning techniques, will enable the 
rapid elucidation of the nucleotide sequence of the whole genome 
of several viruses, so that many questions of the type discussed 
in this section are likely to be solved in the near future. 
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2.3. VIRAL REPLICATION 
The glycoproteins of the viral envelope facilitate the adsorption 
and uptake of the virus by the host cell. Cells have highly spe-
cific receptors for the viral glycoprotein [25,58,194,235). Once 
the virion is taken up by the cell and the viral RNA is released, 
the reverse transcription can start. Theoretically, the viral RNA 
is also free for translation. In fact, after infection with a high 
multiplicity (MOI) viral RNA was found in an EDTA-sensitive asso-
ciation with polyribosomes (256,282) and one publication reports 
viral protein synthesis prior to the onset (or in the absence) of 
proviral DNA synthesis (94). However, in these experiments one 
could not discriminate between RNA originated from infectious or 
from non-infectious virus particles. The biological significance, 
if any, of viral peptide synthesis before proviral DNA synthesis 
remains obscure. 
Presumably, for the transcription of the viral RNA into DNA some 
unknown cellular functions are required (329), but the virus—coded 
reverse transcriptase is the main enzyme involved (100,332). Study 
of the proviral DNA synthesis in vivo is hampered by the fact that 
it constitutes only 10~ of the total DNA in the cell (342). There-
fore, part of the assumed mechanism is based on results obtained 
by in vitro reverse transcription (Fig. 2). Presumably, the in vitro 
reaction is a good reflection of what happens in the cell, since 
it is possible to synthesize in vitro complete double-stranded DNA 
copies of the RNA genome that are infectious (100,249). Viral DNA 
synthesis in vivo takes place primarily during the first six hours 
after infection (342), in the cytoplasm of the cell (328,342). The 
transcription starts at about 100 nucleotides from the 5' end of 
the viral RNA where a primer-tRNA molecule is bound to the genome 
(cf. section 2.2.5.). The tRNA molecule serves as a primer for the 
synthesis of the (-) strand DNA. The first deoxynucleotides are 
covalently bound to this molecule (307,342), that in its turn is 
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removed at some later stage of the process from the newly synthe­
sized DNA (101,193). The DNA synthesis proceeds to the 5' end of 
the RNA, jumps to the 3' end and reads further in З'-^Б' direction 
(307,333,342). Recent results (115) incontrowertibly confirn earlier 
suggestions (e. g. 44,46,146) that the terrrinal redundant sequence 
(cf. section 2.2.5.) is used to elongate the DNA chain past the 5' 
end of the genome. The nascent DNA chain synthesized at the 5' end 
of the genome becomes displaced from the template (by the action of 
viral RNAse H, that is intrinsically associated with reverse tran­
scriptase and degrades RNA in RNA.DNA hybrids; 49) and pairs with 
the repeated sequence at the 3' end of probably the same RNA mole­
cule. The DNA, annealed to the 3' enc of the RNA genome, serves as 
a primer for further elongation. So in this region of the proviral 
DNA only one copy of the З 1 ^ ' terminal redundant sequence is present 
(115). Reverse transcription proceeds to the 5' end of the viral RNA 
until it reaches the primer binding site region ( 101) and then 
"jumps" over to the 3' end of the (+) strand DNA ( 101,330). 
The synthesis of the (+) strand DNA starts before completion of the 
(-) strand (342) and is directed (101,193) by the DNA-dependent DNA 
polymerase activity also intrinsically associated with the reverse 
transcriptase enzyme (106,257,308,333). The (+) strand DNA is pro­
duced in short pieces (342). The first piece that is synthesized 
has a length of 300 bases in the case of avian sarcoma virus (ASV) 
(330) and of 600 bases with murine leukemia virus (MuLV) (193). 
This piece contains sequences of both the 5' end and the 3' end of 
the genome ( 193,330) and therefore must be complementary to the 5' 
end of the (-) strand DNA. It has been shown that the complement 
'of the first approximately 20 nucleotides of the tRNA primer 
- that apparently at this stage is still attached to the 5' end 
of the (-) strand - is present at the ultimate 3' end of this 
piece of (+) strand DNA (101). 
The synthesis of the (-) strand DNA is completed by the transcrip­
tion of this piece of (+) strand DMA (101,330), thus leading to a 
long repeat at the 3' end of a sequence already present at the 5' 
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Figure 2. Model for reverse transcription of murine leukemia virus. 
This picture was reprinted from reference 101 with permission of 
the authors and the publisher. (Copyright held by Massachusetts 
Institute of Technology, Cambridge, Mass.). 
Structure I represents one molecule of the dimeric RNA molecule of 
the virion. In II, minus-strand DNA synthesis, and in V, plus-strand 
DNA is initiated. Various regions - not shown on scale here - are 
represented by letters. Uppercase letters refer to sequences in 
the viral RNA molecule (plus-strand sequences], and lower-case 
letters refer to minus—strand sequences. The cap at the 5' end and 
the poly(A)-stretch at the 3' end of the viral RNA was omitted. 
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end of the (-) strand. 
The pieces of (+) strand DNA complementing the whole (-] strand 
are ligated and a linear double-stranded DMA molecule is formed 
(100,101). Of course, in order to enable this formation, the genomic 
RNA and the primer tRNA must be removed first. Perhaps the viral 
RNAse H works in a concerted action with the reverse transcription 
activity of the same molecule and breaks down the RNA immediately 
after its complementary DNA is formed. The linear double-stranded 
DNA still contains the long terminal repeats of 600 bases in the 
case of MuLV (IOO], 300 bases in the case of ASV (127,26В) and 1200 
bases in the case of mouse mammary tumor virus (MuMTV; 269). This 
molecule noves to the nucleus, where it is converted into a closed 
double-stranded circular DNA molecule (127,241,26B,269,270,342,355). 
Two kinds of circles are found. A minor form is coextensive with 
the linear molecule, but the predominant form of the circular DNA 
misses one of the terminal redundancies present in the linear mole­
cule (100,127,268,269,355). The linear as well as the circular DIMA 
is infective (342). It is believed that the circular form of the 
provirus is integrated into the cellular DNA, presumably just like 
the lambda phage is integrated into the bacterial genome (121), 
thus becoming an integral part of the host genome (327). The pro-
viral DNA can be inserted at several, possibly specific, sites of 
the genome (60,133,156,158,292,321). The integrated DNA is co­
extensive with the linear and the larger form of circular uninte-
grated proviral DNA (133), so it contains the long terminal repeats. 
The second copy of the repeat is not derived from the cellular DNA 
(ІЗЗ), therefore, the most obvious candidate to provide this repeat 
would be the larger circular DNA molecule, although one could 
imagine a mechanism through which the second repeat would be 
generated (133). Therefore, the major form of circular unintegrated 
proviral DNA,that only contains one copy of the 3',5' repeat, is 
probably not infectious. Since this species is the most abundant 
form of circular proviral DNA, it is expected that circular pro-
viral DNA is considerably less infective than linear proviral DNA. 
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In fact, this is what is found: circular proviral DNA has a five-
fold lower infectivity than linear proviral DNA in transfection 
experiments (91). 
Expression of the integrated proviral genome may be (51,52) or may 
not be (52,185) under control of adjacent (promoter) sites on the 
cellular DNA. Transcription into RNA is performed by the cellular 
RNA polymerase II (145,253). Within the nucleus, part of this RNA 
is spliced into subgenomic RNA (cf. section 2.4.4.5.). The RNA is 
transferred to the cytoplasm and can either act as messenger RNA 
or becomes integrated into the progeny virus. Messenger RNA and 
virion RNA have the same polarity. They presumably constitute 
separate pools (cf. section 2.4.3.). 
Core plus inner coat proteins, reverse transcriptase and envelope 
proteins are derived from separate precursor polyproteins (cf. 
section 2.4.2,). The envelope precursor polyprotein is made on the 
rough endoplasmic reticulum and transported via the Golgi-apparatus 
to the plasma membrane where it is processed to the mature envelope 
proteins (117,346). Viral gp70 molecules are expressed on the cell 
surface (77,173,348,353). In some cases the envelope precursor 
polyprotein is present on the outer cell surface too (77), The 
precursor of the core plus inner coat proteins is presumably 
synthesized both on membrane—bound ribosomes and on free polysomes 
(271) or is first made in the cytoplasm and becomes very rapidly 
associated with endoplasmatic membranes (196). The precursor moves 
to the plasma membrane, but remains below the cell surface (175, 
176,353), The core precursor polyproteins presumably associate 
with genomic RNA (143) - which is then still in 30-40S form (37, 
165) - and with reverse transcriptase precursor molecules, estab-
lishing and immature core particle. The virus is released by 
budding of the viral core particle through the cellular membrane 
at sites where envelope proteins are arranged in proper order. 
During budding and directly after virus release the core precursor 
and the reverse transcriptase precursor molecules are cleaved into 
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the mature proteins p15, pIS, p30, p10 and p75 (186,348,353,356), 
concomitant with a rapid morphological maturation of the virus that 
can be seen in the electromicroscope as a change from particles 
with an electron—lucent core center to particles with a condensed 
nucleoid (165,186,356). The major steps of the replication cycle 
are depicted in Fig. 3. 
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Figure 3. Schematic diagram of the major steps in the replication 
of murine leukemia virus. 
(Modified after J.D. Watson, 1976, The molecular biology of the 
gene, 3rd. ed., p. 674. W.A. Benjamin Inc., Menlo Park, Gal.). 
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2.4. RETROVIRAL GENE EXPRESSION 
2.4. 1. THE VIRAL ЗЕШІ Е 
The genome of non-defective RNA tumor viruses contains three or 
four known genes: gag, encoding the structural proteins of the 
viral core, pol, encoding the viral reverse transcriptase, env, 
encoding the (glyco)-proteins of the viral envelope and, in some 
cases, one, that is responsible for oncogenic cell transformation 
(a). 
The genome order has been established for the avian sarcoma virus 
(ASV) (147,337,338,339) and runs S'-gag-pol-env-src-polyCA)^' 
(sre denoting that this virus causes sarcomas). Between the sre 
gene and the poly(A) stretch of ASV a region of about 1000 
nucleotides is located, zhe so-called "C" or comnon region, that 
is conserved in all variants, mutants and recombinants of ASV (306). 
It was never formally proven (because of the lack of suitable 
mutants) but there is ample indirect evidence to believe that the 
gene order for the mammalian leukemia and mammary tumor viruses is 
the same, although most probably these viruses lack a separate one 
gene. 
2.4.2. PRIMARY GENE PRODUCTS 
The primary gene products of the non-defective oncoviruses are 
known. This subject has been described in detail in several recant 
reviews (67,142,298). The internal core proteins, the envelope 
proteins and the reverse transcriptase are synthesized in the form 
of precursor polyproteins that are processed and split into the 
mature virus proteins by cellular enzynes or by enzymatic activi­
ties of the viral proteins themselves (336). In the case of 
murine leukemia virus the precursor of the core proteins, Pr65 , 
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has a molecular weight of 65,000. Ргб5 is phosphorylated [260) 
and is cleaved through several intermediates into the mature core 
proteins p30, p15, ρ 12 and ρ 10 (4,144,272,324). By analyzing the 
gag products formed by defective recombinant viruses that lack part 
of the gag gene (10) and the gag processing intermediates Found in 
cells infected with temperature sensitive mutants each blocked at 
different stages of the gag precursor cleavage (238) the subgenome 
order of the gag gene was established as 5'-p15-p12-ρ30-ρ10-3'. 
This conclusion was confirmed by the results obtainea by studying 
the premature termination products formed during translation of 
viral RNA in cell-free systems (203; see below). In addition to 
Ргб5э э another gag polyprotein of 75,000-30,000 daltons can be 
detected that is rapidly metabolized. This protein .^ as regarded as 
the immediate precursor of Ргбб 9 3 9 (4,144,272,324) but recently it 
was recognized that Pr65 and the 75,000-80,000 gag protein pre­
sumably are translated from two separate initiation sites on the 
viral RNA (66,228). It may even be possible that both proteins P'•• 
made on separate messengers. The mRNA for Pr65 could miss the 
sequence coding for the peptide (259) that the 75,000-80,000 protein 
contains in addition to the Pr65 sequence. 
Alternatively it is conceivable that one gag-mRNA originates from 
the other one by a small splice that creates a new gag initiation 
site. 
The 75,000-80,000 protein was shown to be moderately glycosylated 
(66,260). The unglycosylated form of gPBO has a molecular weight 
of 72,000 (66,260). On further glycosylation дР О 9 3 9 changes into 
gP95 9 a 9. In some cells gP95 9 a 9 can be processed to gPBS 9 3 9 (66,71, 
175,176,260). These glycosylated gag polyproteins contain all 
sequences of p15, ρ 12, рЗО and pio ( 175) but эге hard to detect 
in some systems or when not labeled -appropriately (i.e. with 
mannose). The proteins gP95 and gPB5 are expressed on the 
cell surface of at least some cell lines (174,175,176,320) and 
were shown (176) to represent the Gross cell surface antigen (GUSA). 
The envelope proteins gp70, p15E and p12E have a glycoprotein of 
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82,000 (дРг 2 е ) as their common precursor {№4,152,206,212,324). 
The subgenome order of the env gene is: Б'-дрУО-рЧбЕ-З' (152). The 
envelope protein p12E is a processing product of pISE ( 152,206, 
324). The precursor of the reverse transcriptase has a molecular 
weight of 180,000 to 200,000 and contains both gag and pol 
sequences (Pr 180-200 ; in fact two molecules with slightly 
different molecular weights are synthesized; 144,163,348). In the 
first processing step the gag-pol precursors loose their gag 
sequences and through several intermediates the mature polymerase 
(molecular weight 70,000 to 80,000) is formed (144,163). 
Only on the avian sarcoma virus genome a separate one gene is 
clearly identified. The sre-gene of the virus has a 60,000 daltons 
phosphoprotein (ррбо) with protein kinase activity as its product 
(33,48,180). 
2.4.3. VIRUS-SPECIFIC RNA CONTENT OF INFECTED CELLS 
Several investigators have studied the retrovirus-specific RNA 
content of infected cells using DNA complementary to viral genomic 
RNA as a probe. Depending on cell line and virus used, the amount 
of virus-specific RNA in permanently infected normal host cells · 
ranges from 0.02 to 1 Уо of the total RNA content (32,65,78,113,177, 
245,316,331,344). 
Two to 15 fo of the virus-specific RNA is found in the nucleus (113, 
177,245), coinciding with the total RNA distribution pattern. 
While 70 to 80 ^  of the total cytoplasmic RNA is found in polyribo­
somes only 40 to 60 °k of the cytoplasmic virus-specific RNA is 
polyribosome-bound (65,331). The free cytoplasmic virus-specific 
RNA has a much faster turnover than the ribosome-bound virus-
specific RNA and is thought to represent RNA to be encapsidated in 
virions ( 179). Membrane-bound polyribosomes are enriched for the 
virus-specific RNA since they contain 50 fo of the polyribosomal 
virus-specific RNA (78,98) compared to only 20 "¡i of the total 
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polysomal RNA in mouse fibroblasts [78). Reported ratios of poly(A] 
RNA to total cytoplasmic virus-specific RNA range between 0.2 and 
more than 0.9 (32,65,107,222,245,331,344), depending on the system 
studied or the method used. 
2.4.4. SIZE-CLASSES OF VIRUS-SPECIFIC CELLULAR RNA 
Cytoplasmic virus-specific RNA is present in different size classes. 
Cells productively infected with avian sarcoma virus contain three 
classes of viral RNA (119,222,344): З З (Э.З χ 10 molecular weight), 
28S (1.8 χ IO6) and 22S (1.2 χ 10 б). 
In addition to these three major size classes Krzyzek et al. (167) 
found a minor class of 14S (0.4 χ 10 ) RNA. This W S RNA was also 
seen by Brugge et al. (32) but this group did not detect a 28S 
virus-specific RNA. 
Weiss et al. (344) and Hayward (119) showed by hybridization with 
gene-specific probes that the 385 viral mRNA encodes all four genes 
and is probably identical to the viral genome. The 2BS RNA encodes 
the 3' half of the viral genome: 5'-env-src-C'-poly(A)-3'• The 22S 
viral mRNA comprises the sequence 5'-src-C'-poly(A)-3'. Cells 
infected with deletion mutants that miss either the src or the 
env gene have only two size classes of viral RNA: 35S (3 χ 10 ) 
which comprises the same sequence as the genomic RNA of the de­
letion mutants, and 22S (1.2 χ 10 ) with the sequences S'-env-C — 
polytAj-S' or 5'-src-C'-poly(A)-3', respectively (119,344). 
Murine leukemia virus-infected cells contain at least two size 
classes of virus-specific mRNA (78,80,98,315): 35S (3 χ 10 molec­
ular weight) and 22S (1.2 χ 10 ). In our laboratory 14S (0.4 χ 10 ) 
viral RNA (99,123,325) was also detected, and others (315) found 
heterogeneous virus-specific RNA species between 10 and 18S. One 
should note, however, that at the time these analyses were performed 
well-defined copy-DNAs were not available. Therefore, the W S could 
originate from the infecting virus as well as represent (deleted?) 
42 
endogenous viral sequences or even normal cellular sequences. Fan 
and Verma (BO) showed that the subgenomic 22S mRNA is derived from 
the 3' half of the MuLV genome since the 22S RNA did not hybridize 
with a copy-DNA made specific for the qag-pol sequences (cDNA -, ) . 
Haseltine and Baltimore (113) and Fan (79) studied the viral RNA 
content of the nuclei of MuLV-infected cells. In both studies 35S 
as well as 22S virus-specific RNA was found in the nucleus. This 
was in agreement with studies on mouse mammary tumor virus-infected 
cells by Robertson and Varmus (245) that also showed that the same 
virus-specific RNA size classes were present in the nucleus as 
were present in the cytoplasm (see below). 
Particularly Fan (79) showed in pulse-label experiments that no 
larger precursor to the genome size viral RNA could be detected. 
In addition he found that the 22S RNA is presumably not a direct 
transcription product but is derived from 35S RNA in the nucleus. 
In Moloney murine sarcoma virus-transformed, non—producing cells 
only genome-size (3DS) RNA could be detected with a DNA-probe 
complementary to the parental leukemia virus (315,316), but it is 
conceivable that these cells contained subgenomic virus-specific 
RNA that consisted of sarcoma virus—specific sequences only. Very 
recently a subgenomic viral RNA (22S) was found in a Moloney 
murine sarcoma virus producing cell line that overproduced the 
sarcoma virus relative to the helper leukemia virus (62). This 
subgenomic viral RNA had lost those Mo-MuLV -specific gag se-
quences that are still present in the Mo-MuSV genome (cf. section 
2.5.), but had retained the -incomplete - parental virus-specific 
env sequences of the 30S Mo-MuSV RNA. One should note, however, 
that it is not certain that producing and non-producing murine 
sarcoma virus-infected cells express their sarcoma provirus in 
the same way. 
The mouse mammary tumor virus (MuMTV) is a B-type virus and it has 
main characteristics in common with the C-type retroviruses. 
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Robertson and Varmus (245) showed that treatment of MuMTV infected 
cells with dexamethasone stimulated the viral RNA expression in the 
cell severalfold. These authors as well as Sen et al. [266) found 
three size classes of virus-specific intracellular RNA: 35S (э.1 
χ IO 6), 24S (1.5 χ IO6} and 14S (θ.4 χ IO 6). The 14S RNA was hard 
to detect with a cDNA against the total MuMTV genome but could 
readily be seen with a cDNA made specific for the 3' end of the 
genome (cDNA ·). Groner et al. (107) did not detect the 14S nflNA, 
although they used the same cells and cDNA '. On the other hand 
they found in addition to 35S and 24S virus-specific RNA a 33S 
(2.9 χ 1D ) viral RNA that only could be detected in poly(A)+ 
cytoplasmic RNA but lacked the information of the 3' end of the 
MuMTV genome. 
2.4.5. SPLICING 
It was shown by several groups that the subgenomic virus-specific 
RNAs contained a leader sequence of at least 150 nucleotides 
derived from the 5' end of the genomic RNA. In ASV infected cells 
both 28S and 22S RNA (possibly 14S RNA too; 167) possessed this 
5' sequence of 38S RNA (54,167,191,344). Mellon and Duesberg ( 191) 
and Cordell et al. (54) showed that the three major size—classes 
of viral RNA from ASV infected cells had the same cap structure. 
In MuLV (80) and MuMTV (245) infected cells 35S and 22-24S RNA 
hybridized with cDNA ' but 14S RNA did not. 
Also electron-microscopic analyses of hybrids between subgenomic 
MuLV RNA and genome-length cDNA showed a common 5' sequence for 
35S and 22S RNA that was not present in 14S RNA (220,250). 
Since the 22S virus-specific RNA can be found in the nucleus, 
while viru&-specific nuclear RNA larger than genome size is not 
detectable (79,113,245), it is assumed that the 22Ξ RNA is gen­
erated in the nucleus from the 35S RNA by splicing out the se­
quences between the common 5' leader region and the 3' half of the 
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genome, Stacey and Hanafusa (28θ) showed directly that viral gen­
omic RNA can be spliced in the nucleus into active env-mRNA. They 
microinjected 35S RNA from Rous-associated virus-2 (RAV-S, an 
avian leukosis virus, and, therefore, lacking the src gene and not 
able to transform chicken fibroblasts) into nuclei of cells in­
fected with the env deficient Bryan high titer strain of Rous 
sarcoma virus (BH-RSV). The RA\/-2 RNA appeared to complement for 
the deficient env function of BH-RSV and, therefore, must have 
been spliced into 22S env-mRNA. The possibility that in these 
experiments the injected 355 RNA was reversely transcribed by the 
BH-RSV polymerase present in the cells and that the env-proteins 
were products of 22S mRNA transcribed from newly integrated RAV-2 
proviral DNA, could be excluded for kinetical reasons and by a 
parallel experiment in which 35S RAV-2 RNA was injected into the 
nuclei of chick embryo fibroblasts which expressed no viral func­
tions, that also resulted in the production of infectious (RAV-2) 
viruses. 
2.4.6. TRANSLATION FTODUCTS OF VIRION RNA 
It was shown by several groups that the 35S RNA from virions only 
directs the synthesis of the gag precursor proteins and — as was 
shown more recently - of the gag-pol precursor (155,190,201,202, 
210,223,224,228,255,266,345). Philipson et al. (22В) were able to 
augment the production of the MuLV gag-pol precursor by 35S viral 
RNA with the addition of yeast suppressor tRNA to the cell-free 
system. Therefore they proposed a "read-through" mechanism for the 
synthesis of the precursor of reverse transcriptase: at relative 
low frequencies the gag termination codon - at least the termina­
tion codon of the rrRNA for дРвО9 g - would be suppressed leading 
to the synthesis of a gag-pol precursor protein. These ideas were 
not substantiated by the results of Weiss et al. (345), who could 
not find any effect of suppressor tRNAs on the synthesis of the 
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ASV qag-pol precursor. They suggested that the pol-rrRNA has the 
same size and the same genetic content as the gag-mRNA, except for 
a small sequence spliced out in one of the mRNAs, leading to the 
presence of a termination codon in the gag-mRNA and its absence in 
the pol-mRNA. According to recent findings of Hizi et al. (125) 
and Kopchick et al. ( 164) the gag termination codon would be situ­
ated within the 5' end of the poi gene, since the gag precursor 
protein and the mature reverse transcriptase shared a short se­
quence. 
Translation of virion RNA smaller than genome size did not seem 
to yield any virion protein (155,189,210,224,255,266) but recently 
more sensitive systems showed that virions contain low levels of 
subgenomic viral RNAs that actively direct the synthesis of viral 
proteins. The src gene product of RSV was recognized in transla­
tions of viral RNA of about 22Ξ in nuclease-treated cell-free 
systems (16,150,234). It was made in vitro as a precursor protein 
of 62,000 molecular weight, that was processed to a 60,000 protein 
after the addition of dog pancreas membranes to the cell-free sys­
tem (149), suggesting the presence of a "signal peptide" (28) in 
the primary transcript. By tryptic peptide mapping the 60,000 in 
vitro product was shown to be essentially identical to the product 
found in vivo (234,267). It is uncertain whether the viral RNA 
synthesizing the src protein is a product of 35S RNA cleavage in 
the virion or a cellular messenger RNA encapsulated by the virus 
particle during the budding process. 
2.4.7. TRANSLATION PRODUCTS OF CELLULAR VIRUS-SPECIFIC nflNAs 
Gielkens and Van Zaane et al. translated size-fractionated mRNAs 
from MuLV-infected cells in reticulocyte cell-free systems (99) 
and in oocytes of the frog Xenopus laevis (325) and showed that 
35S mRNA was synthesizing gag proteins and 22S mRNA produced env 
proteins. Mueller-Lantzsch and Fan (200) at the same time found 
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that only polyribgsomes containing 35S virus-specific mRNA could 
be immunoprecipitated with anti-рЗО antibodies. Mature reverse 
transcriptase can be synthesized in oocytes by injection of 35S 
mRNA from infected cells (chapter 4 of this thesis). These results 
are confirmed by those of Murphy and Arlinghaus (204) who trans­
lated cellular messenger RNAs in a nuclease-treated mouse cell 
extract. They showed that 35S mRNA synthesized the qacj-pol pre­
cursor, 25-35S mRNA the gag precursor proteins and mRNA around 
22S the non-glycosylated env precursor. Translation products were 
identified by peptide mapping. Similar results were obtained by 
Sen et al. (266) with mRNA from MuMTV infected cells. 
In the avian system Pawson et al. (225) found the 38S RSV—specific 
mRNA to synthesize the gag precursor protein in a cell-free system 
derived from mouse L cells, while 20-2BS mRNA generated the non-
glycosylated form of the envelope precursor. Stacey et al. (287) 
showed by microinjection of 22S mRNA from fíM-2 infected cells 
into the cytoplasm of BH-RSV infected cells (cf. preceding section) 
that avian leukosis viral cytoplasmic mRNA of 22S size directs the 
synthesis of envelope proteins, since they could detect focus-
forming infectious virus 3 - 10 h after injection. 
Several groups (98,99,325) found virus-specific cellular RNA in 
the 14S region that lacked the 5' sequence which larger sut>-
genomic viral RNAs have in common with the genomic RNA (cf. sec-
tion 2.4.5.). RNA of this size has a maximal coding capacity of 
about 40,000 daltons of protein. No product of the 3' region is 
known and 3' region—specific products - if existing - may not be 
identified unless virus-specific mRNAs are isolated free from 
contaminating cellular messengers. In suggestive, though incon-
clusive experiments we found products of 14S mRNA, both in the 
cell—free system and in Xenopus oocytes, that were immunoprecipi— 
table with antiserum against whole disrupted Rauscher murine 
leukemia virus but not with monospecific antisera (99,325). 
In oocytes this 14S mRNA product has a molecular weight of about 
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Figure 4. Gene expression of murine leukemia virus. 
[The exact nature of the primary transcription product and the gag and дод-роі 
mRNAs is still uncertain). 
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37,000 (325]. Since it is known that virus-coded non-structural 
proteins different from the reverse transcriptase can be encapsi-
dated into the virions (157,236,273) it is conceivable that the 
virus preparation we used for raising the anti-R—MuLV serum con­
tained a product coded for by the ultimate 3' region of the viral 
genome. We could then detect this protein among the translation 
products of 14S mRNA because the anti-R-MuLV serum contained 
antibody activity against it. Alternatively the antiserum con­
tained antibodies directed against some cellular protein contami­
nating the virus. This latter possibility seems to be true, since 
in later experiments we were able to precipitate the 37,000 
molecular weight protein also from the translation products of 
US mRNA fron uninfected cells (chapter 5. of this thesis). 
2.4.B. CELLULAR mRNAs ENCAPSIDATED BY VIRUS PARTICLES 
Not only cellular proteins may "slip" into the virus particle but 
also cellular поп-genomic virus-specific mRNAs may become part of 
the virion. 
If Pr65 9 a s, gP75 9 a g and Pr180-200 9 a g" P D l are indeed synthesized 
on at least three separate mRNAs (cf. sections 2.4., 2.6.), two 
of these mRNAs would be the first candidates for non—genomic ' 
mRNAs in the virion. These two hypothetical non—genomic viral 
RNAs should not be distinguishable in size from the genomic RNA and 
must be encapsidated by the virion efficiently, since 35S viral 
RNA generates P75 g a 9 (the unglycosylated form of gPBO 9 3 9), Pr65 g a 9 
and PrlBO-200 in about the same proportions in vitro as they 
are made in vivo. The 22S RNA present in ASV particles that syn­
thesizes the src gene product would be the third example of a 
virus—specific cellular mRNA present in the virion, although 
Purchio et al. (234) showed that partial ribonuclease digestion 
of 35S viral RNA produced RNA that was able to synthesize src 
products too. 
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Mast groups did not detect any env mRNA activity in virion RNA but 
Philipson et al. (228] showed that their MuLV RNA synthesized the 
env precursor at a very low level. Moreover, by injection of 225 
RAV-2 virion RNA in BH-RSV infected cells which gave rise to the 
production of focus-forming infectious virus, Stacey (2 Э) showed 
the encapsidation of env mRNA by the virion. In this case RNAse 
T.-generated fragments of 35S viral RNA were unable to promote the 
release of infectious virus. 
So it seems that virions can contain поп-genomic virus-specific 
RNA somehow bound to the 50-70S viral RNA complex. In fact, it 
appears that viral RNA is contaminated at low levels with many 
species of cellular mRNA (16,149,150,203,234,266,267; C. Saris, 
personal communication). 
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2.5. RECOMBINANT VIRUSES 
RNA tumor viruses can easily recombine: either with each other, 
when cells are coinfected with different virus strains (340) or 
with a part of the host genoma. In the latter case, either an 
endogenous viral genome or - though very infrequently — an other, 
cellular, sequence may be involved. This distinction becomes rather 
arbitrary, if one assumes that all viral sequences are originally 
cell-derived ("protovirus" hypothesis of Tenin; 309). Differences 
may exist, however, in the evolutionary stability of these host 
cell derived sequences. It is not known whether recombination 
takes place at the DMA level or at the RNA level. Recombination at 
the RNA level may be promoted by the formation of mixed dimers of 
genomic RNA, that presumably readily occurs because of the appear-
ance of heterozygous virus particles at relatively high frequency 
in mixed infections (188,326,343). 
The src-gene of avian sarcoma virus (ASV) and the sarc—regions ' 
of all known mammalian sarcoma virus strains are host cell-derived 
(244,326,334,341) and it is believed that these viruses originate 
from a recombination between an exogenous leukemia virus and some 
host cell sequence (244,326,334,341). Viruses having these cell-
derived sequences integrated into their genome are able to trans-
form fibroblasts in cell culture and to cause sarcomas in vivo. 
Their parental leukemia viruses can not transform fibroblasts. 
They induce haemopoietic malignancies. All sarcoma viruses contain 
the 5' end and the 3' end of their parental leukemia virus (326; 
section 2.2.4.). An important distinction between ASV and mammalian 
1) The use of the term "src" should be restricted to denote a 
genetic function. The term "sarc" is used to indicate the cell-
derived or sarcoma virus—specific sequences in the genome of 
sarcoma viruses (326). 
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fibroblast-transforming viruses is the dependence of the latter 
ones on helper virus activity for replication (cf. section 2.1.). 
In mammalian sarcoma viruses the sarc—region replaces structural 
genes of the parental virus (326), while in ASV the src-gene is 
present in addition to the structural genes derived from the paren­
tal leukosis virus. However, other avian viruses resemble the mam­
malian sarcona viruses in this respect. Avian myelocytomastosis 
virus-29 (MC29) and Mill Hill virus-2 (MH2) are replication-Defec­
tive viruses, which lack the src-gene of ASV but contain a mutually 
related cellular sequence integrated in the middle of their genome, 
replacing the 5' end of the eny-gene, the whole pol-gene and the 3' 
end of the gag-gene of the parental avian leukosis virus (17,64, 
128,129,130]. Other examples are the avian erythroblastosis virus 
(AEV), the myelocytomastosis-type viruses СМИ and OK 10 and the 
myeloblastosis-type viruses AMV and E26 (170,251). These replica­
tion—defective avian viruses cause acute leukemias, lymphomas, 
sarcomas and carcinomas in chickens (104). The host cell sequences 
present in ASV and in MuSV have no homology to known viral sequences 
and are evolutionary much more stable than virus-specific sequences 
of either exogenous or endogenous origin (20,90,92,169,207,281,286, 
293,310,326). Therefore, it is presumed that these src-genes or 
sarc-sequences code for important cellular functions. The cell-
derived sarc sequences are usually not related to each other. One 
exception form the rat cellular sequences present in Kirsten and 
Harvey murine sarcoma virus (Кі-MuSV and Ha-MuSV) (277,326). 
Furthermore, the avian replication defective viruses can be divided 
in three groups on the basis of the homology of their cell-derived 
sequences (251). 
A number of murine viruses exist which have similar properties as 
the sarcoma viruses but which do not induce sarcomas. They cause 
acute haemopoietic malignancies, but are replication-defective and 
are able to transform cells in vitro. Examples are the Friend strain 
of spleen focus-forming virus (F-SFFV) that causes splenomegaly and 
transforms certain bone marrow cells (326), Abelson murine leukemia 
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virus (A-MULV) that induces lymphomas (326) and transforms pre-B— 
lymphocytes as well as fibroblasts (2B4), and replication-defective 
strains of mink cell focus-forming (MCP) virus which cause lymphomas 
and transform mink cells (111,335). MCF-viruses have been isolated 
from a number of mouse strains that were infected with different 
exogenous viruses or that expressed endogenous ecotropic virus (40, 
111,254,335). They emerge concomitantly with a rapid tumor formation. 
When injected in newborn mice, they induce tumors considerably more 
rapidly than ecotropic leukemia viruses do. Therefore, they are 
presumed to play a central role in tumor formation and are, perhaps, 
the primary tumor-causing agents. They have an amphotropic host 
range and derive their name from the cytopathogenic effect they 
exert on mink cells. They have been shown to arise by recombination 
in the env-gene of the ecotropic virus with an endogenous xenotropic 
virus (40,69,246,276). Another example of an amphotropic virus that 
causes rapidly evolving lymphomas and that is an env-gene recombinant 
between ecotropic and xenotropic virus, is the HIX-virus, isolated 
from a Moloney-MuLV stock (74,75,88). 
Finally, F-SFFV is an env-gene recombinant between ecotropic and 
xenotropic virus. The xenotropic eny-regions of F—SFFV and MCF are 
related (252,276). They both express mutually related envelope 
glycoproteins (62,252). It is proposed that all highly oncogenic 
variants of murine ecotropic viruses are derived by genetic recom-
bination leading to the acquisition of a common class of xenotropic 
virus-related envelope glycoprotein determinants, which are pre-
sumably required, but not necessarily sufficient for oncogenicity 
(60). 
The env-proteins of MCF-viruses present on the cell surface do not 
only contain ecotropic and xenotropic determinants but also have 
MCF-virus -specific epitopes (43). An interesting hypothesis 
regarding the mechanism of leukemia—induction by MCF-viruses has 
been put forward by McGrath and Weissman (190). These authors 
showed the gradual emergence of specific MCF-virus receptors on 
preleukemic and leukemic thymocytes of AKR mice. The presence of 
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these receptors correlated with the tumorigenicity of the pre— 
leukemic thymocytes. They suggested that recognition by these 
receptors of MCF-viral antigens would induce a mitogenic stimulus 
to the thymocytes, similar to antigen-induced proliferation of 
antigen-reactive T—lymphocytes. This quality should be attributed 
to the specific determinants on MCF—virus envelope proteins. Since 
in lymphoid organs (pre]leukemic lymphocytes are always surrounded 
by other lymphocytes expressing MCF-viral envelope antigens, they 
are continuously stimulated to proliferate, thus leading to the 
formation of a lymphoma. This model explains the absence of any 
indication for the presence of a separate one—gene in MuLV, since 
in this concept the MCF-viral envelope antigens would be oncogene 
products. 
F-SFFV and some strains of MCF are replication-defective and must 
have deletions or mutations, that occured during or after the re-
combination event. This might well have happened, since replicating 
viruses show a high frequency of aberrant expression caused by 
this kind of events (274). Likewise, it has been shown that isolates 
of simian sarcoma virus (SiSV; also called: woolly monkey sarcoma 
virus, WoSV) that differed in the expression of helper leukemia 
virus-specific gag-proteins, did not differ in the extent of 
their helper virus-derived gag-gene region (243). It was assumed 
that small deletions or mutations caused premature termination of 
translation or the production of immunologically non-reactive 
proteins (243), possibly because of a frame shift. 
Gene expression of mammalian sarcoma viruses and other replication-
defective viruses has been reviewed recently (326). In general, 
sarcoma viruses do not express envelope proteins (with some ex-
ceptions: 24,63,88,237,252) and reverse transcriptase. The regions 
of the leukemia virus genome encoding these proteins were lost 
during recombination and are replaced by cellular sequences. Often 
part of the helper virus-specific gag-gene -products are still 
expressed by the recombinant virus. Apparently, the chance of 
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recombination decreases towards the 5' end of the leukemia virus 
genome, since the probability of the expression of а дад subgene 
by the recombinant virus decreases in S'-^S' direction of the 
gag-gene (323,326). Products of the sarc-region of Moloney murine 
sarcoma virus (Mo-MuSV) are not yet known. Recently a 21,000 
molecular weight phosphoprotein was identified as the product of 
part of the rat cellular sequences present in Ha-MuSV and Ki-MuSV 
(275,27a). The src-gene product of ASV was discussed before (sec­
tion 2.4.2.). A-MuLV (236,239,347), F-SFFV (11), a replication-
defective strain of MCF (254), particular strains of Mo-MuSV (215) 
and a particular strain of feline sarcoma virus (FeSV; 233,297) 
synthesize polyproteins of 00,000-120,000 molecular weight, that 
contain helper-specific ρ 15 and ρ 12 and a smaller or larger part 
of p30 covalently bound to different non-structural proteins that 
may be responsible for maintenance of the transformed phenotype 
of cells infected by these viruses. The avian viruses AEV, MC29, 
С М И and MH2 produce similar polyproteins (118,128,129,192,251). 
Moreover, the non-structural component of the FeSV polyprotein is 
cleaved off, transported to the cell membrane and expressed as a 
cell surface antigen (feline oncornavirus—associated membrane 
antigen, F0CMA), that acts as a target for natural immunosurveil-
lance against tumor development in the cat (70,297; cf. next sec­
tion) . 
In summary one may say that recombination readily occurs with RNA 
tumor viruses, giving rise more or less accidentally to variants 
with new biological properties. For some of these recombinations 
it is thought that they form necessary steps in the process of 
leukemogenesis. Variants that result from this kind of recombi­
nations will be positively selected by the organism. 
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2.6. VIRUS-RELATED CELL SURFACE ANTIGENS 
A number of RNA tumor viruses are able to induce neoantigens on 
the cells in which they are present (14,168,171,1Θ3). All available 
evidence supports the notion that these neoantigens are virus-
coded (14,168,183). They fall apart in three categories: 1. viral 
envelope proteins, 2. glycosylated gag polyproteins and 3. poly-
proteins consisting of the viral gag proteins ρ 15 and ρ 12 covalent-
ly bound to a non—structural, virus-coded protein. 
Viral envelope glycoproteins are expressed on all virus-infected 
cells (41,135,262). Moreover, they are present on normal, non-
virus producing mouse lymphocytes, presumably as the consequence 
of the partial expression of an endogenous virus (42,178,198,318). 
Especially the expression of xenotropic viral proteins in normal 
tissues is widespread in inbred mouse strains (124,198). Examples 
of surface antigens (CSAs) that were recognized as gp7D-related 
proteins are: the FMR-antigen (a subgroup-specific CSA present on 
cells infected with the Friend, Moloney or Rauscher strain of MuLV; 
209,213), the G T -antigen (a CSA present on Gross-MuLV induced 
leukemias; 183,211,317), the G . ..-antigen (defined by naturally 
occuring antibodies directed predominantly against N—ecotropic 
viruses; 212), the G -antigen (defined by natural type-specific 
antibodies against xenotropic virus; 300), the G. —antigen 
(defined by natural antibodies specific for leukemia-accellerating 
MCF-type viruses; 3D0) and the mutually related neoantigens found 
on F-SFFV and MCF-virus infected cells (103). 
The antigens G ^ , G R A D A 1 , G E R L D and G ^ ^ do not only occur on 
virus—infected cells, but they are also present on normal, non-
virus —producing thymocytes. For instance, G occurs on normal 
thymocytes and leukemic cells of the high leukemia incidence, virus 
producing AKR mouse strain, as well as on the thymocytes of low 
leukemia incidence, apparently virus-free mouse strains (e.g. 
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strain 129) (183,211,317,318). G ^ functions as a differentiation 
antigen for thymocytes in normal mice: its expression increases as 
the thymus cells mature (214). 
According to some investigators viral envelope proteins of certain 
murine leukemia viruses are associated with histocompatibility 
antigens on the cell surface (7,35,120). Moreover, the histocompati­
bility antigens were found in released virions, still associated 
with envelope proteins (7,36). These results should be considered 
with care, however, since anti -H-2 sera can contain anti-gp70 
antibodies (89), which are present in most mouse sera (137,139,162, 
208,295). In one of the experiments, though, the association of 
FeLV envelope antigens with HLA antigens on human, FeLV-infected 
cell lines and in released virions was shown (7). It does not seem 
likely that human anti-HLA sera contain anti-FeLV antibodies. Other 
investigators failed to detect any association between mouse H-2 
and murine leukemia virus proteins (з). Yet, the association 
between (subclasses of) histocompatibility antigens and (subclasses 
of) viral envelope proteins would support the "altered self" model 
(though certainly not excluding the "dual recognition" model) for 
H-2 restricted target cell recognition in antigen-directed T-cell 
cytotoxicity, originally described by Doherty and Zinkernagel (357). 
Equally relevant, in this context, is the observation that anti­
serum against xenotropic virus (induced from BALE)/с lymphocytes 
by a B-cell mitogen) could suppress the humoral immune response 
against a non-viral antigen by BALB/c mice in vivo as well as in 
vitro (В9). This result would suggest that viral envelope antigens 
on the cell surface of immunoreactive cells might be involved in 
a more general way in the immune response (recognition and inter­
action of immunoreactive cells; e.g. T-B cell interaction). 
In most immunological studies the exact nature of the gp70-
related CSA was not ascertained. It was shown recently, however, 
that ecotropic and xenotropic viruses only indi'ce the expression 
of the mature gp70 molecule on the cell surface, whereas MCF-virus 
-infected cells also express the env-precursor protein externally 
5В 
(77). 
Glycosylated gag polyproteins (apparent molecular weight about 
95,000; cf. section 2.4.2.) have now been found on the surface of 
cells infected with Gross-MuLV (this antigen was already known as 
GCSA, Gross cell surface antigen; 174,175,285,319,320), Hauscher-
MuLV (260), Friend-MuLV (50,71) and it is probably present on the 
surface of Moloney-MuLV -infected cells too (these cells were 
shown to contain the gag polyprotein, but its location was not 
determined; 66). In some cases a second glycosylated gag poly­
protein with molecular weight of 85,000 (cf. section 2.4.2. and 
Fig. 3) was found (71,174,175,285,319,320). No studies are avail­
able on the presence of this gag polyprotein on cells producing 
endogenous virus or on non—virus -producing cells. Antigens re­
lated to p30 are present, however, in tissues and sera of numerous 
mouse strains ( 124). 
Polyproteins containing gag ρ 15 and ρ 12 (plus a varying part of 
ρ3θ) covalently bound to a non-structural protein sequence are 
synthesized by a number of replication-defective, highly oncogenic 
viruses (cf, section 2.5.). The non—structural protein that is 
cleaved off from the polyprotein synthesized by FeSV, can be 
precipitated by an antiserum against the feline oncornavirus-
associated cell membrane antigen (F0CMA) (297). Remarkably, this 
CSA can be found either on FeSV-induced tumors and FeSV-transformed 
fibroblasts or on FeLV-induced lymphomas, but not on FeLV-infected 
fibroblasts (70,168). 
The polyprotein synthesized by Abelson—MuLV is processed similarly 
(at least in some cells; 236,239,347) and the non-structural 
protein is expressed on the outer surface of the infected cells 
(350). The relation of this CSA, that has a non—identical but 
cross-reacting counterpart in normal lymphoid cells (309), to the 
A-MuLV -related differentiation alloantigen found on A-MuLV -
infected cells and on haemopoietic cells (bone marrow, spleen, 
Tabic 3 Virus-related cell surface antigens. 
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fetal liver] of young BALB/c mice, but not on adult liver, thymus 
or peripheral blood lymphocytes, either from BALB/c or from other 
mouse strains (242), is not yet clear (351). 
Since the Moloney cell surface antigen (MCSA) is the subject of 
part of the experimental work described in this thesis, this 
antigen will be discussed here in more detail. MCSA is found on 
lymphomas induced by Mo-MuLV in newborn mice (160,161). The 
"standard" antiserum is raised by injection of heavily irradiated 
cells of a Mo-MuLV -induced lymphoma (YAC) of A mouse origin into 
(A χ C57BL)F or (A χ C 5 7 L ) F mice (ΐ6θ). MCSA could also be found 
on Mo-MuLV or B-MuLV -infected JLS-V9 cells (a cell line of BALB/c 
bone marrow origin; 352), but not on Mo-MuLV or R-MuLV -infected 
NIH-Swiss/3T3 or BALB/ЗТЗ cells (fibroblasts of whole embryo 
origin; 311) (307; E.M. Fenyb, personal communication). It should 
be noted here, however, that we could detect MCSA on Mo-MuLV -
infected NIH-Swiss 3T3 cells with membrane immunofluorescence, 
though at considerably lower levels than on Mo-MuLV -infected 
JLS-VS cells (see chapter 6.). Although gp70 and gag-related 
proteins were shown to be present on the YAC lymphoma cells (against 
which the antiserum is raised) (85,86,151), E.M. Fenyö and her 
colleagues obtained several lines of evidence that MCSA is distinct 
from the viral structural proteins: Jl^  Two sublines of the lympho-
ma line made immunoresistant to anti-MCSA by immuno—selection in 
vivo and in vitro did not express MCSA anymore, but were as sensi-
tive as the parental YAC line to the cytotoxic effect of mono-
specific h'eteroantisera against viral structural proteins (B5). 
2. The cytotoxic effect of anti-MCSA to the YAC cells could not 
be inhibited by virus or viral proteins (86). 3^ In membrane 
immunofluorescence MCSA did not co-cap with gp70, pISE or H-2. 
4. By chromatographic (283) as well as by electrophoretic (314) 
means MCSA-activity (measured by cytotoxicity-inhibition) could 
clearly be separated from viral structural proteins and H-2 anti-
gens. On the other hand, MCSA did co-cap with p30 and ρ 12 on the 
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cell surface in membrane immunofluûrescence and could be bound for 
maximally 15 ^a to an anti-p15 immunosorbens column [151]. 
Moreover, on a lectin affinity column part of ρ 15 co—chromato— 
graphed with MCSA (283). This led to the speculation (151), that 
MCSA would closely resemble FOCMA and that it is synthesized as a 
polyprotein of ρ 15 (and ρ 12 ?) covalently linked to a non—structu­
ral protein (MCSA). This polyprotein would then be further pro­
cessed to the mature, non-gag-linked MCSA—molecule, that would 
become loosely associated with the gag proteins on the cell 
surface (151). 
In this thesis (chapter 6), however, we show ample evidence that 
MCSA is env-related, but distinct from the exogenous Mo-MuLV env 
proteins. We conclude, that anti-MCSA recognizes some other 
MuLV env protein. The expression of that protein could be caused 
by a contaminating defective virus present as a pseudotype in some 
Mo-MuLV isolates. 
The significance of virus—related cell surface antigens in immuno— 
surveillance against tumor development is not yet clear. In mice 
natural anti-viral antibodies are predominantly directed against 
gp7D (110,136,137,295). In addition, anti-p3D antibodies can be 
found at low levels (140). Although virus-induced tumor cells can 
elicit strong anti-viral antibodies (213,242), it is not clear 
whether natural antibody production is induced by virus—related 
CSAs or by viral structural proteins present in the serum. In 
virus-producing mice viral structural proteins are found in the 
serum as constituents of the released virions. It was shown that 
the glycosylated gag polyproteins are not incorporated into 
virions, but still are shed into the medium in cell culture (66, 
175), so it is presumed that these polyproteins can be found in 
the serum of infected mice too. In fact, gp70- and p30-related 
antigens are found in the sera of most mouse strains, either 
virus-producing or not (124,178). Quantitatively, large dif­
ferences may exist between various mouse strains. The serum of 
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normal mice contains a xenotropic virus-neutralizing activity, that 
is not, however, immunoglobulin-mediated (В7,1Ві). 
The anti-envelope antibodies neutralize the infectivity of the 
virion (ISS) and are able to prevent, albeit incompletely, viral 
replication in vivo and in vitro (59,95,131,132,153,227). Moreover, 
these antibodies are cytotoxic for virus—induced tumor cells ( 105, 
110,135,138,208). 
Not only a humoral response can be elicited by viral envelope 
proteins, but a cell-mediated cytotoxic activity is also induced 
(102,138, 154,171). 
MCSA is related to the tumor-associated transplantation antigen 
(TATA) of Mo—MuLV -induced lymphomas, since the amount of MCSA 
present on a particular tumor correlates quite well with the 
immunosensitivity of the tumor in vivo, as judged by the rejection 
of small tumor grafts in preimmunized mice (lol). In addition it 
was shown in genetic experiments that mice which could produce 
high titers of anti-MCSA were better protected against lymphoma 
transplants (53). There was no correlation between successful 
tumor rejection and anti—viral response. 
A system in which it was incontrovertibly settled that a virus-
related CSA is the main target in natural tumor rejection, is the 
FeLV/FeSV infected cat system. FeLV/FeSV is endemic in cats (312), 
Titers of antibodies to FOCMA correlate inversely with the rate 
of tumor progression (70). On the other hand, the level of virus-
neutralizing antibodies does not appear to influence the course 
of the disease to a great extent (70), although passive immuni­
zation with anti-FeLV can temporarily prevent the development of 
FeLV/FeSV --nduced tumors (59). 
So in the only case where an important role of a virus-related CSA 
in tumor rejection is clear, gp70 is not the target, although this 
antigen and antibodies to it are most widespread. However, virus-
induced tumors might not only grow by cell proliferation, but also 
by virus spread and transformation of new cells (232). Therefore, 
a humoral and cellular response against the virus could be effica-
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cious in preventing the development of tumors. 
It should be kept in mind, that leukemia viruses are only leukemo-
genic when injected into newborn animals, suggesting that adult 
animals can build up an efficient immunological defense against 
these viruses and/or neoplasias they induce (108,312). When 
young mice are infected with leukemia virus they develop tumors, 
after a latent period. Concomitantly, their immune response becomes 
generally impaired (3θ), apparently because the immunoreactive cells 
are the targets for the leukemogenic activity of the infecting 
virus (108,312). Moreover, the impairment of the immune system may 
also be related to the finding mentioned before, that anti-viral 
antibodies are able to suppress the immune response (197). 
In the latent period before tumor outgrowth, tumor development 
could be blocked by circulating antibodies and cellular immunity. 
This immunological barrier would then be overcome by the rapid 
appearance of a highly oncogenic new virus type: the MCF recombinant 
virus. A model for the mechanism by which this type of virus could 
induce tumor formation (namely by mitogenic stimulation of specific 
MCF-receptor bearing target cells) has been described already in 
section 2.5. Perhaps this virus, or the CSAs present on the cells 
that express the virus, elicit antibodies that enhance tumor growth, 
either by blocking cell-mediated cytotoxicity or by suppressing 
general immunoreactivity of lymphoid cells through interaction 
with specific viral envelope proteins on these cells. 
Since this is still all hypothetical, it is clear, that further 
studies (e.g. on the quantity and quality of virus and tumor cell 
antibodies in the serum during the lifespan of AKR mice or neo-
natally infected mice) are needed. 
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IDENTIFICATION OF RAUSCHER MURINE LEUKEMIA 
VIRUS-SPECIFIC mRNAs FOR THE SYNTHESIS OF 
GAG- AND ENV-GENE PRODUCTS 
The author of this thesis likes to acknowledge 
the larger contribution of D.v.Z. and A.L.J.G. 
to this work. 
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Identification of Rauscher murine leukemia virus-specific mRNAs 
for the synthesis oí gag- and env-gene products 
(proletn synthciis/oocvles/radiüimiminupricipitalion/ßel eleclrophorciis) 
D V A N j Z A A N b * , ^ L J (WtLKbNS* V\ С I I I SSM INK AND H F J Bl.OFVIFRS 
Drpjrtmuil oí liiiK'hcrni,>lr> I iiivrrsi(\ ifNijnuRin t.etrl (.ΠΗΙΙ( μΐιπι N<x>ril 21 NijmeRrn Tht Ntthrrljnds 
Communicated by Ccorge hiein Геіггиагц 7 W7, 
ABSTRACT Pol\adfn\l>laled m R W isolated from cells 
infected with Rauscher murine leukemia virus was fractionated 
by сепІпГицаІюп in a denaturing sucrose gradient into different 
si/cs Lach R N \ fraction was injected into ooevtes of \rnopus 
Ucii* and the \irus-specific products wire analyred h\ im 
munoprecipilation with poK ν aient and monospecific antisera 
against polypeptides of Rauscher murine leukemia virus, and 
then by gel electrophoresis and scinllllalion autoradiography 
ll was shown that a 15S niRNA species directs the synthesis of 
a pret u r sor of the internal or group spi ι ific antigens of the \ i-
rion (the дад-gene products) A 22S m H W species directs the 
synthesis of two \iral envelope poK peptides and their precursor 
pois peptide (em-gene products) The rt suits indicate that the 
gag and en\ -related pok peptides of Rauscher murine leukemia 
virus are synthesizeduncoordmalely and provide evidence for 
open and closed cistrons on (he virus-specific mRNAs 
Τίκ' structural ¡юі) peptides of the mm me leukemia viruses am] 
prcsiiniabl) alv) those nf all otlu г U N \ tumor wrusts art 
subgfiie pnxlucls derived from th( |)гііпаг translation рг(к1 
nets precursor Polypeptides) of the gag a n d l h c c n i gene il or 
a review see rcf Π In our studits with Jl S \ 9 (ells infrcled 
witli Rauscher murine lenkt ima virus ili Mul \ ) we have 
xleritifiecl a glvcosvlatecl [HI1\ [H'pliclt with a molecular wughl 
of 82 (XX) u " i prh2) as tht рпч ursor of two polv [X'ptules of the 
viral envelope gpf)c) 71 and pl r ) ibi »2 Ì ) I he ртК peptide 
pi 2(1') ((lesignaled ρ 12 in reí V share s с hvmolrvptic peptides 
with рІ^Л Ì therefore pl2([ ) is also derived fremi the env 
ргес игч)г poK peplule lour unpublished results and ref 1) In 
I hi» same slutlies (2 3) we re'eogm^ed two mulualK related 
(юКpeptides with molecular weights of 14 000 (еаііечі gag-
рг75)аімІ 65 (KH) (callexlgag prh5)as the precursors of the in 
ternal virion iKilv[>epliel4's рЗОаікІ p l 5 Recent К Barlwcidfí 
al (5) detnt>nslrate4l that (he two other internal р(>К|мірІіііс^ 
p]2 and plO are also derivili from the precursor of i>-30 and 
p l 5 \\] lliese data are' consistent with those reported In seve'ral 
other authors (4 6-9) 
1 he existente of virus spet ific mRN \ species of different 
si/e classes (10) suggests that the synthesis of gag and етіі 
precursor polypeptides is programmenl In difierent mRNAs 
rather than In one poKcistronu mRN \ In agreemenl with this 
suggestion it w as show η that eat h virus spe-cific mHN \ SJX-CICS 
tn< diated the svnthesis of its own virus specific productts) in 
a rabbit reticulocyte ce 11 free ss stem i l l ) Of the two virus-
SJM1! ιίκ products formed in this system under the diretlionof 
the 354 mRN \ fraction onec-omigrattKl during sexhum elodee\ I 
sulfate (NdDtxlSO|l polvatrvlamide gi 1 de i Irophoresis with 
the gag pr65 mentioned аію е the other one with gag pr72 
a gag re lated роК|х>р1к1е found in inf<4 ted cells m the presence 
Althre vialmns R Mul V Rauscher munne leukemia viras NaI>ndS(>4 
sodium dodi4\ I sulfate gag ¿ml ι m are < Jt li \irj | geiKH 
* Prese nt address De jjjrlmcnl of \ irnlngv С entrai \ rtt ruury Insti 
Iule lelystdd The Netherlands 
of the arginine analog canavanme (V Similar prexlucts were 
ftiund in various protein synthesuing svsteins programme4l with 
RNA isolateci from virions of ΗΝ К tumor viruses and identified 
asgflg related products (12 17) In none of these experiments 
with virion RNA however, could erw related prexlucts be de 
let Іечі 
lu addition to these results obtained with genome size 
virus sptuf i t RNA OïS) (whether isolated from virions or as 
[NihatlenvMated mRNA from infetted cells) two observations 
elescnbed in our previous study are notcwnrlh)
 ti) the 22S 
mRNA fraclum isolated from cells infetted with R Mul V 
ішчіми el the sv nlhe'sis of a virus specific 70 000-dalton polv 
[M^ptiele m a e l l free system from reticulocytes i l l 1 a pok 
peptide of the same si/e as ihe РПР rel.itеч) prexlucl formed in 
nifetleel cells when gkcosvlalion is inhibited (ref Я and W J 
M van de \ en unpublislitil) (IT) in an entlogenems cell free 
system derived from cells infected with R VluLV free poly π 
Uisomes e-ontaining 15S RNA as the main virus-spet die mRNA 
protluttd gag-products only whereas the membrane bound 
|X)|ynUisomcs gave rise to Іюііі gag and eno products and 
Loiitaint4f 22S virus specific mRN A in addition to the "ÌSS RNA 
(11) Themse· results prompted us lo localize the gag and env-
rnessengcr activity among the helemIogt)us virus-spetific 
n iRN\s 
VIATKRULS A N D M E T H O D S 
Cells and Virus The JI S-V9 cell line derived from bone 
marrow tells t>f Balb с mice intet ted with anel producing R 
Mul \ was grown in tagle s basal minimal essential medium 
supplemenleel with lO1^ ta l i serum (18) I abehng of J LS V9 
tells anel preparation of cell I ν sales for Immunopret ipilatmn 
was described elsewhere [V 
Isolation of Polyribosomes. For the preparation of tolal 
|K)lyribosonies tells were treated and subseepientlv harvested 
as tlcsenbed U'fore (11) After the cells i2-S ml) were washed 
and swollen m hypotonic buffer vl l) they were disrupted by 
10 strokes of a Donner liomogem/er tfì ¡jeslle) in 12 ml of Ivsis 
buffer (50 mM I n s HCl pH Τ 4 Mg^Ada 5 mM КАс 150 
т М Nonidel Г-А0 І ^ ,,νοί vol) scxlium eleosjcholate 05£c 
\,\KI vol) ehthiothreitol 2 m M and 100 Mg ml of an RNase 
inhibitor from bovine eye-lens purified on DFAL cellulose 
(оЬіатечІ from H Blcxrncndal) Nuclei and cell debris were 
removed bv centnf ligation for 4 mm at lop speed (20 000 rpm) 
m a TñO rotor (Be<-kmannl The supernatant was layered onto 
I 0 ml of 2 M sucrose in 20 mM Tns-IK 1 pH 7 -1 KAc 120 
mM Mg(At)2 5 mM and 2 mM dithiolhreitol and polyribo-
somes were collected b> cenlnfugation for 2 5 hr at 56 000 rpm 
in an SW 56 rotor (Beckmann) 
Isolation and Frachonal ion of mRNA. Polyaden>Iylaled 
mRNA was isolated from total ptilvribosomes bv affinity 
chromatography on oligo(dT)-cellulose as describes! (11) with 
e j 
Biochemistry Van Zaane et al Ртос \atl Acad Sci l SA 74(19~7) 
the following mixlificatmns polvnbosom« were incubat(4l in 
buffer \ for 10 min al Ύ7 with PronascfRNase free) 0 5 
mg/ml and \aDodSO4 was omitted from column buffer В 
mRNA was fractionated hv centnfuçalion in a denaturing su 
trost gradient into various si/es as desi ribed in the legend to 
Fig 1 
Antiscra Antistra raised against R Mul V (ЮІ> peptides and 
used for immunoprecipiUtmn wtre described »Isewhere (3) 
Wc observed no crossreactiMt\ among the monospecific anti 
stra пччі in thi<) slud> a slight copreupHation however of 
gpf)*) 71 pl 'JÍF) and pl2(F) was observed in immunopreci 
pitation reactions with anliserum against gpß^ "1 and antise 
rum against both pi J(L·) and pl2(l· ) (designated mil ρ Π ί ! · ) 
pI2 s* rum in ref 3) due to an asscx lation of thest viral envelope 
polvpcphdcs (3) The antiserum against pl5(L·) pl2(F) was 
raistd against a mixture of p l ^ F ) and pl2( l ) (3 moreover 
it is now known that p l 5 ir) and pl2(b contain common amino 
acid sequences (D \ an Zaane unpublished results and ref 4) 
To rule out contamination with antil>odics against reverse 
transe ripiase we tested the antiscra against R MuL\ gp69/71 
and p30 for tht ir capacit> to inhibit theenzvme activity The 
sera did not react in this test (not shown) and therefore the> 
will probably not immunoprecipilate reverse transcriptase 
RI· SUI TS 
Virus Specific m R W Actmlv of Total Polyadenylylaled 
RNA from Infected Cells Translation of Ì5S RNA isolated 
from R M u L \ in oocytes of Xenopus laetts has clearlv dem 
onslraled that this RNA preparation directs the svnlhesis of 
gag pr65 onlv (15) In a prclimmarv experiment with these 
oocytes we observed tht t a mixture of virus specific mRNfAs 
of different size cbsses ( U S 22 S and 35 S) isolated from 
JI S V 9 cells infected with R Mul \ mediale d the synthesis of 
the gag gè ne produci gag prb5 as well as the em gene 
products ent pr82 gpfi*) "I and ρL5(t) (not shown) These 
observations indicate lhal at least Iwose parate m R \ A functions 
are present among the population of virus specific mRNAs a 
gag specific and an env specific mRNA To idtntifv іюіЬ 
mRNA activities vverepeattxt this experiment, with fractionated 
mRNA 
Virus-Specific mRNA Activity of Fractionated mRNA The 
frachonalion of mRN \ from infected cells was pe rformed by 
sucrose gradient centnfugation 111 the presence of formamidc 
as a denaturing agenl The sedimentation pattern of virus-
sprcific mRNA in the gradient was determined bv hybndiza 
tion with DNA compie me ntarv to R \1uL V R N \ ( b i g 1) The 
repulís are essentiallv I he same as those re ported Ы fon ( I P and 
the virus specific mRN \ spe cu sof 1-1 S 22 S and 35 be an l>e 
distinguished OocUes of Xenopus ¡aevts were injecled with 
RNA from eac h fraction ind нк иЬаІечІ with l ^ niethiomne 
The newlv svnlhesi/ed virus s[xcifit poKpe ptides were sepa 
rated from the large excess of JI S-\ 9 specific pol\ pe pi ides and 
endogenous<xx\te pe>]v|xptieles bv iinmunoprecipitation with 
anti R Mul \ serum this ч г ш п reacts with both gag and 
env related products (3) The inimune)pre4-ipitales were ana 
lyzedbv NaDodSOj polvacrvlamidc gel electrophoresis and 
scintillation autoradiography (Hg 2) ТІігеч polvjX'ptides two 
in the 50 000 dalton region and one with a very high molecular 
weight were precipitated in a controle xptnnient wilh oocyte's 
injected with water (Fig 2 slot 5) as well as in all other analyses 
of injected ехк tes (big 2 slots в ¡9 \pparenllv these poly 
peptides are not virus spe< ific and therefore will be ignored 
in furlher discussions A nutnlx r of \ irus six cific polv peptide s 
can be recogni/ed whichcornigrate with the R MuL\ specific 
precursor polviX'ptides or with the mature virion pol\peptides 
30-
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tract on number 
20 
Ь К I Sucrose jiradient rentrifupalmn ol viru·. ^pecifir mRNAs 
fnm JIS V9 cells mfw ted *ith R Mul \ PoKadenvMated mRNA 
( ) ; μ^,) is In l ed as described in Чаи rials and Met h >d sciti m wis 
denatured iL ib" le г t mm with furmnmide ΗΉ (vol vol) in 2 ) m M 
I ris Ж I р Н - НУГЛ ImM/andO A. NaDexISO« (wt/vol) After 
thlulMnwilhonev lume o l l \ h (10 mM I пч H( I pH " 4/Na( 1 100 
mM/hDIA 1 m\1l thcRNA [)re[)arat] η was lavercd < ntc un isolo 
nelicsuir sepradienl in 1 NI1 с intaming Γι()% (ν )l/v )I) for m am id e 
|( Mop) - >v (wl/vol) Сь (hiKh) = \4 4Ή (wt/voll \ „ (mm) = 1 > 9 
ml| The lubes were spun in a SB ¿HI rotor (IH > for 1 1 hr al Io at 
II 000 rpm RNA from each fraction was precipitateci with nlrnhol 
aller additie η of HI ßg of ^hS RNA Irenn calf eve lens nhosomes as 
a carrier I he relative ami tint of virus specific RS \ was delermined 
in e ich friction hv hvhndizalion with UNA complementary tu R 
Mul V RNA f 10) 
immunoprecipitated from infected cells (Fig 2 slots 20 and 
2 ] ) 
The aulnrul iognm of virus specific translation products 
(Fig 2) suggests a sharp separation of virus specific mRNA 
which is in conlrasl wilh the diffuse hvbridi/ation pattern de 
picled in Fig 1 This inav be explained bv the nonlinear 
blackening of the film during se mlillation autoradiographv and 
by the unknown representation of the. viral RNA in (he cDNA 
probe used for hvbndi7alion 
Identification of the gag mRNA In agreement with our 
previous studv in which we used a cell free svslem from retic 
u locytes( l l ) the 'Î5S mRNA species (big 1 fractionnels 17 
and 18) direc ted the s\ nthe sis of a 65 000 dalton pok peptide 
( b g 2 slots 17 and IH) H g 1 1 К shows lhal the b5 000 
dalton polype piule svnthtsi/ed in exxvlcscan lie pre cipitated 
with antiserum against |>30 as we II as wilh ani is* rum against 
p l 5 but not with anliM rum to gpòQ 71 Incidentalk il should 
be noted here that the antiserum against gpi)9 "1 precipitates 
a polv peptide about 32 (XK)daltons) from IXKV tes injected ei 
the г with the various RNA fractions (Ьig I F F and К ) o r with 
waler(Fig II) indicaling that this polv pepitele t sanendoge 
nous сихчіе prwluct Wt COIR luck that the (i5 OOO-dallon po-
lypetule is similar if not idenlical lo the gag gene product 
gag pr65 found in mfee ted ее lis This conclusion is consiste nt 
with a reverse t\ix rime nt carried out bv Mueller 1 inlzsch (21) 
showing that the polyribosomes taken from cellsinficttHl wilh 
Moloney murim It ukenna virus lhal wert Immunopretipilalcd 
with antistrum against i>30 c4)ntaintd '13S RNA as the mam 
virus s i e d l e RN \ species 
Identification of the env mRNA The 22S mRNA fraction 
(l· ig 1 frac tion no 11 ) піечіі »te s the sv nthe sis of three poly 
peptides (Fig 2 slot II which were identified is I he e n t gene 
products em prS2 gpf/i 71 and p i ^ l · ) the ν comigrated with 
the ^nt» gene products found in inflated ce Ik (1 ig 2 slots 20 
and 21) the ne vi k s\nlhesi/ed pok pept idccoimgrating wilh 
env pr82 could be ітпшпоргечijulatexl with antiserum against 
gpeO/"! and antiserum against pl5^L) pl5(F) whereas lhase 
; • / ! 
Вин liemistry \ an Zaanc ei al Proc \atl Acad.Sci l'SA 74(1977) 
tes 28 S 
I 
огШ2 Zpr75 
-Í)P69/71 
-Ρ'65 
<J IO 11 12 13 M 15 16 17 18 19 20 21 
FIG. 2 Radioimmunoprecipitatiou anat^îs with antiserum against H MuIV ni the virus specilli- products svnthesi7ed after injection of 
<KH-vtes of Xeno pus ¡arns with fractionated polvadenylylaled RNA Imm -11.8 Vit cells infected with К MuLV RNA precipitated from each 
fraction of the gradient shown m Pïg. 1 was dissolved in ΙΟμΙ of H3O: 0 "> μΙ was injected into 20 oocytes (19). The oocytes were incubated for 
20 hrat 20° with ІЬцСі of l.|'''Sjmethionine (specific activity. 329 Ci/mmol; from The Radiochemical Centre. Amersham, Knglandl and. sub 
sequently, homogen ized in 1 25 ml of immunoprecipitation buffer ('t) The homogenale was ι lea red hv centrifugal ion for 10 mm at 220.OOÜ X 
^ in a Ti-r)0 rotor (Beekman) Virus sped fit polv peptides from the supernatant were analv/ed by NaDodSO^polsatrvlamide gel electrophoresis 
111) and scintillation autoradiography (20) after indirect immunoprecipitation with antiserum against R MuLV (2,3) SU U в /9 correspond 
with the fraction numbers of the gradient shown in Fig I Slat 5: (control) (Immunopret ipitation anal ν sis with antiserum against R MuLV 
ol products s\nlhesi/ed alter injection ol 0 Γ> μ| ol HjO into 20(H»cytes) Slni Jll vims spei ific polypeptides immunoprecipitated with antiserum 
against R MuLV fn)m infected ILS V9 cells treated for 15 min with a "( labeled amino acid mixture {'Λ). Slot 21: the same as slot 20 except 
that the radioactivitv was chased for 8 hr with an excess ol unlabeled amino acids (.4). 
comigrating with gp69 71 and p l 5 ( t ) wert- immunoprecipi 
taled with the corresponding antisera {Fig 3 F a n d G ) Fig 3i/ 
shows that the geg'SpecIftc antiserum against p3() dtx's not 
precipitate translation products of 22S m R \ A 
Immunoprecipitahle Translation Products of the I4S and 
25S mRNA Fractions. The -15 OOtKlaltnn i>..i\ peptide formed 
after injection of I4S RNA (Fig 1. fraction no b) and immu­
noprecipitated with the antiserum against R MuLV (Fig 2, slot 
H) was not precipitated with the monosiH-cific antiserum against 
p$0, antiserum against pi 5. or antiserum against gi>69''71 (Fig 
3C'-E) The nature of this product remains unknown we cannot 
exclude the possibility that it is coded for In a host 14S inRNJA 
Finally, the 25S mRNA fraction (Fig 1 fraction no 13) directs 
the synthesis of a minor polypeptide (S5,()()0 90.000 daltons) 
which was precipitated with antiserum against R Mul.V (Fig 
2 slot 13) but not with antiserum against p30 or antiserum 
against g p09 71 (not shown) This polypepUde could represent 
a host-specific product from JLS-V9 cells recognized by the 
antiserum against R-MulA Some unidentified polypeptides 
in the same si/e range were precipitated In the antiserum 
against R MuLV when 25 2SS m R W from infected cells was 
translated in the reticnloc> te system i l l ) 
DISCUSSION 
Open and Closed Cislrons on Oncnrnaviral mRNA. In 
1974, Baltimore (22) proposed four 'genetic elements ' for the 
avian sarcoma yiruses gag (for the precursor polypeptide of 
the major core protein) cnt (lor the major envelope protein) 
pol (for the RNA dependent Ι ) \ λ polymerase) and one (for 
cell transformation) He discussed them as if thev were genes 
Constituting most of the genome of an RN \ tumor virus ' Since 
that time, all known structural polypeptides of the murine 
leukemia viruses could be assigned to either the gag- or the 
antigène These two genes, therefore contain "subgenes"; their 
primary translation products are precursor polypeptides that 
are cleaved into subgene products 
Our present results show that each of the two genes, gag and 
ent?, is expressed by translation of itsown specific mRNA Such 
virus-specific mRNAs although functionalK monocistronic may 
apparent!) overlap other genes and. therefore, be structurally 
polycistronic This is obvious for the genome size 35S gag-
mRNA and probable for the 22Sem)-mRNA with its estimated 
molecular weight of 1 2 X ^ ( l O ) Similar conclusions follow 
from h\ bndization data on oncornav irai mRN As of different 
si/e classes ! 10 23 25) It is tempting to speculate that asa rule 
the open u e translated) cistron would Ы· the 5-terminal one 
Otherwise a more complicated model would be required to 
explain the recognition of the open initiation site For the 
gag mRN λ this speculation would be in agreement with the 
probable gene order proposed for the avian RNA tumor viruses. 
Ъ gag polem опс-фо\у{\у\ (26) Ry assuming the same gene 
order the em -mRNA would then have the structure S'-ent?-
om ροΚι Л ! I 
Much less is known on ihe expression of pol and one: the 
latter gene although identified from mutants of murine sarcoma 
viruses (27) is still hypothetical in the case of leukemia viruses 
If poi and one also have separate mRNAs the model predicts 
the following structures 5-po/-É,nt;-onc-pol>(A)-3' and 5'-
cme-poKi \) 3 
Ver> Large Virus-Specific Polypeptides. The concept of 
separate mRN \s for the gag and the ^nu-gene agrees with data 
on the uncoordmate expression of p30 and gp69/71 in cells 
harl>oring endogenous or defective RNA tumor viruses (28. 29) 
l ikewise some recent ex|)eriments in which the initiation of 
protein synthesis was influenced by high salt conditions (30) 
indicated that different sites for the initiation of protein syn-
thesis are Operative in the expression of the gag- and the enu-
gene of nondefectiye mouse mammar) tumor virus From these 
experiments and from the results described m this paper, we 
вь 
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л MS ι ? s j s 
цг^-*· — 
л В O t t С H I К 
F u . I Monospei i f icant i sera idpnt i f ica l ionol H M u l V specific 
proflucLs formed m т к іе* <)Г \*ηιψιι*> lot 11 ^ dflPr injeclum u i l h 
mRNA fractions Irctm II S \Ч colls infwtwl wilh II Mul \ I cc brinai 
de t t i l s ami fraction m i m l ^ r s o f m H N A i r p H s d c s c n l w d i n Ihr lcRcnd 
to FIK ¿ I vs i lesof iKKVles injPt l rd with ] IS tnHNA ( f r u i u η η > 8 
•.ífí^f f ) 22S mHNA (frai lion no II ν/»is/- / / t a n d I I S m H N A 
( f r a r t i o n n o IH s /o í s / К) 'Aoreanalv/J 'd « U h incmnvpetiltc nntisora 
I h« lolloping тошь|>о<іП< ant i spr i чего used antiserum n^ainst \)M) 
(sir ί·(( HI a n d / ) a n t i s e r u m -i^dinst p i >(sir)/% /J J a n d M) an 
l i serum against рр( 4/"l (sit ί t f h a n d M ant i serum aj,iiinst 
ρ 1 ) ^ ί pllib Hs/f ί d) As a t ont ml similar an ih ses were pi rft nnetl 
with iHxUes injected with H 0 IN/< ÍS / \ ) ind is Ί re(( r e n t e the 
virus specifu pi Ιγ pepi ides Ir »m m b e t e d tells ire she wn (s/»ív 4 and 
fi) (S/of 4) \ irus spetifit |Mi1\p( p t ides immunnpre t ip i t itod with 
dnlisenim apiinsi К Mul \ І г п т Ivsatesof Jl S V'U-ells m f « ted wnh 
H M u l V t reated for Ir> m m w i l h ' Ч 1 ihelerl i m i n o a c i d s іЧі Hi 
I h e s a m e n s s / f \ except IhdL iht radii d< Livitv v. is chased for H hr 
with an е м ess of unlabeletl a m m o acid-
conclude that translation of the genome of RNA tumor viruses 
into ont giant precursor polvpt phdr (250 (КЮ 300000 daltons) 
as found for pitornavirusest'il 32)isunlik(l> or al i tasi is nol 
the principal pathway for the s\ntliesis of the virus s[>ecific 
polvpephdes Some authors h i\< noticed var\mg amounts of 
large viriLS specific poKixptideb (> 100 000 daltons) in inftnUd 
cclls(8 9) tlieir physiological sigtuficaiKt how ι ver remains 
obscure 
S\nlhesis of the en* and gag Products in the Oocyte 
System In our preuous study a 70 (XW-dalton jx)K pephdt was 
synthesized in a cell frtt system from riluulocvles dit r the 
addition nf 22S mHNA isolattd from ni l s infettici with Η 
Mul \ (11) PresumabK this polvptplide was iht proUin 
moietv of the (cluubilaledtfu pr82(3) iKtausea70OOtKlallon 
jx)Kpeptide was also fotintl in iiif(4tt4l (ЧІК wht η gUCOSY laiton 
was inhibited with [) 2 deowgliuost ttr t\toclialasin В yrtf 9 
W J \1 van dt Ven unpublishctl rtsults^ In tXKYtestif \( η 
орич Іаі іч liowtver l l i t t m ргскііи Is wire apparentK glv 
сов\ІаІе<Пхчаііч |1н\ conugntcd withi ш pr82 ami Ц|Я>1) " I 
The synthesis offrii prK2 was abt) ob4'rv«tl m an cntlt)g<nous 
cell free system from mfecled i t Ils containing |К)І\ rilmsomes 
still attached to membranes 11) It is generally a c t t p t e d (3Ì) 
that an enzyme system assotnled with the endoplasmahc 
reticulum recognizes signals for iht glvcosvlation of nascent 
polypeptide*. This enzyme svstem is apparently well conserved 
during the evolution of the vertebrates Tht samt seems to be 
true for another posttranslational attiwty the cleavage of 
precursor polypeptides because in addition to em pr82 the 
subgene products gp69 71 and p l ^ b ) arc also formed in the 
amphibian ooc\ tes The gag related poly peptides were less v\ ell 
represented in oocytes although in some с x|)erinients a partial 
processing of gag prb5 was observed {not shown) In the ex 
perirne nts presented he rt gag prfvi Y\as the sole£a# specific 
product formed in the t>tx\tes in mfecled cells we had pre 
viouslv identified ι pok pept idi called gag рг"э is tin immi 
thatc precursor to gag prb5 O) 
It should l>c noted that tht melt |м neh nt confirm ition of our 
contlusionsbv trvptk (Kptideanalysis has not Іхчп undertaken 
Інчаіізс the low amcnint of rachoacliviU that was tnc4)ri)t>raled 
in virus sjMtific products (арргоч "SiKtcpm 20tKK'vles) 
Translation of 14b RNA in the Oocyte System In contrast 
to the 4з (HX) dalton ]ЮІ\peptide svnthesized after injection of 
MS πιΒΝΛ from mfe cteel tells mio ooevtes one 30 (MIO and 
two 15 000 dalton polv[K piules were produceti in a cell free 
svstem from rt ticulocytes in response to tht same mHNA 
fraction ( I I I Although it is rt mark ible that all the se products 
Iprmpitahlc wilh antiserum against Η Mul V are formed 
linde г the ehret lion of an m ΗΝ \ fraction that t oincides w ith 
a small peik in the h ν brie ligation profile obtained with Η 
Mul \ c I ) \ A ( b i g I) the origin the nature and the possible 
relationship f)etv\ee η these polyp« ptidt s are not ve t clear 
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4 . IDENTIFICATION OF VIRUS-SPECIFIC mRNA SYNTHE-
SIZING MURINE LEUKEMIA VIRUS RNA-DEPENDENT DNA 
POLYMERASE (REVERSE TRANSCRIPTASE) 
о 
IDENTIFICATION OF VIRUS-SPECIFIC mRNA SYNTHESIZING MURINE LEUKEMIA 
VIRUS RNA-DEPENDENT DNA POLYMERASE [REVERSE TRANSCRIPTASE] 
ABSTRACT 
In order to investigate the size-class of virus—specific messenger 
RNAs that are involved in the synthesis of the murine leukemia 
virus (MULV) enzyme reverse transcriptase (HT), we translated size-
fractionated mRNAs from Moloney-MuLV -infected cells in oocytes 
of Xenopus laevis. Reverse transcriptase was either detected by 
its enzymatic activity or by immunoprecipitation. Although we were 
not able to detect reverse transcriptase activity in oocytes in­
jected with mRNAs from virus-infected cells, we did precipitate 
reverse transcriptase molecules from lysates of injected oocytes. 
It appeared that reverse transcriptase was synthesized on genome-
size mRNA. These results are in accordance with those obtained 
earlier by translating virion RNA and with recent results of 
translation studies with cellular nflNAs in cell-free systems. 
This chapter, however, shows for the first time the synthesis 
of mature reverse transcriptase in vitro. 
э 
INTRODUCTION 
The genome of mammalian non-defective RNA tumor viruses contains 
three known genes: gag, encoding the structural proteins of the 
viral core, pol, encoding the viral reverse transcriptase, and 
env, encoding the proteins of the viral envelope (4). 
The genome order has never been formally proven for mammalian 
viruses, but most probably it is the same as for the avian leuko­
sis virus genome: 5'-gag-pol-env-polyfАІ-Э' (17,48,49,50). It has 
been shown that the gag gene is translated from a virus-specific 
messenger RNA with the same size and genetic content as the 35S 
genomic RNA (15,26,32,37,38,46; chapter 3.)· The viral envelope 
proteins are synthesized on a 22S size mRNA (37,38,46; chapter 3.). 
The 22S virus-specific mRNA arises by splicing of the genomic RNA: 
it contains both the ultimate 5' end of the 355 RNA (at least 150 
nucleotides long; 35) and the 3' half of the genome (7,11,19,24, 
34,35,51). 
The primary gene product of the pol gene is not the mature reverse 
transcriptase molecule itself, but a precursor polyprotein encom­
passing both gag and pol sequences with a molecular weight of 
180,000-200,000, Pr180-200 9 a g" p o 1 (16,18,53). In the first pro­
cessing steps the gag sequences are split off and through several 
intermediates the mature polymerase (molecular weight 70,000-
80,000) is formed (16,18). The presence of gag sequences in the 
precursor to reverse transcriptase requires that the mRNA coding 
for this polyprotein would at least contain both gag and pol 
sequences. This is contradictory to the structure we tentatively 
proposed earlier for the pol-mRNA (46; chapter 3.): 5'-pol-env-
(onc)—poly(A)-3'. Translation of virion RNA in vitro showed, that 
the gag-pol precursor polyprotein could be synthesized by genome-
size RNA (23,27,30,33,52). Philipson et al. (ЗЗ) were able to 
augment the production of the murine leukemia virus (MuLV) gag-
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pol precursor by the addition of yeast suppressor tRNA to the cell-
free systeT. Therefore, they proposed that the precursor to reverse 
transcriptase would be made on the sane RNA molecule as the gag 
(precursor) polyprcteins РгбЕ and gPBO9 are made on, by a 
process of incidental "read-through" of the gag termination codon. 
Weiss et al. (52), however, did not detect any effect of yeast 
suppressor tRNAs on the synthesis of the gag-pel precursor of 
avian sarcoma virus (ASV). They suggested a separate pol-mRNA iden­
tical to the gag-mRNA, except for a small sequence that would be 
spliced out fron one of the mRNAs. Thus, a termination codon would 
be present at the end o^ the gag gene in the gag-mRNA and absent 
in the pol-mRNA. A final answer on this point is not yet available. 
Suppression of a termination codon present on mammalian cell mRNA 
by yeast suppressor tRNAs in a heterologous cell-free system seems 
to be rather artificial, yet suppressor tRNAs have also been found 
in normal mammalian cells (12) and nay have a significant function 
in the fine regulation of gene expression in higher eukaryotes. 
In order to investigate whether reverse transcriptase was also made 
on genome—size mRNA in the infected cell, we translated size-frac­
tionated mRNA from Moloney murine leukemia virus (Mo-MuLV) -infected 
cells in living oocytes of the African clawed frog Xenopus laevis. 
Detection of reverse transcriptase was attempted by two means: 
enzymatically, by measuring the polymerase activity in a poly(A). 
aligo(dT) template.primer system, or by immunoprecipitation with 
an antiserum directed against reverse transcriptase, followed by 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
MATERIALS AND METHODS 
Materials. L-( S)methionine (spec. act. 800-1200 Ci/mmol), 
1Д (U- C)protein hydrolysate (spec. act. 54 mCi/matom carbon) and 
(methyl- H)thymidine 5'-triphosphate (40-60 Ci/mmol) were ob­
tained from Radiochemical Centre, Amersham, England. Oligo(dT)-
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cellulose (Τ-2 and Т-З), poly[A) and oligofdT) . were from 
Collaborative Research Inc., Waltham, Mass.. Heparin (sodium salt, 
medical grade; 160 U/mg) was purchased from Organon, Oss, The 
Netherlands, Proteinase К was from Boehringer, Mannheim, West-
Germany, Protein A-Sepharose CL-4B was from Pharmacia, Uppsala, 
Sweden. 
Antisera. The rabbit antiserum directed against Mo-MuLV reverse 
transcriptase (anti-RT) was a generous gift of Drs O.IM. Witte 
and D. Baltimore. According to their findings this antiserum con­
tained contaminating anti-p15 activity. Rabbit antisera against 
disrupted R-MuLV and (R-MuL\/)p15E,p12E were prepared and described 
by Van Zaane et al. (45). 
Cells and virus. In this study the clonal NIH_3T3 line NCL5611P3 
(a gift of Dr J.R. Stephenson) infected with Mo-MuLV was used. 
Cells were grown in monolayer cultures in Dulbecco's modified 
Eagle's medium with Earle's salts supplemented with 10 % newborn 
calf serum. Mo-MuLV was isolated from concentrated medium of clone 
1A cells (a clonal Mo-MuLV -infected NIH-3T3 line; 10) by the 
method of Duesberg and Robinson (9). 
Cell labeling and lysis procedure. Cells were labeled as described 
earlier (44,45). In short, cells were grown to about Θ0 ^  conflu-
ency, starved for 10 min in labelmedium (see below) without radio­
active amino acids and labeled in 0.0Θ ml/cn¿ Hanks' balanced salt 
solution supplemented with 10 % dialyzed calf serum, vitamins, 
essential amino acids (except for the radioactive ones) and 50 
/uCi/ml L-( S)methionine or 25 /uCi/ml (U- C)protein hydrolysate 
(labelmedium). After 15 min the labelmedium was removed and replaced 
by normal medium. Now the cells were either lysed or radioactivity 
was chased for В h. Lysis was performed by the addition to cells 
and medium of 1/4 volume of fivefold concentrated immunoprecipi-
tation buffer (see below). The lysate was forced 10 times through 
a 21 gauge needle and cleared by centrifugation at 220,000 χ g for 
15 min. Lysates were stored at -20 С when used within three months 
or at —Θ0 С for longer periods. 
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Isolation and fractionatian of mRNA. All solutions were treated 
with 0.1 % diethyl pyrocarbonate and (except for the sucrose solu­
tions) autoclaved; glassware was heat-sterilized. Indicated pH 
values are at 25 С 
NIH-3T3(NCL5611P3)/MCI-MULV cells were grown to BO - 90 ^  confluency, 
removed from the culture flasks by trypsinization and washed 
twice with isotonic buffer (10 nM Tris-pH 7.2, 146 nM NaCl). RNA 
was isolated from these cells by the magnesium-precipitatiün Tiethod 
of Palmiter (29) at 0 - 2 C. Cells were quickly swollen in 
hypotonic buffer (25 mW Tris-pH 6.9, 25 mM NaCl, 5 nM MgCl ) and 
then lysed by forcing them through a 21 gauge needle in 9 ml lysis 
buffer (hypotonic buffer containing 2 "/ί Triton X-100 and 1 mg/ml 
heparin) per gram of unswollen cells. After 10 min on ice the ly-
sate was centrifuged for 10 min at 12,000 χ g. To the supernatant 
one volume of precipitation buffer (four volumes of lysis buffer 
plus one volume of 1 M MgCl„) was added and the RNA was let to 
precipitate for one hour on ice. The precipitate was collected by 
centrifugation in 30 ml siliconized glass tubes through a layer of 
5 ml of 0.2 M sucrose in hypotonic buffer for 30 min at 20,000 χ g. 
The pelleted RNA was dissolved in 10 m№ Tris-pH 6.9, 20 mM NaCl, 
10 mM EDTA and 0.5 ^ SDS to a concentration of 1 - 2 mg/ml and 
treated with preincubated (1 h at 37 C, 1 mg/ml in 10 mM Tris-pH 
6.9, 20 mM NaCl) proteinase К ( 100 /ug/ml) for 15 min at 37 aC. 
The solution was then heated for 2 min at 100 C, chilled, brought 
to 0.5 M NaCl final concentration, and applied on an oligo(dT)-
cellulose (Т-2) column (з). The column was washed with 10 mM Tris-
pH 7.4, 0.5 M NaCl, 1 mM EDTA, 0.5 % SDS until A , was below 0.02, 
then washed with 10 mM Tris-pH 7.4, 0.25 M NaCl, ImM EDTA, and the 
poly(A)-tagged RNA was eluted with 10 mM Tris-pH 7.4. This procedure 
was performed at 25 C. The mRNA was precipitated overnight at -20 
С in siliconized glass tubes by the addition of 1/10 volume of 2 
M NaAc—pH 5.2 and 2 volumes of ethanol. The precipitate was col­
lected by centrifugation for 30 min at 10,000 χ g and -20 С, the 
pellet was dried in vacuo, and the RNA was dissolved, heated and 
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cycled απ oligo(dT)-cellulose for a second time. The thus selected 
mRNA was alcohol-precipitated and stored at -20 C. Messenger RNA 
from NIH-3T3(NCL5611P3) cells infected with cloned Rauscher-MuLV 
wild type virus (wt-248) or a mutant of R-WuLV with temperature-
sensitive reverse transcriptase (ts-2S] (39,42) was isolated in the 
same manner and given to us by Dr W.J.M, van de Ven from our 
laboratory. The viruses wt-248 and ts-29 were originally obtained 
from Dr J.R. Stephenson. 
The mRNA (50 - 150 /ug) was fractionated according to size by 
centrifugation for 6.5 h at 40,000 rpn and 20 0C in an IEC SB-263 
rotor on a 15 - 37.5 % (w/w) isokinetic sucrose gradient (43] in 
low salt buffer (20 mM NaAc-pH 5.2, 2mM EDTA, 0.2 "f, SDS). Prior to 
centrifugation the RNA was denatured in low salt buffer containing 
85 ii formanide by incubation for 5 min at 37 С and 30 sec at 68 0C. 
Fractions (0.5 ml) from the gradient were collected and alcohol-
precipitated after the addition of 10 /Ug rat lens 2BS ribosomal 
RNA as a carrier. 
Translation of mRNA in Xenopus oocytes. Messenger RNA was trans­
lated in Xenopus laevis oocytes as described by Asselbergs et al. 
(i). Unfractionated mRNA was dissolved to 1 mg/ml, rrfìNAs from 
gradient fractions were dissolved in 10 - 20 /ul distilled water 
and 40 nl of the solution was injected per oocyte. When RT had to 
be detected by its enzymatic activity oocytes were incubated for 
16, 40 or 64 h at 19 DC in modified Berth's medium. Lysis of these 
oocytes is described below. For immunoprecipitation studies 20 
oocytes per fraction were injected and labeled for 20 h at 19 С 
in 100 /ul modified Berth's medium containing 1 mCi/ml L-( S) 
-methionine. These oocytes were lysed in 1 ml of immunoprecipitation 
buffer (see below), using a small Potter-Elvehjem -type homogenizer. 
The lysates were cleared by centrifugation for 15 min at 220,000 
χ g and carefully aspirating the lipid containing upper layer, and 
they were stored at -20 C. 
Enzymatic detection of reverse transcriptase in oocyte lysates. 
Reverse transcriptase activity could not be measured directly in 
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the lysates of oocytes, since under these conditions activity was 
completely blocked. After a number of pilct experiments we decided 
to the following procedure that was based on the method developed 
by Gerwin and Mustien (14). Indicated pH values are at 25 C. 
After incubation the injected oocytes were washed with fresh Barth's 
medium, succed dry, and per 50 oocytes 100 /Ul of buffer A (50 mM 
Tris-pH 7.4, 5 mM MgAc , 0.1 mW, EDTA, 0.1 VI 2-mercaptoethanol, 0.2 
% NP-40 and 25 % (w/v) glycerol; rcf. 4?) made to 0.5 M KCl, and 
10 /ul NP-40 and 10 ,ul of 10 "/o (w/v) sodium deoxycholate was added. 
Lysates were prepared by 20 strokes in a small Potter—Elvehjem 
homogenizer. The lysate was diluted to 1 ml with buffer A (50 mM 
KCl final concentration) and stored at -20 С About 25 mg of dry 
oliga(dT)-cellulose (Т-З) per ml of lysate to apply was swollen in 
0. 1 M NaOH, washed with 0. 1 M NaOH and equilibrated with buffer A. 
The lysate was added and the reverse transcriptase was let to bind 
to the aligo(dT)-cellulose, while shaking every 5 nin. This and the 
following steps were carried out at 0 - 2 С in 1.5 ml conical 
polypropylene centrifuge tubes. After one hour the tubes were cen­
trifugea for 1 min at 12,000 χ g, the supernatant was removed, and 
the oligD(dT)-cellullose was washed four times for 2 min with 0.5 
ml of buffer A, and four tines with 0,5 ml of buffer A containing 
100 mM KCl. Reverse transcriptase was eluted by washing the oligo 
(dT)-cellulose eight times for 2 min with 0.2 ml of buffer A .con­
taining 600 mM KCl. 
From each fraction 20 /Ul was tested for reverse transcriptase 
activity. The assay system (70 /ul) contained (in addition to the 
concentrations contributed by the samples): 45 mM Tris—pH 8.2, 
0.25 mM МпС12, 2 mM dithioerythritol, 0.3 A ,^ml of poly(A), 0.1 
A -.^ml of oligo(dT) and 5 ,uCi (5 »uM) of (methyl- H)thymidine 
5'—triphosphate. The final concentration of KCl was corrected to 
170 mM when necessary. Incubation was at 37 С After one hour 
0.5 ml of 0. 1 M Na 4P 20 7, 40 ,ug of yeast RNA, and 0.5 ml of 20
 0/. 
trichloric acetic acid was added to precipitate the multimeric 
nucleic acids. Precipitates were collected on nitrocellulose 
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filters and radioactivity was counted in a liquid scintillation 
counter. Counting efficiency was about 20 0/>. 
Immunoprecipitation and Polyacrylamide деі electrophoresis. Immuno— 
precipitation of radioactive polypeptides from lysates of nouse 
cells and Xenopus oocytes was performed as described by Van Zaane 
et al. (as) in about G.B ml of 10 mM sodium phosphate-pH 7.2, 0.9 ^ 
NaCl, 1 % Triton X-100, 0.5 І sodium deoxycholate and 0.1 ^ SDS. 
5 
About 1-2.5 χ 10 TCA-precipitable cpm of cellular lysates and 
about 1—2.5 χ 10 cpm of oocyte lysates were taken for each pre­
cipitation. One /ul of antiserum was added, incubation was for 16 
h (overnight) at 0 C, 50 <ul of a 10 ^  (v/v) suspension of Protein 
A-Sepharose CL-4B was added and the mixture was shaken for 30 min 
at room temperature. The immunoprecipitates were collected by cen-
trifugation through a layer of 0.2 ml of 10 % (w/v) sucrose in 
immunoprecipitation buffer for 5 min at 12,000 χ g and were washed 
three times with immunoprecipitation buffer. The immunoprecipitates 
were dissolved by heating them for 5 min at 95 С in 20 /ul of 62.5 
mM Tris-pH 6.8, 2 'jt SDS. 5% 2-mercaptoethanol, 6 M urea, 10 % gly­
cerol and 0.1 % bromophenol blue, and were applied on the gel. 
Sodium dodecyl sulfate—Polyacrylamide gel electrophoresis was per­
formed according to Laemmli (20) using 0.75 mm thin 7 — IB % 
Polyacrylamide gradient slab gels. Radioactivity was visualized 
after treatment of the gels with dimethylsulphoxide/2,5-diphenyl-
oxazole (DMSO/PPO) (6) by scintillation autoradiography with pre-
flashed (21) Kodak XR films. 
RESULTS 
Enzymatical detection of reverse transcriptase activity in oocytes 
injected with mRNA from infected cells. 
When we first started these investigations little was known about 
the biosynthesis of reverse transcriptase. Antisera directed against 
this viral enzyme were not available to us. We decided to use the 
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RNA-dependent DNA polymerase activity of reverse transcriptase for 
its detection. First, we optimized the assay that was routinely 
used in our laboratory for the detection of retrovirus. In the fi­
nal form of the assay (see Methods section) an incorporation of BOO 
pmol (5 χ 10 cpm) thymidine S'-monophosphate with 1 #ug of virus 
(MO-MULV) was obtained. To estimate whether we would have any 
chance to detect reverse transcriptase activity in this manner in 
lysates of oocytes injected with mRNA from MuLV—infected cells, we 
made the calculations as indicated in table 1. 
On the basis of this tentative calculation we decided to attempt in 
this way to determine the size of pol-mRNA. Since poly(A).oligo(dT) 
is not a template-primer combination that is specific for the viral 
RNA-dependent DNA-polymerase (although it is the combination that 
gives the highest TMP incorporation with reverse transcriptase in 
the exogenous RT assay (25]), we planned to control virus-specifi­
city of detected polymerase activity by using different combinations 
of synthetic templates and primers (13,36), and by testing the 
thermosensitivity of the polymerase activity found in oocytes that 
were injected with mRNA from cells infected with a thermosensitive 
mutant of R-MuLV, ts-29. 
Reverse transcriptase of this mutant has been shown to be more 
thermolabile than reverse transcriptase of the corresponding wild-
type parent (42). 
In pilot experiments it appeared that reverse transcriptase activity 
could not be measured directly in the oocyte lysate. Therefore, 
we adapted a simple one step purification procedure (14) to our 
conditions. Reverse transcriptase present in oocyte lysates was 
bound to oligo(dT)-cellulose, поп-bound proteins (and nucleic 
acids) were removed by extensive washing and the enzyme was eluted 
with a high salt buffer. A phosphate buffer could not be used for 
this purpose, since minimal concentrations ( 1 — 5 mM) of phosphate 
already inhibited reverse transcriptase activity completely. This 
effect, that was confirmed later in the literature (25), was not 
2+ 
due to complexation of divalent cations (Mn ) by the phosphate 
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Table 1. Feasibility of enzymatic detection of newly synthesized 
MuLV reverse transcriptase in oocytes. 
. protein synthesis in oocytes : 19-25 ng.h- /oocyte (θ) 
. weight °f¡ of newly synthesized 
proteins in oocytes, injected with 
40 ng/oocyte of mRNA from MuLV-
infected cells, that is virus-
related : 0.1 % (a) 
. weight % of viral proteins that is 
RT : 1 ^ (40,41) 
. amount of RT synthesized in oocytes 
injected with mflNA from MuLV-
infected cells : 0.2 pg.h /oocyte 
. ('Tl)TMP incorporation in the assay 
when a virus sample was tested : 5 cpm.pg (b) 
. (ΤΗ)TMP incorporation in the assay 
expected when pure RT molecules 
_1 
would be tested : 500 cpm.pg 
. reverse transcriptase activity 
expected in 100 oocytes injected 
with 40 ng/oocyte of mRNA from MuLV-
infected cells and incubated for 24 
h : 2.4 χ 10 cpm 
a) Calculated from immunoprecipitation results using anti-MuLV 
serum. 
b) See fore—going text; weight of virus based on protein amount. 
эв 
Figure 1. Characterization of 
the anti-RT serun. 
NIH-3T3(NCL56l1P3]/Mo-MuLV 
cells were pulse-labeled for 
15 min with (U- 1^) protein 
hydrolysate (lanes a,b) and 
radioactivity was chased for 
В h (lane с). Lysates were 
prepared and immunoprecipita-
tion was carried out with anti-
p15E,p12E (lane a) and anti-
RT (lanes b,c). Precipitates 
were analyzed by SDS-PAGE 
followed by scintillation 
autoradiography. Lane m 
contains 'Qc—labeled molecular 
weight marker proteins. Marker 
proteins were: cytochrome С 
(12,500), ct-crystallin (20,000), 
ovalbumin (45,0G0), bovine 
serum albumin (68,000), Phos­
phorylase a (95,000), and 3-
galactosidase (116,000) 
Figure 2. (page 99) 
RT-positive translation products made in oocytes on mRNAs from 
Mo-MuLV -infected cells. 
Messenger RNA from NIH_3T3(NCL5611P3)/MO-MULV cells was isolated 
(100 /ug) and size-fractionated on an isokinetic sucrose gradient. 
Samples of each fraction were injected into 20 oocytes of Xenopus 
laevis. The oocytes were labeled for 20 h at 19 0C with |_-( 3bs J 
methionine in modified Barth's medium, lysates were prepared and 
immunoprecipitation was carried out with anti-RT. Precipitates 
were analyzed by SDS-PAGE followed by scintillation autoradio­
graphy. Positions of IBS and 2BS nbosomal RNA on parallel gradients 
are indicated by big arrows. Small arrows indicate calculated S-
values of RNA. Lanes ρ and с contain polypeptides that were preci­
pitated from pulse and chase lysates of L-( S)methionine-labeled 
NII-l-3T3(NCL5611P3)/Mo-MuLV cells. As a control, precipitates from 
lysates of oocytes injected with water are shown in lane "HgO". 
Lane m contains ^C-labeled marker proteins described in the 
legend to Fig. 1. 
m a b с 
116 — 
95 — 
6 8 — 
~ 1 8 0 
^1140 130 
Î I 1 1 0 100 
- 82 
— 65 
• R I ( 75 ) 
45 — 
20 — 
12 5— 
~ 15 
288 18S 
35S I 22S I I f S ,oS 
тНзО » f » f * » P C 
116— 
9 5 - . 
68— 
45-« 
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Figure 2. RT-positiue translation products made in oocytes on mRNAs from 
Mu-MuLV -infected cells. (Legend on page 98). 
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ions since it could not be overcame by the addition of extra MnCl 
(our own results and ref. 25). Instead of phosphate we used KCl 
(600 mVi) to elute reverse transcriptase from oligo(dT)-cellulose. 
In the pilot experiments 90 °/o of the reverse transcriptase activity 
that we had added to oocyte lysates was recovered in the first four 
eluted fractions (total volume: 0.8 rrl). We injected (unfractio-
nated) mRNA from cells infected with wild-type R-MuLV (wt-248) and 
from cells infected with ts-29 into oocytes. Oocytes (80 - 120 in 
each experiment) were incubated for 16 h, 40 h or 64 h. By immuno— 
precipitation we found that viral аад and env proteins were synthe­
sized (not shown). We were not able to detect any reverse transcrip­
tase activity in the lysates of these oocytes, however. Since only 
relatively small samples of the high salt eluate from the oligo(dT)-
cellulose column could be used in the assay, we attempted to con­
centrate the eluate by micro-ultrafiltration. These efforts failed, 
because, as we found in control experiments, reverse transcriptase 
activity was lost during this procedure. At this stage of our study 
an antiserum directed against Mo-MuLV reverse transcriptase became 
available to us (courtesy of Drs O.N. Witte and D. Baltimore). 
Characterization of the anti-RT serum. 
14 
Mo-MuLV -infected cC's were labeled with C-labeled amino acids. 
On the lysates immunoprecipitations with anti-RT were performed. 
The precipitates were analyzed by Polyacrylamide gel electrophoresis 
in the presence of sodium dodecyl sulfate (SDS-PAGE). A S shown in 
Fig. 1, lane b, after a 15 min pulse several polypeptides were 
precipitated. A double band with apparent molecular weight of 
180,000 and bands at 140,000, 130,000, 110,000, 100,000, 82,000, 
65,000, 30,000 and 15,000 are seen on the gel. The weak band at 
15,000 is the gag protein ρ 15 to which the antiserum is also di­
rected (O.N. Witte, personal communication). The nature of the band 
at 30,000 is unknown; it is nut the gag protein рЗО, since it is 
absent in the chase (Fig, 1, lane cj, whereas рЗО is present in 
much higher amounts in the chase than in the pulse (45). The band 
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at 65,000 is the дад precursor polyprotein PrC5 , precipitated 
by the contaminating anti—ρ 15 antibodies m the antiserum. The band 
at 82,000 is presumably the envelope precursor polyprotein gPr82 
(corr-pare Fig. 1, lanes a and b) for reasons given m the next section. 
The higher molecular weight bands represent the precursor poly­
protein to reverse transcriptase, Pr180 , and its intermediary 
processing products (cf. réf. 16,18). After a chase of В h, the 
mature reverse transcriptase molecule with apparent molecular 
weight of 75,000 and the gag protein ρ 15 are precipitated (Fig, 1, 
lane c). 
Radioimmunoprecipitation of RT-positive translation products made 
in oocytes on size-Fractionated mRNAs from MuLV-infected cells. 
Messenger RNA was isolated from Mo-MuLV -infected NIH-3T3 cells by 
the magnesium—precipitation method of Palmiter (29), followed by 
selection on oligo(dT)-cellulose (з). In our hands this method was 
superior both in rapidity, yield and in translation efficiency of 
the isolated messenger RNA, conpared to other methods, which in­
cluded polyribosome isolation and/or phenol-extraction steps, used 
in our laboratory earlier (15,46]. Messenger RNA was size-fractiona-
ted on isokinetic sucrose gradients and samples from each fraction 
were injected into Xenopus oocytes. Oocytes were labeled with 
тс 
L—( S)methionine. Immunoprecipitations were perfomed on the 
lysates. The results obtained by immunoprecipitation with antiserum 
directed against most of the MuLV proteins (anti-MuLV) are shown 
m chapter 5 (Fig. 1A) and chapter 6 (Fig. З В ) . These results are 
similar to those obtained earlier (46, chapter 3): on nflNA of 35S 
size gag proteins f e.g. Pr65 and p30] are synthesized and 22S 
mRNA directs the synthesis of the enν proteins gPrB2 , gp70, 
p15E and p12E. Immunoprecipitations with anti-RT on the same 
lysates are shown here, Fig. ¿. S-values of the injected n-RNAs are 
indicated in the figure. As a reference, anti-RT imnunoprecipitates 
35 
from Mo-MuLV -infected cells, pulse-labeled for 15 m m with L-( S) 
-•nethionine (lane p) and chased for 8 h (lane c) , are shown. Note, 
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that ρ 15 is missing in these precipitates, because ρ 15 lacks 
methionine (45). 
It can be seen that anti-RT precipitated polypeptides from lysates 
of oocytes injected with nRNAs of 15S, 22S and 35S size. The 
200,000 molecular weignt protein precipitated frorr the translation 
products of 15S mRNA was not further identified. A polypeptide of 
similar size was precipitated by anti-MuLV and anti-MCSA (Moloney 
cell surface antigen) (chapter 6, Fig. 3 ) . As calculated in chapter 
6, this 200,000 molecular weight protein is not a primary transla­
tion product of 15S mRNA, since mRNA of that size does not have 
sufficient coding capacity for such a large protein. The 22S pro­
ducts that were precipitated by anti-RT seem to represent the viral 
envelope proteins p15E and p12E. The results presented in Fig. 3 
confirm this conclusion. It appeared that the 22S products precipi­
tated by anti—RT (Fig. 3, lane b) comigrare with the products 
precipitatale with anti-p15E,p12E (lane c) and that their precipi­
tation could be inhibited by the addition of Mo-MuLV (lane a). This 
strongly indicates that the anti-RT serum contained contaminating 
antibodies not only directed against ρ 15 but also against p15E, 
p12E. These latter antibodies presumably caused the precipitation 
of the 82,000 molecular weight protein by anti-RT from lysates of 
pulse-labeled cells (Fig. 1, lane b). From the lysates of oocytes 
injected with 35S mRNA a polypeptide of 65,000 apparent molecular 
weight, Pr65 , and the mature reverse transcriptase, P75, was 
precipitated by anti-RT. Therefore, it was concluded that the most 
characteristic component of RNA tumor viruses, the RNA—dependent 
DNA polymerase, is synthesized, at least in MuLV-infected cells, 
by genome-size messenger RNA. 
DISCUSSION 
Xenopus oocytes are well suited ^or translation studies. Messenger 
RNAs are remarkably stable in this systen and, in contrast to cell-
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Figure 3. Anti-p 15E,ρ12E activity in the 
anti-RT serum. 
Messenger RNA of 22S size from NIH-3T3 
(NCL5611P3)/MD-MULV cells was injected into 
oocytes. Oocytes were labeled for 20 h with 
L—(35s)methionine, lysates were prepared and 
immunoprecipitations were carried out. 
Precipitates were analyzed by SDS-PAGE followed 
by scintillation autoradiography, (a) Immuno— 
precipitation with anti-RT in the presence of 
100/ug of added Mo-IVIuLV(clone 1A); (b) anti-
RT; (c) anti-p 15E,ρ 12E. 
a b 
, ~-p30 
_p15E 
- — p12E 
m a D c σ
 Figure 4. Translation 
kinetics of viral poly­
peptides in oocytes. 
Unfractionated mRNA from 
NIH-3T3(NCL5611P3)/MO-MULV 
cells (lanes a-c) and 
116— purified poly(A)+ 35S viral 
95— __gPr82env R N A from clone 1A Mo-MuLV 
6 3 _ , - «·>•· »• ^gp70 (lane d) were injected 
**** "** ""Pres^3^ into oocytes. Oocytes were 
labeled for 16, 40 or 64 
h (indicated at the bottom 
•^
5
"* of each lane] with L-(35S) 
methionine, lysates were 
prepared and immunoprecipi— 
tation was carried out with 
anti-R-MuLV. Precipitates 
^pl5E were analyzed by SDS-PAGE 
2°-» - ^ ^ ^ ^ —p1¿E followed by scintillation 
autoradiography. Lane m 
1 2 5
— contains ^^C-labeled 
h 16 40 64 16 marker proteins (cf. Fig. 
1)· 
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free systems like those of rabbit reticulocytes or wheat germ, 
oocytes are not only able to translate exogenous mRNAs into their 
primary translation products, but these products are also processed 
to the final form in which the proteins are present in vivo. Post-
synthetic modifications like proteolytic processing of pre- and 
polyproteins, glycosylation, phosphorylation, and N—terminal 
acetylation are faithfully carried out by the oocyte (for a review 
on this subject, see F.A.M. Asselbergs, thesis, Nijmegen, 1979), 
The oocyte seems to be the system of choice if one wishes to detect 
a translation product by its enzymatic activity, since a non-proces-
sed precursor protein may well be enzymatically inactive. 
The purpose of the experiments described in this chapter was to 
establish the size of the pol-mRIMA in a similar manner as the 
sizes of the gaq-nfìNA and env-mRNA were established previously (46; 
chapter 3). At the time we started these investigations the synthe-
tic pathway of reverse transcriptase was not known (46; chapter 3] 
but soon it was shown that genome-size viral RNA directs the synthe-
sis of minor amounts of polyproteins reactive both with antisera 
directed against gag proteins and with anti-reverse transcriptase 
antisera (23,27,30,33,52). Similar polyproteins were found in in-
fected cells (16,18,53). These results suggest but do not rigorously 
prove that gag-pol polyproteins synthesized on genome-size virus-
specific mRNA would also be the intracellular precursors to reverse 
transcriptase. A direct translation of intracellular virus-specific 
mRNAs would complete the evidence. For this purpose we developed 
a sensitive enzymatic assay to detect reverse transcriptase in 
oocyte lysates, since no antiserum to this viral protein was avail-
able to us at the time. Despite of all our efforts, however, we did 
not find any polymerase activity in oocytes injected with unfractio-
nated mRNAs from infected cells. The mRNA preparation was active in 
translation, for gag and env (poly-)proteins were synthesized (not 
shown). 
Variations of the incubation time of the injected oocytes and ef-
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forts to concentrate the 600 mM KCl eluate from the oligo(dT)-
cellulose column (to enlarge the fraction of the total potential 
HT activity recovered from the oocytes that could be tested in the 
enzyme assay) were unsuccessful. A number of explanations for the 
apparent lack of reverse transcriptase activity in this system are 
available. Failure of the oocyte system to synthesize reverse 
transcriptase or to process the primary (inactive) translation 
product, or to produce the enzyme in sufficient quantities for 
detection (due to breakdown of enzyme and/or mRNA) can be excluded, 
since we detected mature reverse transcriptase in oocyte lysates 
by immunoprecipitation (this method having about the same lower 
detection limit as the enzymatic assay). 
Alternatively, one could imagine that mature reverse transcriptase 
molecules were made in oocytes, but in an inactive form. A third 
possibility is the inhibition of pol-mRNA translation by competition 
with the large excess of other mRNAs in the mixture containing all 
mRNA size-classes. Exogenous mRNAs in oocytes have to compete with 
each other and with the endogenous mRNAs for the translation ma­
chinery (2,22). The injected unfractionated mRNA samples contained 
more mRNA than the fractionated mRNA samples (see Methods section). 
Positive (5) and negative (З) reports have been published on the 
preference of the oocyte system for smaller mRNAs. From immuno­
precipitation studies (see below) we know that reverse transcriptase 
is made on a large messenger. Supporting the hypothesis of compe­
titive inhibition of pol—mRNA translation when unfractionated mRNA 
is injected into the oocyte, is our finding (Fig. 4) that the gag 
proteins were synthesized much slower when unfractionated mRNA was 
injected than when 35S mRNA was injected. In the latter case p30 
is formed within 20 h (chapter 5, Fig. 1A and chapter 6, Fig. ЗВ), 
whereas in the former case p30 only emerged after more than two 
days of incubation (this chapter, Fig. 4, a-c). When highly puri­
fied 35S poly(A) viral RNA was injected, p30 was formed even more 
quickly than with 35S infected cell mRNA (Fig. 4.d). 
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The anti-RT serum WR received in a later stage of our study was 
not only directed against reverse transcriptase, but also against 
the gag protein ρ 15, Therefore, it precipitated Pr65 and ρ 15 
(Fig. 1]. Apparently, anti-RT was also directed against p15E,p12E. 
In oocytes injected with 22S rrRNA from KuLV-infected cells proteins 
were made that were precipitable with anti-RT and comigrated on the 
gel with pISE and p12E (Figs 2 and 3), Precipitation was inhibited 
by the addition of an excess cf unlabeled VuLV (Fig. 3]. From ly-
sates of pulse-labeled MuLV-infected cells a protein of 82,00G 
apparent molecular weight was precipitated with anti-RT that comi­
grated on the gel with gPrB2 ' (Fig. 1) and probably was identical 
to the envelope precursor polyprotein. We can not firmly explain, 
why anti-RT did not precipitate p15C and p12E from infected cells 
after a chase ana gPr82 fron lysates of injected oocytes. 
With anti-MuLV both gFr82 and p15Elp12E can be precipitated 
from infected cells as well as from oocytes injected with virus-
specific mRNAs (chapter 6, Fig. 1,2,4В). We can only interprete 
this inconsistency by assuming an environmental influence (mouse 
cell or frog oocyte) on the kind of enν antigenic determinants 
that are exposed. 
The experiments illustratec in Fig. 2 clearly indicate the size 
of pol-mRNA: the imnunoprecipitation results show that reverse 
transcriptase is made on genome-size (35S) rnRNA, We were not able 
to strengthen this conclusion by tryptic peptide mapping, since 
the amount of precipitated reverse transcriptase was too low. 
Higher molecular weight precursor proteins to RT were not found 
in oocytes (Fig. 2). Presumably they are processed quickly to the 
mature enzyme in the oocyte. In contrast, only higher molecular 
weight polyproteins were found in translations of virion RNA in 
vitro by Murphy et al. (2θ) who recently translated rnRNA from 
MuLV—infected cells in a mouse cell—free system. In this system, 
gag-pol 
35S intracellular RNA directed the synthesis of PrISO 
3y a much broader size-class of nRNAs Pr65 was formed. A simi­
lar phenomenon is observed in our systerr (Fig. 2 ) . Murphy et al. 
1D7 
(28) interpreted this as evidence that Pr1B0 9 a g~ P O and Pr65 9 a g 
are synthesized on separate mRNAs. Since maximal synthesis of both 
Pr1809 and Pr65 seems to be directed by -che same mRNA 
fraction this interpretation is rather speculative. In fact, the 
best indication that separate дад- and pol-mRNAs are involved is 
given by Philipson et al. (ЗЗ) who showea that addition of yeast 
suppressor tRNAs to a cell-free translation of MuLV virion RNA 
enhanced the synthesis of the qag-pol polyprotein at the expense 
of Pr72 g a g I but did noz influence the synthesis of Ргб5
3 а 9
. The 
exact mechanism by which uhe reverse transcriptase precursor pro­
tein is generated in vivo needs to be clarified further. 
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A 14S MESSENGER RNA DIRECTING THE SYNTHESIS OF PRESUMABLY HOST-
CODED PROTEINS PRESENT IN MURINE LEUKEMIA VIRUSES. 
ABSTRACT 
In chapter 3 a protein is described that was immunoprecipitated 
by an anti-MuLV serum from the Xenopus oocyte translation products 
of 14S messenger RNA isolated from Rauscher murine leukemia virus 
(R-MULV) infected BALB/c cells. We extended this study by transla­
ting messenger RNAs from a different cell type (NIH-ЗТЗ) infected 
with a different virus (МоІопеу-MuLV) in the oocyte system. Similar 
results were obtained as before: a protein with an apparent molecu­
lar weight of 37,000 was precipitated by the anti-MuLV serum from 
lysates of oocytes injected with 14S mRNA. The 37,000 product was 
not precipitated by any mono-specific antiserum. 
The same protein was synthesized in oocytes injected with 14S nflNA 
from uninfected NIH-3T3 cells. Therefore, the protein is presumably 
coded for by the host genome. Attempts to confirm this conclusion 
by hybrid-arrested translation with virus-specific DNA unfortunate­
ly failed, apparently due to the fragility of the mRNAs under hybri­
dization conditions. 
Other 14S mRNA translation products could be precipitated with an 
antiserum directed against Moloney-MuLV and an antiserum against 
Moloney cell surface antigen ( M C S A ) . The nature of these 14S nflNA 
translation products that were shown to be present in virions will 
be discussed. 
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INTRODUCTION 
In chapter 3 a model was proposed for the gene expression of murine 
leukemia viruses that consists of two separate messenger RNAs for 
the synthesis of gag and env proteins (35S mRNA and 22S mRNA, 
respectively). Moreover, we also considered the possibility of the 
existence of separate mRNAs for the synthesis of reverse transcrip­
tase and of a putative one protein (that would cause cell transfor­
mation and oncogenesis]. At the time of that study (1976) the 
existence of a separate one (or luk) gene of murine leukemia viruses 
(in analogy to the presence of a separate sre gene in avian sarcoma 
viruses) was a speculation on which much research in this field was 
focussed. Although the absence of a separate one gene in these 
viruses is not yet rigorously established, most experimental evi­
dence (discussed in chapter 2 of this thesis) suggests a mechanism 
for viral leukemogenesis that is no longer based on this concept. 
Pol— and one—nRNAs of different size classes were considered by 
us at the time because their existence would generalize the data 
obtained for the expression of the gag and enν genes and because 
of the following suggestive indications. From the translation pro­
ducts of 25-2BS mRNA a protein with apparent molecular weight of 
85,000-90,000 and in the 14S region a 40,000-45,000 molecular 
weight protein was precipitated. Moreover, by molecular hybridi­
zation of size-fractionated JLS-Vg/R-MuLV mRNA with copy-DNA 
prepared against R-MuLV viral RNA a peak at 14S was found in the 
hybridization profile. We could not detect a MuLV-specific mRNA 
of 25S size by molecular hybridization. A 14S mRNA was not detected 
by other investigators who have published on this subject (11,13), 
but its existence was reported for feline leukemia virus (θ) and 
mouse mammary tumor virus (23,27) infected cells. In both cases 
weak (θ) or strong (23) evidence indicated that the 14S mRNA was 
a specific degradation product of 35S RNA encompassing the 3' end 
of the genome. If a 14S virus-specific mRNA also would exist in 
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MuLV-infected cells, it certainly would not share a common 5' 
terminus with 35S and 22S virus-specific mRNAs (13,20,24). 
In order to assess whether or not the imnunoprecipitation of 
products of 25S and of 14S mRNA was restricted to a particular cell 
line or a single virus type, we isolated mRNA from Mn—VuLV -in-
fected NIH-3T3 cello that subsequently was size-fractionated on 
isokinetic sucrose gradients and translated in oocytes of Xenopus 
laevis. The 25S mRNA product was not found, but anti-MuLV precipi-
tated a 37,000 apparent molecular weight protein from the 14S rrflNA 
translation products. 
In the fore-going chapter it was shown that reverse transcriptase 
is not made on 25S mRNA but on genone-size mRNA. In this chapter 
the nature of the 14S mRNA product is further described. 
MATERIALS AND METHODS 
Materials. Radiochemicals and other materials used are described 
in the corresponding sections of chapters 4 and 6. 
Antisera. Rabbit antisera against disrupted R-MuLV, (R-MuLV)p30 
and (R-MuL\/)p15E,p1?E were prepared and described by Van Zaane et 
al. (34). Rabbit antisera against (R-MuLV)gp70 and (AKR)p10 were 
a gift of Dr J.N. Ihle, goat anti-(R-MuLV)p12 was a gift of Dr 
J.R. Stephenson, and goat anti-(R-MuL\/)p15 was a gift of Drs M. 
Strand and J.T. August. Goat anti-Mo-MuLV was obtained through the 
Office of Program Resources and Logistics of NCl/NIH, Bethesda, 
Md. (Dr J. Gruber). 
Cells and virus. NIH-3T3 cells (clone NCL5611P3) (32) were ob-
tained from Dr J.R. Stephenson and infected with Mo-MuLV (cf. 
chapter 6). A recloned NIH-3T3 line was obtained from Dr R.A. 
Weinberg. Uninfected and VIo-MuLV -infected JLS-V9 cells (37) 
were obtained from Dr E.M. FenyH. 
Cells were grown in monolayer cultures in Dulbecco's modified 
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Eagle's medium with Earle' s salts supplemented with IG "/a newborn 
calf serum. R-MuLV was isolated from the plasma of viremic BALB/c 
mice. Mo-MuLV, isolated from roller-bottle cultures of NIH-ЗТЗ/Мо-
MuLV (clone 1A) cells was a gift of Dr A.J.M. Berns. 
Isolation and fractionation of nRNA and translation in Xenopus 
oocytes. Messenger RNA was isolated from Mo-MuLV -infected and 
from uninfected cells, size-fractionated and translated in oocytes 
of Xenopus laevis as described in chapter 4. 
Immunoprecipitation and Polyacrylamide gel electrophoresis. See 
corresponding section of chapter 4. 
Hybrid arrested translation using in vitro synthesized copy-DNA. 
A single-stranded DNA-copy of Mo-MuLV vRNA was synthesized in an 
endogenous reverse transcription reaction with predigested calf 
thymus DNA (30] as a primer, 
A reaction mixture of 1 ml contained: 50 mM Tris-pH 8.3, 3 mM 
Mg(Ac) , 60 mM NaCl, 20 mM dithioerythritol, 0.04 mM (0.5 mCi] 
(methyl-TH)thymidine 5'-triphosphate, 1 mM each of dATP,dGTP and 
dCTP, 2 mg calf thymus DNA, 0.016 % Nonidet P-40, 75 ,ug actinomycin-
D and 1 mg virus. After incubation for 2.5 h at 37 C, EDTA was added 
to 10 mM, SDS to 0.5 'jt and NaOH to 0.3 M (final concentration). The 
mixture was incubated overnight at 37 С to degrade the RNA and was 
desalted on Sephadex G-50, using 10 mM Tris-pH 7.4, 1 mM EDTA 
(TE-buffer) as elution buffer. The DNA was phenol-extracted and 
alcohol-precipitated at neutral pH. 
The DNA (26 /ug) was self-annealed for 3 h at 68 С in 10 mM Tris-
/ 1 
pH 7.4, 1 M NaCl, 1 mM EDTA (c t = 2.75 Mol.sec.1~ ) and fractio­
nated on a hydroxyapatite column (Bio-Gel HTP, Bio-Rad Labs, 
Richmond, Cal.) (з). Of the single-stranded DNA fraction 10 iug 
was hybridized to 6 /ug of Mo-MuLV/ 35S viral RNA in 2 ml of 0.12 
M sodium phosphate - pH 7.2, 0.2 % SDS. The viral 35S RNA was a 
gift of Mr C.J.M. Saris. It was isolated from Moloney clone 1A 
virus (12) as a 60-70S RNA-complex, oligo(dT)-selected and size-
fractionated as described for cellular mRNA. 
Hybridization was at 68 С for 105 min (this was the time needed 
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to just reach the maximum level of hybridization, as determined by 
the S.-nuclease procedure (16)). The hybrids were isolated by 
hydroxyapatite chromatography, dialyzed against TE-buffer and 
alcohol-precipitated with E. coli tRNA as a carrier. The RNA was 
hydrolyzed by incubation for 2 h at 50 DC in 0.3 M NaOH in TE-
buffer and the DNA was alcohol-precipitated twice at neutral pH. 
Hybridization of an excess of cDNA to virus-specific mflNA was per­
formed as described by Hastie and Held (15). In 5 /ul reaction 
mixtures 0.5 or 0.05 /ug of cDNA was hybridized to 1/Ug of cellu­
lar (unfractionated) rrRNA in 20 mM Hepes-pH 7.3, 180 mM KCl for 30 
min at 65 С (с t = 0.625 or 0.0625 Mol.sec.I- , respectively). 
After quenching on ice samples were injected into oocytes. Controls 
consisted of mRNA alone subjected to the same procedure, mRNA.DNA 
mixtures heat—denatured for 30 sec at 100 С after hybridization, 
non-hybridized mRNA.cDNA mixtures and mRNA alone injected into 
oocytes directly. 
Hybrid-arrested translation using molecular cloned proviral DNA. 
pBR322 Plasmid with the proviral Mo-MuLV genome (large form; refs 
14,38) integrated at the Hind III site (36) was obtained from the 
group of Dr D. Baltimore at the 1Э79 Cold Spring Harbor RNA Tumor 
Virus Course by Mr H. van der Putten from our department. 
The recombinant-plasmid DNA was alkali-digested in 0.75 M NaOH, 
0.5 mM EDTA for 15 min at 100 C, and, after neutralizing the 
mixture with acetic acid, DNA was alcohol-precipitated. Three /ug 
of DNA was hybridized to 2 .ug of cellular NIH-3T3(NCL5611P3)/MO-
MuLV rtflNA according to the procedure of Peterson et al. (21) in ВО 
$ formamide, 15 mM Pipes-pH 6.4, 0.4 M NaCl and 2 mM EDTA. The 
mixture was heated for 30 sec at 6B С and then incubated for 2 
h at 48 C. After hybridization the mixture was quickly chilled 
in C0Vmethanol and diluted 10-fold with ice-water containing 4 
/ug of rat lens 28S rRNA. 
After heat-denaturing half of the diluted hybridization mixture for 
60 sec at 80 0C the nucleic acids of both fractions were alcohol-
precipitated at pH 5.2. 
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Each fraction was dissolved in 2 #ul of distilled water and samples 
were injected into oocytes. Controls consisted of mRNA alone sub­
jected to the same procedure, mRNA and mRNA.DNA mixtures kept at 
О С instead of being incubated at 48 С and mRNA that was injected 
into oocytes directly. 
RESULTS 
Translation of size-fractionated mRNAs from Mo-MuLV -infected and 
uninfected NIH-3T3 cells in Xenopus oocytes. 
Cellular messenger RNAs were isolated from Mo-MuLV -infected and 
from uninfected NIH-3T3(NCL5611P3) cells, size-fractionated on 
isokinetic sucrose gradients and samples of each fraction were 
injected into oocytes of the African clawed frog Xenopus laevis. 
As a control, H O was injected. After incubating the oocytes for 
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20 h in the presence of L-( S)methlonine the oocytes were lysed 
and the extracts were subjected to immunoprecipitation with anti-
R-MuLV followed by SDS-polyacrylamide gel electrophoresis (Figs 
1A, 1B; note, that Figure 1A is identical to Figure 3B in chapter 
6). S-values of the injected mRNAs are indicated at the top of 
the figures. The gel analysis of the immunoprecipitate formed 
by anti-R-MuLV with lysate of H„0-injected oocytes serves to 
indicate which protein bands were due to aspecific precipitation. 
Fig. 1A shows the antl-R-MuLV precipitates obtained from lysates 
of oocytes injected with mRNA from Mo-MuLV —infected cells; the 
immunoprecipitable products of mRNAs from uninfected cells are 
shown in Fig. 1B. The results presented in Fig. 1A are similar to 
those reported and discussed by us before (35; chapter 3), except 
that we were not able to precipitate a 85,000-90,000 molecular 
weight protein from the translation products of 25S mRNA. The gag 
(poly)proteins Pr65 and p30 were synthesized on genome-size 
(35S) mRNA. The lower molecular weight structural core proteins can 
not be seen, since ρ 15 and ρ 10 lack methionine and ρ 12 is not recog-
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Figure 1. (Ά + В] (page 121]. 
Virus-related translation products made in oocytes on mRNAs from 
Mo-MuLV -infected and uninfected cells. 
Messenger RNA from Mo-MuLV -infected and uninfected NIH—3T3 cells 
was isolated and size-fractionated on isokinetic sucrose gradients. 
Samples of each fraction were injected into 20 oocytes of Xenopus 
laevis. After labeling the oocytes for 20 h at 19 DC with L-[^bsJ 
methionine in modified Berth's medium, immunoprecipitation was 
carried out on the lysates with anti-R-MuLV. Precipitates were 
analyzed by SDS-PAGE followed by scintillation autoradiography. 
(A] Messenger RNA from Mo-MuLV -infected cells; (в] mRNA from 
uninfected cells. Positions of 185 and 28S ribosomal RNA on parallel 
gradients are indicated by big arrows. Small arrows indicate 
calculated S-values of RNA. 
Lanes ρ and с (в] contain polypeptides that were precipitated from 
pulse and chase lysates of L-f^^S]methionine labeled NIH—3T3 cells, 
in lane "fH-c" [A] precipitated polypeptides from combined pulse 
and chase lysates of NIH-3T3/Mo-MuL\/(clone 1A] cells are shown 
(cf. chapter 6]. As a control, precipitates from lysates of oocytes 
injected with water are shown in lanes "H2O". Lanes m contain 
I^C-labeled molecular weight markers. Marker proteins were: 
cytochrome с (12,500],α -crystallin (20,000] ovalbumin (45,000], 
bovine serum albumin (68,000], Phosphorylase a (95,000] andß -
galactosidase (116,000]. 
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Figure 1. [Л + B). Virus—related translation products 
made in oocytes on mRNAs from Mo-MuLV -infected and 
uninfected cells. (Legend on page 120). 
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nized by the antiserum used (34). The gag polyproteins gP80 , 
gP959 9, and gP859 9 are not found in oocytes after labeling 
periods longer than 1Q h (25,35; F.A.M. Asselbergs, thesis, 
Nijmegen, 1979). Presumably these products are synthesized on a 
relatively unstaole mRNA and have a rapid turnover. On 22S mRNA 
the env (poly-)proteins gPr82 , gp70, p15E, and p12E were made. 
In the 14S region a protein with an apparent molecular weight of 
1) 37,000, tp37 ', that was immunoprecipitable by anti-R-MuLV was 
synthesized. The molecular weight that we have calculated for this 
protein is slightly lower than we reported earlier for a similar 
protein synthesized on 14S mflNA from R-MuLV -infected JLS-\/9 cells 
(35; chapter Э), yet both proteins migrate to the same positions 
when run on parallel lanes in a SDS-polyacrylamide gel (not shown). 
When mRNAs from uninfected NIH-3T3 cells (or uninfected JLS-\/9 
cells; not shown) were translated in oocytes, only the 37,000 
molecular weight product of 14S mRNA was precipitable by anti-R— 
MuLV (Fig. IB). Therefore, tp37 is presumably a host-coded protein. 
Analysis of the 37,000 molecular weight product of 14S mRNA with 
mono—specific antisera. 
Messenger RNA of 14S size from NIH-3T3(NCL5611P3)/Mo-MuLV cells 
was translated in oocytes and immunoprecipitations were carried 
out on the oocyte lysate with antisera directed against the gag 
proteins p30 (Fig. 2, lane a), p15 (lane c), p12 (lane d) and p10 
(lane f), with antisera directed against the env proteins gp70 
(lane b) and pISE.ptëE (lane e), and with an anti-Mo-MuLV serum 
(lane g). Only anti-Mo-MuLV precipitated a protein of 37,000 
molecular weight. Anti-gp70 weakly precipitated a protein with 
l) To simplify notation, but avoiding the accepted nomenclature 
for retroviral proteins, this product is called tp37, denoting 
a translation £roduct of 37 thousand molecular weight. 
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apparent molecular weight of 40,000. This protein was maximally 
produced by 285 mRNA, however (not shown). Faintly, p15E and p12E 
can be seen in lane e (immunoprecipitation with anti-p15E,p12E). 
Apparently (compare with Fig. ΙΑ), resolution of the isokinetic 
sucrose gradient system was not very high. Anti-p12 and anti-Mo— 
MuLV precipitated several products of 14S mRNA (lanes d and g), 
some of which comigrated on the gel. The nature of these products 
is not known. Anti—ρ 12 and anti-Mo-MuLV were completely mono- or 
virus-specific when lysates of virus-infected cells were used for 
immunoprecipitation (not shown). 
From these results we concluded that the 37,000 molecular weight 
protein synthesized on 14S mRNA from MuLV—infected or uninfected 
cells can only be precipitated by antisera directed against com­
plete MuLV. 
Hybrid-arrested translation. 
In order to confirm the conclusion that tp37 is not coded for by 
the virus we performed hybrid-arrested translations (15,21). 
Messenger RNA to be translated was pre-hybridized to proviral DNA. 
If the genetic information for tp37 forms an integral part of the 
viral genome, the translation of 14S nflNA into this protein would 
be inhibited by hybrid formation. If not, translation would be un­
impaired. Two methods of hybrid-arrested translation were followed. 
First, a single-stranded copy-ONA, representing the complete 
genome in equal amounts, was prepared by reverse transcription in 
the endogenous system in the presence of actinomycin D and using 
nucleasB-digested calf thymus DNA as a primer (30). Minor double-
stranded pieces of DNA were removed by self-annealing followed by 
hydroxyapatite selection. Possible contaminations with cellular 
sequences were eliminated by hybridization of the cDNA against 
highly purified poly(A)+ Mo-MuLV 35S viral RNA, followed by 
hydroxyapatite chromatography. Hybridization of the purified cDNA 
against (unfractionated) mRNA from Mo-MuLV -infected NIH-3T3 cells 
was performed under conditions that enabled the injection of the 
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Figure 2. Analysis of US mRNA 
translation products with mono­
specific antisera. 
Messenger RNA of 14S size from 
NII-)-3T3[NCL5611P3)/Mo-MuLV 
cells was translated in oocytes. 
Translation products were 
analyzed by inmunoprecipitation 
with: (a) anti—рЗО; (b) anti-
gp70; (c) anti-p15; (d) anti-
p12; (e) anti-p15E,p12E; (f) 
anti-pIO and (g) anti-Mo-MuLV, 
followed by SDS-PAGE and 
scintillation autoradiography. 
Lanes m contain C-labelerf 
molecular weight marker 
proteins described in the 
legend to Fig. 1. 
m а Ь с d e f g 
116 — 
95 — . 
Figure 3. (page 125). 
Hybrid—arrested translation. 
Unfract ionated mRNA from NIH-3T3(NCL5611P3)/MO-MULV c e l l s was 
hybridized t o highly pur i f ied s ing le-s t randed copy-DNA of Mo-
MuLV v i r a l RNA and a sample of t h e h y b r i d i z a t i o n mixture was 
i n j e c t e d i n t o oocytes ( see Methods s e c t i o n ) , (a) 1 /og/5 y/ul mRNA 
hybridized t o 0 . 0 5 / u g cDNA; (b) 1 / u g / S / u l mRNA hybridized t o 
0.5yug cDNA; (c) 1 / u g / 5 / u l RNA mock-hybridized- (d) same a s (a) 
but heated a f t e r hybr id iza t ion for 30 sec a t 100 С to melt the 
hybrids; (e) same as (b) but with hybrids melted; ( f ) same as (c) 
but with "hybr ids" melted; (g) 1 / u g / 5 / u l mRNA mixed with 0.5 
x-ug cDNA, non-hybridized; (h) l / u g / S / u l mRNA, non-hybridized; 
( i l 0 . 5 / u g / 5 / u l cDNA, non-hybridized; ( j ) hybr id iza t ion buffer; 
(к) H2O. Lanes m contain ^'^D-labeled molecular weight marker 
p r o t e i n s (cf. F ig . 1.). 
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Пдиге 3. Hybrid-arrested t r a n s l a t i o n . (Legend on page 124]. 
m a b с d e τι 
Figure 4. Presence of p37 in 
cells, serum, and virus. 
Messenger RNA of 16-185 size 
from NIH-3T3(NCL5611P3]/MD-
'gs- «S ·· р,
я
, п MuLV cells was injected -into 
oocytes. On the lysates immune— 
precipitations were carried 
out with anti-R-MuLV in the 
- · —
 3
' presence of added: (a] none; 
(b) 10 /ид рЗО; (c] 100 /jg · 
Mo-MuLV; (d) 200 / Л of a 
r?3|i concentrated ( IO7 cells/ml) 
lysate of NIH-3T3 cells; (e) 
25 /ul of newborn calf serum. 
Lanes m contain '^C-labeled 
molecular weight marker 
proteins (cf. Fig. 1.]. 
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complete mixture into oocytes directly after finishing the hybri­
dization ( 15). The results of these experiments are shown in Fig. 
3, It can be seen that the hybridization procedure caused a func­
tional inactivation of the mRNA. After hybridization with cDNA 
(lanes a,b) or after mock-hybridization (lane c) no translational 
activity of the virus—specific messengers was left. This activity 
was not restored by melting the hybrids (lanes d - f). This indi­
cates that the mRNA was broken down. On the other hand, a non-
hybridized mixture of cDNA and mRNA also did not synthesize virus-
specific translation products (lane g), except for tp37 (compare 
with lane h; in fact this protein is also found as a faint band in 
lanes a - d). The presence of tp37 in this case is not due to an 
artifact caused by the cDNA or the hybridization buffer (lanes i -
к ) . If this would mean that the translation of the virus—specific 
messengers was inhibited by cDNA without hybridization, the conclu­
sion would be that tp37 is not coded for by the viral genome. 
Although unlikely, on the basis of these results we can not totally 
exclude, however, that traces of RNAse activity have caused the 
break-down of the larger gag and enν mRNAs without destroying the 
smaller 14S mRNAs completely. 
Hybridization in the presence of 50 % or more formamide subjects 
the mRNA to milder conditions since hybridization can be carried 
out at lower temperatures (з), but it necessitates an extra alcohol-
precipitation step before the injection of the hybridization 
mixture into oocytes. 
Despite of the selection procedure, the cDNA probe could theoreti­
cally still have contained cellular sequences. Molecular-cloned 
Mo-MuLV DNA, on the other hand, is absolutely free of cellular S9-
quences. In order to prevent the double—stranded cloned Mo-MuLV 
DNA sequences to hybridize with themselves, special hybridization 
conditions had to be chosen that favoured the formation of RNA.DMA 
hybrids (19,22). This hybridization procedure (see Methods section) 
with the cloned DNA probe was successfully used by Mr C.J.M. Saris 
in our laboratory for hybrid-arrested translation of viral RNA in 
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the nuclease-treated reticulocyte cell-free system. Unfortunately, 
these milder hybridization conditions still caused the loss of the 
mRNA translational activity in oocytes completely (not shown), 
Presence of tp37 in cells, serum and virus. 
The 37,000 molecular weight protein was made on ICS cellular mRNA 
in oocytes, but was not detected in lysates of labeled, infected 
or uninfected, cells (chapter 6, Fig. 2). It was only precipita-
ted by antisera directed against complete MuLV (this chapter, Figs 
1 and 2). Therefore it seemed logical to assume that tp37, or a 
related protein, was present in the virions against which the anti-
R-MuLV serum was raised. These virions, isolated from infected mice, 
might have contained a cellular or a serum protein that cross-
reacts with a protein present in calf serum. Since the cellular 
lysates contained calf serum (see Methods section), this would 
explain why we were not able to find tp37 on autoradiograms of gels 
run with anti-R-MuLV precipitates from lysates of labeled mouse 
cells. To test this hypothesis, competition experiments were per-
formed. The anti-ñ-MuLV precipitation was carried out on lysates 
of oocytes injected with 16-IBS mRNA from Mo-MuLV -infected NIH-
3T3 cells. From these lysates both env-proteins and tp37 could be 
precipitated (Fig. 4, lane a; compare with Fig. 1A). By this means 
an internal control on the function and specificity of the compe-
tition system was established. An other control of the specificity 
was achieved by competition with p3G. This protein should not com-
pete with tp37 or the enν proteins. This indeed appeared not to be 
the case (Fig, 4, lane b). On the other hand, R-MuLV isolated from 
the plasma of viremic BALB/c mice competed with the env-proteins 
as well as with tp37 (lane c). The virus preparation used in this 
experiment was similar to the one used for raising the anti-R-MuLV 
serum (33,34), Moreover, Mo-MuLV isolated from roller-bottle 
cultures of infected NIH-3T3 cells (clone 1A ) also competed with 
tp37 (chapter 6, Fig, 6). Apparently, calf serum nor a lysate of 
uninfected NIH-3T3 cells contained the 37,000 molecular weight 
12Θ 
protein (or a cross-reactive activity) (Fig. 4, lanes ΕΙ,Β)· 
We conclude from these results that tp37 is a, presumably host-
coded, virion protein that has no counter part in calf serum and 
that is not present in substantial amounts in lysates of mouse 
fibroblasts. 
DISCUSSION 
Not only 14S mRNA from JLS-V9 cells (35; chapter 3), but also mRNA 
of the same size from NIH-3T3 cells (this chapter, Fig. 1) directs 
the synthesis in oocytes of a 37,QUO molecular weight protein pre— 
cipitable with anti-MuLV serum. 
It is tempting to speculate on a putative one—gene origin of tp37, 
comparing this product with the sre gene-product of avian sarcoma 
virus (ASV). The 3' end of the ASV genome contains a genetically 
and biochemically defined gene, called sre, that is responsible for 
the sarcomagenic activity of the virus in vivo and its cell—trans­
forming capacity in vitro (for a review: ref. 2 and chapter 2.4,). 
The product of this gene, pp60 , is a 60,000 molecular weight 
phosphoprotein with cAMP-independent protein kinase activity (5, 
10,17), that originally was found by immuncprecipitation with a 
serum from ASV-induced tumors-bearing rabbits in lysates of ASV-
transformed chicken and hamster cells (4). This protein did not 
cross—react with any of the viral structural proteins, and, initially, 
was not found in normal cells, in cells infected with a transfor­
mation-defective (td) strain of ASV or in cells infected at the 
non—permissive temperature with an ASV mutant having a temperature-
sensitive expression of its transforming capacities. Mainly there­
fore it was considered as the product of the sre-gene (4). 
This conclusion was amply confirmed by in vitro translation of the 
3' one-third (22S) of the ASV genome (1,10,22). It soon appeared, 
however, that a 60,000 molecular weight phosphoprotein with protein 
kinase activity, closely related to the sre-gene product, was 
129 
present in normal cells, though at lower levels than in ASV-trans­
formed cells [6,7). This was in accordance with the finding of src-t 
related mRNA in normal cells (28,29). 
The nost striking difference between the expression of the avian 
src-product and that of the murine 14S mRNA 37,000 molecular weight 
product is the absence of the latter protein in MuLV-infected or 
uninfected mouse fibroblasts. One should bear in mind, however, 
that fibroblasts are not the target cells for leukemia viruses and 
that these cells can not be transformed by MuLV (2). It would be 
conceivable that the expression of a putative one-gene -related 
protein is repressed in fibroblasts. This would explain why tp37 
was not precipitated from lysates of labeled, infected or uninfec­
ted, fibroblasts and why immunoprecipitation of tp37 formed in 
oocytes could not be inhibited by the addition of a concentrated 
extract of unlabeled NIH-3T3 cells (Fig. 4, lane e). The repression 
should act on the level of translation, since mRNA able to synthe­
size tp37 is present in the fibroblast cells (Figs 1A and IB). 
The sre-protein is not present in ASV particles (4), but tp37 or 
a related protein is present in R-MuLV and Mo-MuLV virions (Fig. 4, 
lane с and chapter 6, Fig. 6). The presence of tp37 in Mo-MuLV 
particles is hard to explain if one assumes that tp37 is not expres­
sed in fibroblasts, since Mo—MuLV was grown in NIH-3T3 fibroblast 
cells (12). Although the lysates might have lacked some nuclear 
constituents which therefore escaped detection by immunoprecipi­
tation or competition, it is hardly conceivable that a nuclear cell 
protein would enter the virions. 
The 37,000 molecular weight protein is not a serum protein aspecifi— 
cally adsorbed to the virus particles, since it did not compete with 
calf serum (Fig. 4, lane d). The complete unrelatedness to other 
known structural virus proteins is a common feature of ррбО and 
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tp37. We labeled oocytes with P-phosphate, but this kind of 
protein—labeling is - for unknown reasons - very inefficient in 
oocytes (Or W.J.M. van de Ven, personal communication) and we were 
not able to detect phosphoproteins (not even without immunoprecipi-
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tation] (not shown). Therefore it could not be assessed whether tp37 
is a phosphoprotein like ррбО or not. 
The src—related nRNA of normal chicken cells is not of the same 
size as the virus-specific src-nfìNA (28,29). In the murine case 
tp37 is synthesized on 14S nflNA both from MuLV-infected and from 
uninfected cells. The viral src-mRNA has its 5' terminus in common 
with the gag- and onv-mRNAs (9,19). The WuLV-specific I^IS RNA found 
by hybridization (35; chapter 3) might either be the product of an 
artifact or a degradation product of genome—size RNA not derived 
by a splicing mechanism in which the genomic 5' terminus is con-
served (8,11,13,20,23,24,27,35). The anti-Mo-MuLV serum not only 
precipitated tp37, but also, even more strongly, proteins with 
apparent molecular weights of 33,000, 24,000 and 22,000. 
The immunoprecipitation of these proteins could also be blocked 
by the addition of Mo-MuLV virions (not shown). Finally, anti-MCSA, 
an antiserum raised against a Mo-MuLV -induced lymphoma in syn— 
genetic mice, precipitates still other protein products of 14S nflNA 
that cross-react with proteins present in Mo-MuLV virions, but that 
could not be precipitated from infected or uninfected fibroblasts 
(chapter 6). 
The nature of all these 143 mRNA products still remains obscure. 
The circumstance that all these products are made on mRNA of the 
same size and are encapsidated into virions, whereas messengers of 
different size did not give rise to the production of such non-
structural virion proteins may have a significance that is not yet 
understood. 
In summary, we conclude that tp37 and other products formed in 
oocytes of Xenopus laevis upon injection with 14S mRNA from MuLV-
infected or uninfected mouse fibroblasts are identical to or cross-
react with proteins present in MuLV virions. 
Because of our failure to perform hybrid-arrested translations, we 
can not exclude rigorously that tp37 is coded for by the viral and 
src 
by the cellular genome, as is the case with ррбО of ASV. Yet the 
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present state of our knowledge of the genetic organization of the 
murine leukemia viruses does not favour that possibility. 
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ABSTRACT 
Moloney cell surface antigen (MCSA) is serologically detectable on 
Moloney murine leukemia virus (Mo-MuLV) -induced lymphomas. It is 
probably related to the tumor-associated transplantation antigen 
of these lymphomas. 
We characterized MCSA by using the typing antiserum in radioimmuno-
precipitations followed by sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis. For comparison, immunoprecipitations with antisera 
directed against viral proteins were also carried out. 
Surface-iodinated Mo-MuLV -infected cells were used to identify the 
molecular nature of MCSA. It appeared that MCSA was expressed as a 
single entity of 82,000 apparent molecular weight (р 2 ]. The 
biosynthesis and turnover of this molecule, that comigrated on the 
gel with дРг82 , was studied with metabolically pulse—chase 
MCSA 
labeled cells. It was found that p82 had a high turnover but 
no immunoprecipitable processing products were found. Translation 
of size-fractionated mRNAs from infected cells in oocytes of 
MCSA 
Xenopus laevis showed that p82 was made on a mRNA of the same 
size (22S) as that coding for the Mo-MuLV env proteins. Moreover, 
p82 was processed in oocytes to proteins exactly comigrating 
on the gel with gp70, p15E and p12E. 
Competition experiments with unlabeled virus and viral proteins 
showed that MCSA was not related to any of the Mo-MuLV structural 
proteins. 
We concluded that MCSA is an env gene product presumably derived 
from a contaminating defective type—С virus present in the Mo-
MuLV isolates as a pseudotype. 
13В 
INTRODUCTION 
Moloney cell surface antigen (MCSA) is present on lymphomas induced 
by Moloney murine leukemia virus (Mo-MuLV) in newborn mice (Klein 
and Klein, 1964; Klein et al., 1966). 
The typing antiserum is raised against an irradiated Mo-MuLV 
-induced lymphoma (YAC) of A mouse origin in (A χ C57Bl)F. or 
(A χ C57L]F1 mice (Klein et al., 1966). 
MCSA is not present on normal lymphoid cells but can be found on 
some Mo-MuLV or Hauscher murine leukemia virus (R-MuLV) -infected 
fibroblast cell lines (FenyH and Klein, 1976; Grundner et al., 
1974; Kurth et al., 1979). It seems to be closely related to the 
turner-associated transplantation antigen (TATA) of Mo-MuLV -induced 
lymphomas, since the amount of MCSA present on tumors correlates 
quite well with the immunosensitivity of the tumors in vivo, as 
measured by the rejection of small tumor isografts in preimmunized 
mice (Klein et al., 1966). 
Although YAC lymphoma cells, used to raise the anti-MCSA serum, 
express viral proteins on their surface (Fenyti and Klein, 1976; 
FenyH et al., 1977; Karande et al., 1979) and the anti-MCSA serum 
contains some antibody activity against gp70 (FenyB et al., 1977), 
several lines of evidence indicate that the main activity in the 
antiserum is not directed against antigen(s) present on structural 
proteins of Mo-MuLV. First, it was found that two sublines of the 
YAC line that were made immunoresistant to the anti-MCSA serum by 
immunoselection in vivo and in vitro did not express MCSA anymore, 
but were as sensitive as the parental YAC line to the cytotoxic 
effect of monospecific hetero-antisera against structural proteins 
of the Friend-Moloney-Rauscher subgroup of MuLV (FenyB and Klein, 
1976). Second, the cytotoxic effect of anti-MCSA to the YAC cells 
could not be inhibited by viral proteins or virus of the FMR sub­
group (FenyB et al., 1977). Finally, by chromatography (Siegert et 
al., 1977) as well as by electrophoresis (Troy et al., 1977) MCSA 
139 
activity (measured by inhibition of anti-MCSA directed cytotoxicity) 
could be separated from viral strucuural proteins and H-2 antigens. 
On the other hand, though MCSA did not co-cap with the exogenous 
viral envelope proteins gp7D and p15E in membrane immunofluorescence 
(Fenyö et al., 1977), it did so with the viral core proteins p30 
and p12 (Karande et al., 1979). Moreover, on a lectin affinity 
column ρ 15 partially co-chromatographed with MCSA (though ρ 15 it­
self is not glycosylated) (Siegert et al., 1977) and on an anti-
p15 immunosorbens column part (maximally 15 %) of the MCSA activity 
was bound (Karande et al., 1979). 
Therefore, it was suggested (Karande et al., 1979), that MCSA 
resembles the feline oncorna—virus associated cell membrane antigen 
(FOCMA) (Stephenson et al., 1977) in that it is synthesized as a 
polyprotein of ρ 15 (and ρ 12?) covalently linked to a non-structural 
protein. This polyprotein would be further processed to the mature, 
non-gag—linked MCSA molecule, that could become losely associated 
with the gag proteins on the cell surface. 
We characterized MCSA by means of sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) of immunoprecipitates obtained 
with anti-MCSA and antisera against viral structural proteins from 
lysates of surface-labeled and metabolically labeled cells and of 
Xenopus laevis oocytes injected with size-fractionated cellular 
messenger HNAs. 
The results confirm that MCSA is not serologically related to any 
of the Moloney virus proteins. On the other hand, they also indicate 
that anti-MCSA recognizes enν gene—products of some other type—С 
virus or viruses. 
MATERIALS AND METHODS 
Materials. L-( S)methionine (spec. act. 800-1200 Ci/mmol), 
(U- C)protein hydrolysate (spec. act. 54 mCi/matom carbon), 
D_( WTH)glucosamine (spec. act. 54.1 Ci/mmol) and iodine-125 
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(carrier-free) were obtained from the Radiochemical Centre, 
Amersham, England. Iodo-Gen (1,3,4,6-tetrachloro-3a,6a -diphenyl-
glycoluril) was purchased from Pierce Chem. Co., Rockford, 111. 
01igo(dT)-cellulose (T-2) was from Collaborative Research Inc., 
Waltham, Mass. Heparin (sodium salt, medical grade, 160 ll/mg) was 
purchased from Organon, Oss, The Netherlands. Proteinase К was from 
Boehringer, Mannheim, West-Germany. RNAse A and DNAse I (both 
purest grade) were from Sigma, St. Louis, Mo. Protein A—Sepharose 
CL-4B was from Pharmacia, Uppsala, Sweden. (R-MuL\/)gp70 was a gift 
of Dr J.R. Stephenson. 
Antisera. The anti—MCSA serum was a gift of Dr E.M. FenyH. Rabbit 
antisera against disrupted R-MuLV, (R-MuLV)p30 and (R-MuLV)p15E, 
p12E were prepared and described by Van Zaane et al. ( 1976). 
Rabbit-anti-(R-MuL\/)gp70 was a gift of Dr J.N. Ihle. Ascites fluids 
containing monoclonal antibodies directed against six different 
env antigenic determinants (Lostrom et al., 1979) were a gift of 
Dr R.C. Nowinski. FITC—conjugated goat antiserum against mouse 
immunoglobulins was purchased from Nordic Immunological Labs., 
Tilburg, The Netherlands. 
Cells and viruses. Recloned NIH-3T3 cells (Todaro and Green, 1963) 
were a gift of Dr R.A. Weinberg. The uninfected and Mo—MuLV 
-infected JLS-V9 cells (Wright et al., 1967) were a gift of Dr 
E.M. FenyB. Two Mo-MuLV infected NIH-3T3 lines were used: one was 
the subclone A of the clone no. 1 cells described by Fan and 
Paskind (1974) and given to us by Dr H. Fan; the other was the 
clonal NIH-3T3 line NCL5611P3 (a gift of Dr J.R. Stephenson) 
infected with Mo-MuLV obtained from the JLS-V9/Mo-MuLV cells. 
Mink lung cells (CCL 64) infected with NZB xenotropic virus, AKR 
virus-infected NIH-3T3 cells (clone 56-n) and (AKR)MCF-247 virus-
infected SC-1 cells were a gift of Dr F.С. Jensen to Dr A.J.M. 
Berns in our laboratory. 
Cells were grown in monolayer cultures in Dulbecco's modified 
Eagle's medium with Earle's salts supplemented with 10 ^  newborn 
calf serum. 
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Moloney murine leukemia virus (Мо-MuLV) was isolated from concen­
trated medium of roller bottle cultures of clone 1A cells as 
described by Duesberg and Robinson (1966) and was given to us by Dr 
A.J.M. Berns. These virus preparations contained relatively low 
amounts of envelope proteins, presumably because of the partial loss 
of the viral envelope by shear forces during the concentration 
(ultrafiltration) of the medium. 
Membrane immunofluorescence. Cells were plated in the wells (6 mm 
diameter) of Flow multitest slides (Flow Labs Ltd., Irvine, England). 
At about 50 Іа confluency the cells were washed three, times by gently 
shaking the slides with Tyrode's balanced salt solution containing 
0. 1 ^  sodium azide to prevent cap formation. Subsequently, 20 /ul 
of the antiserum (anti-MCSA) or the control serum (normal BALB/c 
or NIH Swiss mouse serum, depending on the cell line used) was 
added in a 1 : 40 dilution; incubation was for 30 min at room 
temperature; cells were washed three times and 20 /ul of 1 : 80 
diluted FITC-conjugated goat-anti-mouse (igG) was added. After an­
other 30 min incubation, the cells were washed six times, covered 
with a cover slip and examined with the aid of a Leitz Ortholux II 
immunofluorescence microscope. 
Cell surface labeling and preparation of lysates. Cells were 
surface-iodinated using solid phase-bound 1,3,4,6-tetrachloro-3o, 
6a -diphenylglycoluril as the iodinating agent (Markwell and Fox, 
197B). Monolayer cells in 50 cm glass culture flasks grown to 
subconfluency were rinsed eight times with Hanks' balanced salt 
solution (HBSS) and finally overlaid with 2.5 ml of HBSS to which 
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1 mCi of I was added. Chloroglycoluril was dissolved in chloro­
form and a 25 mm diameter glass fiber filter was impregnated with 
100 /ug of the iodinating reagent. The filter was dried, rinsed 
with HBBS and placed at one end in the culture flask. Labeling was 
continued for 30 min and finished by removing the filter. Cells 
were rinsed eight times with HBSS containing 10 % calf serum, 
finally overlaid with 4 ml of this medium, and lysed by the addition 
of 1 ml of fivefold concentrated immunoprecipitation buffer (see 
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below). Lysates were incubated for IB h at 6 С after the addition 
of 200 /ug/ml of RNAse A, 10 /ug/ml of DNAse I, 5 iul/ml of normal 
rabbit serum and 1.0 ml/ml of a 10 % (υ/ν) suspension of Protein 
A-Sepharose CL-4B and clarified by centrifugation for 30 min at 
200,000 χ g (Van de Ven et al., 1ЭВ0). 
Metabolic cell labeling and lysis procedure. Cells were labeled 
with L-( S)methionine, (U- C)protein hydrolysate or D-(1- H) 
glucosamine according to the methods published by Van Zaane et al. 
(1976), with small modifications as described earlier (Van de Ven 
et al., 1977). Lysates were prepared by the addition of 1/4 volume 
of fivefold concentrated immunoprecipitation buffer (see below) to 
cells and medium and were cleared by centrifugation at 220,000 χ 
g for 15 min. 
Isolation and fractionation of mRNA. Cells were grown to 80 - 90 % 
confluency, removed from the culture flasks by trypsinization and 
washed twice with isotonic buffer (10 mM Tris-pH 7.2, 146 mM NaCl). 
Cellular RNA was isolated from these cells by the magnesium-preci­
pitation method of Palmiter (1974). The precipitated RNA was dis­
solved in 10 mM Tris-pH 6.9, 20 mM NaCl, 10 mM EDTA and 0.5% SOS to 
a concentration of 1 - 2 mg/ml and treated with preincubated pro­
teinase К (100 /ug/ml) for 15 min at 37 C. The solution was then 
heated for 2 min at 100 0C, chilled, brought to 0.5 M NaCl final 
concentration and applied on an oligo(dT)-cellulose column. mRNA 
was collected by the method of Aviv and Leder (1972), except that 
we used NaCl instead of KCl. 
The mRNA (50 - 150 /ug) was fractionated according to size by 
centrifugation for 6.5 h at 40,000 rpm and 20 DC in an IEC SB-2B3 
rotor on a 15 - 37.5 Іа (w/w) isokinetic sucrose gradient (Van der 
Zeijst and Bloemers, 1976) in low salt buffer (20 mM NaAc-pH 5.2, 
2 mM EDTA, 0.2 % SOS). Prior to centrifugation the RNA was denatured 
in low salt buffer containing 85 "fa formamide by incubation for 5 
min at 37 С and 30 sec at 68 C. Fractions (0.5 ml) from the 
gradient were collected and alcohol—precipitated after the addition 
of 10 /ug rat lens 28S ribosomal RNA as a carrier. 
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Translation of mRNA in Xenopus oocytes. The mRNA fractions were 
translated in Xenopus laevis oocytes as described by Asselbergs et 
al. (197В). In short, RNA was dissolved in 10 to 20 ,ul distilled 
water and 4-0 ni of this solution was injected per oocyte. For each 
mRNA fraction 20 oocytes were injected and labeled for 20 h at 19 
С in 100 /ul of modified Berth's medium containing 1 mCi/ml 
L-( S)methionine. Lysates were prepared by homogenizing the 
oocytes in 1 ml of immunoprecipitation buffer (see below). The 
lysates were cleared by centrifugation for 15 min at 220,000 χ g 
and carefully aspirating the lipid containing upper layer. 
Immunoprecipitation and Polyacrylamide gel electrophoresis. Immuno­
precipitation of radioactive polypeptides from lysates of metaboli— 
cally labeled mouse cells and Xenopus oocytes was performed as 
described by Van Zaane et al. ( 1976) in 10 mM sodium phosphate-pH 
7.2, 0.9 ^ NaCl, 1 % Triton X-100, 0.5 % sodium deoxycholate and 
0.1% SDS. Immunoprecipitation on lysates of iodinatsd cells was 
carried out in the same buffer, except that the SDS concentration 
was raised to 0.25 $>. For precipitation of rabbit antisera we used 
Protein A-Sepharose CL-48 (50 /ul of a 10 % (v/v) suspension per 
,ul of antiserum). For precipitation of mouse antiserum either 
Protein A-Sepharose CL-4B or a rabbit-anti-mouse(lgG) serum was 
used. Immunoprecipitates were analyzed by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis according to Laemmli ( 1970) on 
0.75 mm thin 7 to 18 ^ Polyacrylamide gradient slab gels. 
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H, С or S labeled protein bands were visualized after treat­
ment of the gels with dimethylsulphoxide/2,5-diphenyloxazole 
(DMSO/PPO) (Bonner and Laskey, 1974) by scintillation autoradio­
graphy with preflashed Kodak XR films (Laskey and Mills, 1975). 
Autoradiographic detection of iodinated protein bands was acceler­
ated by using Du Pont Cronex Lighting-Plus X-ray intensifying 
screens (Swanstrom and Shank, 197B). 
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RESULTS 
Membrane immunofluorescence. 
The presence of the Moloney cell surface antigen on several Mo-
MuLV -infected and uninfected cell lines was analyzed by membrane 
immunofluorescence. The MCSA-positive Mo—MuLV -infected JLS-V9 cell 
line obtained from Dr E.M. Fenyö was used as a reference. The other 
cell lines studied were two different Mo—MuLV -infected NIH—3T3 
lines - NIH-3T3(NCL56l1P3)/Mo-MuLV and NIH-3T3/Mo-MuLV(clone 1A] -, 
and the uninfected NIH-3T3 and JLS-V9 parental lines. All lines 
were negative with the non—immune control sera. As expected, the 
uninfected cell lines were also negative with anti-MCSA. The Mo-
MuLV infected cell lines all showed a positive fluorescence with 
anti-MCSA although the expression of MCSA on the Mo-MuLV -infected 
NIH—3T3 cells was much lower than that on the JLS-V9/Mo-MuLV cells. 
Molecular characterization of Moloney cell surface antigen. 
To characterize the polypeptide species recognized by anti-MCSA on 
the surface of Mo-MuLV -infected cells, these cells were surface-
iodinated. As a control, uninfected cells were also iodinated. 
Lysates were prepared and immunoprecipitation was carried out with 
anti-MCSA and anti-MuLV. Immunoprecipitates were analyzed by means 
of Polyacrylamide gel electrophoresis in the presence of sodium 
dodecyl sulfate (SDS-PAGE). Of the infected cell lines only the 
JLS-V9/Mo-MuL\/ cells expressed MCSA in sufficient amounts to be 
readily detected by immunoprecipitation. This is in agreement with 
our results obtained by membrane immunofluorescence (see above). 
In Fig. 1 it is shown that both anti-MCSA (lane d) and anti-MuLV 
(lane c) precipitated polypeptides of 70,0G0 and 82,000 apparent 
molecular weight from the lysate of iodinated infected cells, 
though in different ratios. In the anti—MuLV precipitate the 
70,000 molecular weight protein clearly predominates, whereas in the 
anti-MCSA Precipitate the 70,000 and 82,000 molecular weight proteins 
are present in about equal amounts. A 70,000 molecular weight 
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Fiflure 1. Molecular characterization of MCSA. 
Mo-MuLV -infected and uninfected JLS-VS cells were surface-labeled 
with '^^1. Lysates were prepared and immunoprecipitations were 
carried out with anti-MCSA and anti-MuLV. As a reference, to 
identify viral proteins, anti-MuLV precipitates from Mo-MuLV 
-infected NIH-3T3(NCL561IPS) cells, pulse-labeled for 1 h with 
(U-'^C)protein hydrolysate and chased for 20 h, were used. 
Precipitates were analyzed by SOS-PAGE followed by autoradiography. 
(a) ^ C pulse; [b) '^C chase; [c,d) iodinated infected cells; 
(e,f) iodinated uninfected cells. Antisera: [a,b,c,e] anti-R-MuLV; 
Ìd,fÌ anti-MCSA. Lanes m contain ^C-labeled molecular weight 
marker proteins. Molecular weights are indicated in thousands. 
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protein could not be precipitated From the lysate of uninfected 
cells (lanes e, f), but a low amount of anB2,00Q molecular weight 
protein was present in the 'anti-MuLV precipitate of this lysate 
(lane e). This protein is completely absent from the anti-MCSA 
precipitate of uninfected cells (lane f). The 70,000 molecular 
weight protein comigrated on the gel with the viral envelope glyco­
protein gp70) precipitated from the lysates of Mo-MuLV -infected 
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cells labeled with C-amino acids (lane b). Likewise, the 82,000 
•nolecular weight protein comigrated with the env precursor poly-
protein gPr82 (lane a; cf. next section). The 70,000 molecular 
weight protein precipitated by anti-MuLV from the lysate of iodi-
nated infected cells is probably identical to gp70 since gp70 is 
expressed on all MuLV-infected cells (Famulari and Jelalian, 1979; 
Witte and Weissman, 1976). It is known that the anti-MCSA serum 
contains some anti-gp70 activity (FenyH et al., 1977) and, there­
fore, the precipitation of the 70,000 molecular weight protein by 
anti-MCSA, which is relatively weak (compare lanes с and d), 
is presumably due to this contaminating activity in the antiserum. 
We tentatively concluded from these results that MCSA is present 
as a single protein with an apparent molecular weight of 82,000. 
Biosynthesis and turnover of MCSA in Mo-MuLV -infected cells. 
To study the biosynthesis of MCSA, Mo-MuLV -infected cells were 
labeled with L-( S)methionine or with a C-labeled amino acid 
mixture in pulse—chase experiments. Immunoprecipitates from cellu­
lar lysates obtained with anti-MCSA as well as with antiserum 
directed against viral polypeptides were analyzed by SDS-PAGE. As 
shown in Fig. 2 (lanes b), after a 15 min pulse, a protein with 
an apparent molecular weight of 82,000, ρθ2 , could be preci­
pitated with anti-MCSA from the lysates of all three Mo-MuLV 
—infected lines tested. This MCSA-positive protein comigrates on 
the gel with the MCSA molecule present on the cell surface (Fig. 1) 
and with viral precursor-polypeptides (Fig. 2, lanes a). By 
analysis with monospecific antisera these were shown to be the 
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Fiçiure 2. Biosynthesis and turnover of MCSA. 
Mo-MuLV -infected cells were pulse-labeled for 15 min with 
L-[3^S)methionine or (Ll-^^C)protein hydrolysate and chased for 8 
h. Lysates were prepared and immunoprecipitation was carried out 
with anti-MCSA or with anti-R-MuLV. 
Precipitates were analyzed by SDS-PAGE followed by scintillation 
autoradiography. [A) 35S-labelBd NIH-3T3/Mo-MuLV[clone 1A] cells; 
[В] 35S-labeled NIH-3T3(NCL5611P3)/Mo-MuLV cells; (C] 14C-labelBd 
NIH-3T3(NCL5611P3)/Mo-MuLV cells; (θ) 35S-labeled JLS-V9/Mo-MuLV 
cells, (a] Pulse, anti-R-MuLV; (b) pulse, anti-MCSA; (c) chase, 
anti-R-MuLV; (d) chase, anti-MCSA. '^C-labeled proteins were used 
as molecular weight markers. 
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precursor polyprotein of the envelope proteins, gPr82 , and the 
gag polyprotein gPBO (results not shown; cf. Ledbetter et al. , 
197Θ; Van Zaane et al., 1976, Wood and Arlinghaus, 1979). Like 
gPrB2 e n v, рвгЫСБ* from NIH-3T3/MO-MULV(clone 1A) cells but not 
from NIH-3T3(NCL5611P3)AO-!/ULV or JLS-V9/Mo-MuLV cells is some­
times seen as a double band (Fig. 2A, lanes a, b]. A double band 
for gPrB2 is found more often and was attributed to a variation 
m glycosylation (Van Zaane et al., 1976; Witte and Baltimore, 1979), 
although recent results indicate, that the heterogeneity of gPr82 
(and gp70) can also be caused by the presence of multiple, closely 
related, genomes in the virus (Murray and Kabat, 1979). 
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After a chase of В h, p62 had completely disappeared; no obvious 
processing product(s) could be found (Fig. 2, lanes d). Only faint 
bands are visible on the gel, the most prominent one being a band 
at 87,000 molecular weight. The viral precursor proteins gPrB2 
and gPBO are chased to the envelope proteins gp70, p15E and 
p12E and to the glycosylation variants of gPBO9 S, gP959 9 and 
gP85 9 a 9, respectively (Ledbetter et al., 197B; Van Zaane et al., 
1976; Wood and Arlinghaus, 1979) (Fig. 2, lanes c). Presumably the 
anti-(Mo-MuLV)gp70 activity in the anti-MCSA serum is too low to 
be detectable ir this case. 
It should be noted here, that we were hardly able to detect the 
glycosylated gag polyproteins after ammo acid labeling (Fig. 2, 
lanes c). This is in accordance with earlier work (Van Zaane et 
al., 1976). The band of 105,000 apparent molecular weight seen in 
anti-MuLV precipitates of chase lysates (Fig. 2, lanes c) is not 
gag-related for it was not precipitated by anti-рЗО (not shown). 
Both anti-MuLV and anti-MCSA only very weakly precipitated some 
polypeptides from the lysates of uninfected cells. Moreover, none 
of these polypeptides comigrated with the viral (poly—)proteins 
or the MCSA—related protein that could be precipitated from in­
fected cells, except for a 87,000 -nolecular weight protein that 
was precipitated by anti-MCSA from both infected and uninfected 
cells after an В h chase (results not shown). 
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According to the literature (Edwards and Fan, 1979; Ledbetter et 
al., 1978; Van Zaane et al., 1976], both дРг82 е П and gPBO 9 3 9 are 
glycosylated. It was already known that MCSA is also glycosylated 
(Siegert et al., 1977). The gag polyprotein can be labeled with 
mannose but not with glucosamine, whereas дРг 2 (and gp70) is 
readily labeled with the latter carbohydrate (Edwards and Fan, 1979; 
Ledbetter et al., 1978; Van Zaane et al., 1976). We found that 
p82 could be labeled with glucosamine (results not shown]. 
An MCSA-positive protein was also detected in Rauscher murine 
leukemia virus (R-MuLV) -infected cells. The glycosylated gag poly­
protein of R—MuLV clearly moves faster than the enν precursor on 
the gel (Van Zaane et al., 1976). The MCSA protein found in JLS-V9/ 
R-MuLV cells comigrated with the env precursor and lot with the 
gag polyprotein on the gel (results not shown). From these intro­
ductory results we concluded that the main MCSA-positive polypeptide 
found in pulses of infected cells might be env-related. The pro­
cessing of p82 differs from the processing of Mo-MuLV poly-
proteins, indicating that MCSA is distinct from Mo-MuLV proteins. 
Characterization of the MCSA-mRNA. 
The existence of intracellular virus-specific mRNAs of different 
size classes can be demonstrated by translation of size-fractionated 
RNA from virus-infected cells in Xenopus laevis oocytes followed 
by immunoprecipitation and SDS-PAGE (Van Zaane et al., 1977). 
The sane method enabled us to detect intracellular mRNAs that code 
for MCSA-positive products. Poly(A)+ RNA from NIH_3T3(NCL561ІРЗ) 
cells infected with Mo-MuLV was fractionated by centrifugation on 
isokinetic sucrose gradients. Samples from the fractions were 
injected into Xenopus oocytes. As a control, H O was injected. 
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After incubation for 20 h in the presence of L-( S)methionine 
oocyte extracts were prepared and subjected to precipitation with 
either anti-MCSA or anti-MuLV followed by SDS-PAGE (Fig. З А , В). 
S—values of the injected mRNAs are indicated in the figure. Only a 
very low percentage (less than 0.1 %) of the proteins made in the 
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Figure 3. ("A + В] (page 151). 
Messenger RNA coding for MCSA. 
Messenger RNA from Mo-MuLV -infected NIH-3T3(NCL5611P3) cells was 
isolated ( 100 /tig) and size-fractionated on an isokinetic sucrose 
gradient. Samples of each fraction were injected into 20 oocytes 
of Xenopus laevis. 
After labeling the oocytes with L-(3Ss)methionine, immunoprecipi— 
tation was carried out on the lysates with anti-MCSA (ЗА) or with 
anti-R-MuLV (3B). 
Precipitates were analyzed by SDS-PAGE followed by scintillation 
autoradiography. 
Positions of IBS and 2BS ribosomal RNA on a parallel gradient are 
indicated by big arrows. Small arrows indicate calculated S-values 
of RNA. Lanes "p+c" show the imtiunoprecipitable polypeptides found 
in the combined pulse and chase lysates of NIH-3T3/Mo-MuL\/(clone 1A) 
cells. As a control, precipitates from lysates of oocytes injected 
with water are shown in lanes "H2O". Lanes π contain '4C—labeled 
marker proteins. 
151 
A 35S 
m Η,Ο I 
28S 
f i « 18S 14S IOS 
n e -
9 5 -
68 — 
•I II · 
«4 » · 
1 
• 
# * p 8 2 MCSA 
20— 
2-5-
mfected anli-MCSA 
B
 m M O
 3 5 S 
28S IBS 
22S I 14S I Ψ i f ' ,0 8 P*c 
i t e -
6 8 -
Ьіт*ш**ее~ІШ 
¥* if* É*É "4 
gPeOenv 
-gP82 
— Pres gag 
- р з о 
20— 
2.5 — 
^.ptSE 
—pl2E 
infected anti-R-MuLV 
Figure 3. (A + ВІ• Messenger RNA coding for MCSA. 
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injected oocytes are virus-specific. Therefore, a rather high back­
ground of aspecific protein bands is seen on the gels. The blank 
control serves to discern these aspecific bands from the immuno-
precipitable proteins specifically made in response to the injected 
RNA. Fig, ЗА shows the immunoprecipitates with anti-MCSA; the 
precipitates with anti—MuLV from the same lysates are shown in Fig. 
3B. The results presented in Fig, 3B are similar to those reported 
and discussed by us before (Van Zaane et al., 1977). Apparently, 35S 
mRNA did not code for any protein precipitable with anti-MCSA. 
With anti-MuLV the gag (poly-)proteins Pr65 and p3D are found 
in this RNA size region. Note, that ρ 15, ρ 12 and ρ ID can not be 
seen, because ρ 15 and ρ 10 lack methionine and ρ 12 is not recognized 
by the antiserum used (cf. Van Zaane et al., 1976). Moreover, the 
gag polyproteins gP80 g a g, gP95 9 a g and gPB5 9 a g are not found in 
oocytes after labeling periods longer than 10 h (Salden et al., 
1976; Van Zaane et al., 1977; F.A.M. Asselbergs, Ph.D. thesis, 
University of Nijmegen, Nijmegen, The Netherlands, 1979). 
Apparently, these proteins have a rapid turnover in oocytes and 
their messenger RNA is quickly degraded. 
The p82 molecule was synthesized on 22S mRNA. This molecule is 
processed in oocytes to proteins that comigrate exactly with gp70, 
p15E and p12E, precipitated with anti-MuLV from the same oocytes 
(compare Figs ЗА and 3B). The perfect comigration of these four 
MCSA-positive proteins with the viral enν proteins can be seen 
more accurately in Fig. 6. 
The polypeptides that were precipitated in the 9-18S region by 
either anti-MCSA or anti-MuLV are not specific translation products 
of infected cell mRIMAs. The protein with apparent molecular weight 
of 200,000 has a much higher molecular weight than corresponds to 
the size of the mRNAs in this region (0.2 - 0.7 χ 10 ) (Dudov et 
al., 1976). Other proteins (apparent molecular weights 50,000, 
43,000, 37,000, 17,000, 13,000) could also be found by immuno-
precipitation of the translation products of 9-IBS uninfected cell 
nRNAs. Messenger RNAs of 35S and 22S size from uninfected cells 
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did not direct the synthesis of precipitatile products (results not 
shown). 
In the previous section some indications for the env-like nature 
of p82 were described, although, unlike gPrB2 , pB2 was 
not chased into products comparable to gp70, p15E and p12E in the 
infected cells. In oocytes, however, precisely such a processing 
seems to occur. Moreover, the size of the mRNA coding for these 
MCSA-positive env-like molecules corresponds exactly with the 
size of the mRNA coding for the Mo-MuLV env proteins (compare the 
lanes between the 28S and 18S markers). This strongly emphasizes 
the env-like character of pB2 
Competition experiments. 
It was clearly shown by FenyH and her colleagues that MCSA is 
unrelated to the Mo-MuLV structural proteins (FenyH and Klein, 
1976; Fenyö et al., 1977). 
We were able to confirm this in competition experiments, carrying 
out immunoprecipitations in the presence of an excess of unlabeled 
viral proteins. In the first experiment we studied the effect of 
the addition of Moloney virus, supplemented with an extra amount 
of gp70, on the precipitation by anti-MCSA and anti-MuLV of iodi— 
nated surface proteins of Mo-MuLV —infected cells. 
It fallows from Fig. 4 that precipitation of gp70 by both anti-
MuLV (lane c) and anti-MCSA (lane b) was inhibited completely, 
whereas the precipitation of the 82,000 molecular weight proteins 
remained unimpaired. Apparently, the surface—labeled gp70 is 
related to Mo-MuLV. The surface-labeled p82 , on the other hand, 
is absent in Mo-MuLV particles and serologically different. The 
lack of competition for the weak band of the 82,000 molecular 
weignt protein in the anti-MuLV precipitate indicates that this 
protein does not represent Moloney gPrB2 . It can not be p82 , 
precipitated by cross-reacting antibody in the anti-MuLV serum, 
either since anti-MuLV also precipitates an 82,000 molecular weight 
protein present on the surface of uninfected cells (Fig. 1, lane e). 
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Figure 4. Competition of MCSA with MuLV 
proteins. 
Immunoprecipitations on surface-iodinatec 
JLS-Vg/Mo-MuLV cells were carried out in 
the presence of 100 /ug of Mo-MuLV and 1С 
/jg of [R-MuLV)gp70. 
Precipitates were analyzed by SDS-PAGE 
followed by autoradiography, (a) Anti-R-
MuLV, no addition; (b) anti-MCSA, plus 
uirus and gp70; (c] anti-R-MuLV, plus 
virus and gp70. 
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Figure 5. Competition of 
pa2ML;tiA
 w
ith MuLV proteins. 
Lysates of NIH-3T3/Mo-MuLV 
(clone 1A) cells, labeled 
for 15 min with L-(35S] 
methionine, were immune— 
precipitated with anti-
MCSA (A) or with anti-R-
MuLV (B). 
For competition, virus or 
viral proteins were added. 
[a] No addition; (b] 100 /jg 
of Mo-MuLV; (c) 10 /jg of 
[R-MuLV)gp70; fd] 100 Aig of 
Mo-MuLV and 10 yug of 
(R-MuLV)gp70. 
Precipitates were analyzed 
by SDS-PAGE followed by 
scintillation autoradio­
graphy, Lane m contains 
I^C-labeled тагкег proteins. 
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Figure 6. Competition of MCSA-positive oocyte translation products 
with Mo-MuLV proteins. 
Lysates of oocytes injected with RNA of 22S, 14S and IOS size from 
NIH-3T3[NCL5611P3]/MO-MULV cells [cf. Fig. 3] were immunoprecipi-
tated with anti-R-MuLV [a] or with anti-MCSA [b), in the presence 
(+] or absence [-) of 100 /ug of Mo-MuLV. 
Precipitates were analyzed by SDS-PAGE followed by scintillation 
autoradiography. Lane m contains C-labeled marker proteins. 
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Similar results were obtained in competition experiments using the 
lysate of pulse—labeled infected cells (Fig. 5). The Moloney virus 
preparation apparently contained a low amount of viral envelope 
proteins, probably due to the isolation procedure (see Methods 
section), since virus alone only partially inhibited the precipi­
tation of gPr82 by anti—MuLV under these circumstances (lane 
B.b). In contrast, labeled Pr65 was lost completely from the 
precipitate (lane B.b). Added gp70 competed better with the enν 
precursor polyprotein (lanes B.c, d). Precipitation of the MCSA-
positive protein was not affected by the addition of unlabeled Mo-
MuLV and/or gp70 (lanes A.a - d). 
When unlabeled Mo-MuLV was added to the immunoprecipitations of 
oocyte translation products it completely blocked the precipitation 
of env-proteins by anti-MuLV, but had no influence on the precipi­
tation of the MCSA-related env-products (Fig. 6). These results 
indicate that in Xenopus oocytes р 2 is processed to mature 
"env-like" proteins and that "gp7D-like" and "p15E,p12E-like" 
molecules were not precipitated by a contaminating anti—Mo—MuLV 
activity in the anti-MCSA serum. Apparently, p82 is expressed 
on the cell surface in such a way that it is able to elicit anti­
bodies to its gp70 moiety as well as to the p15E portion of the 
molecule. The proteins that could be precipitated by anti-MuLV or 
anti-MCSA from the translation products of 9-14S mRNA from either 
infected or uninfected cells had cross-reacting counterparts in 
the virus (Fig. 6). Supposedly, these are cellular proteins, 
associated with the viral proteins on or close to the cell surface 
and thus encapsidated in the virion during the budding process. 
These proteins are not present in large quantities in the cells 
(Fig. 2), nor are they exposed on the cell surface well enough to 
be labeled with iodine (Fig. 1). 
In summary, the competition experiments show that the main activity 
in the anti-MCSA serum is directed at env-like proteins of a type-
C virus serologically different from Mo-MuLV. 
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Figure 7. Relationship of MCSA to the envelope proteins of 
prototype viruses. 
AKR virus-infected NIH-3T3 cells (A), (;AKR}MCF-247 virus-infected 
SC-1 cells (в) and NZB xenotropic virus-infected CCL64 cells (θ) 
were pulse-labeled for 15 min with L-(^^S)methionine and chased 
for 8 h. 
Immunoprecipitates were applied on SDS-PAGE and radioactivity was 
traced by scintillation autoradiography, [a) Pulse, anti-MCSA; 
(b) pulse, anti-R-MuLV; [c] chase, anti-MCSA; [d] chase, anti-R-
MuLV. As a reference, immunoprecipitates with anti-R-MuLV from 
NIH-3T3(NCL5611P3]/MO-MULV cells, labeled for 1 h with L-[35S) 
methionine (C.b) or chased for 20 h (Cd) were used. Lanes m 
contain ^C—labeled marker proteins. 
ІЬ 
Reactivity of anti-MCSA with proteins of prototype viruses. 
To further investigate the specificity of the anti-MCSA serum, we 
carried out immunoprecipltations on lysates of pulse-chase labeled 
cells that were infected with three different prototype viruses. 
These viruses were the N-ecotropic AKR virus (Fig. 7, A), the N-
amphotropic (AKR)MCF-247 virus (в) and the xenotropic NZB virus 
(θ). These were all three cloned virus isolates. The (AKR)MCF-247 
virus is an env gene recombinant between ecotropic AKR virus and a 
xenotropic virus (Elder et al., 1977; Rommelaere et al., 1978). 
The gag sequences of the recombinant are AKR-related, whereas part 
of the env sequences are of xenotropic origin. Lysates of NIH-3T3 
(NCL5611P3) cells infected with Mo-MuLV were used as a reference (C). 
The anti-MuLV serum recognized gag and env proteins of all three 
prototype viruses (lanes b, d). Although the corresponding envelope 
(precursor) proteins of the four viruses presented in Fig. 7 have 
about the same molecular weight, slight differences in their elee— 
trophoretic mobilities can be seen. This has been reported before 
(Famulari and Jelalian, 1979; Wood and Arlinghaus, 1979). 
Clearly (lanes a, c), anti-MCSA reacted with the envelope (pre­
cursor) proteins gPrB2 , gp7D, p15E and p12E of both AKR virus 
and (AKR)MCF-247 virus, but did not recognize NZB xenotropic 
virus proteins. 
DISCUSSION 
Most of the work on MCSA has been performed with the Mo-MuLV 
-induced YAC lymphoma cell line (cf. Introduction). We used Mo-
MuLV -infected fibroblast cell lines. Yet, we could not have missed 
antigens that are present on the YAC cells and not on the infected 
fibroblast lines, because in two of the three infected cell lines 
(JLS_V9/MO-MULV and NIH-3T3(NCL56l1P3)/MO-MULV) the Moloney virus 
was originally derived from the culture fluid of YAC cells (FenyB 
and Klein, 1974); this virus transfers MCSA activity (Grundner et 
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al., 1974) and it was shown that JLS-Vg cells infected with this 
virus absorb all YAC—cell -directed cytotoxic activity in the anti-
MCSA serum (Grundner et al., 1974). This does not necessarily mean 
that MCSA is present on the same molecule(s) in YAC lymphoma cells 
as it is in Mo-MuLV -infected fibroblast cells. On the latter cells 
MCSA is expressed as a single glycoprotein of 82,000 apparent 
molecular weight (our results). Molecular weights for the YAC cell-
derived MCSA have been reported before (Siegert et al., 1977; Troy 
et al., 1977). In those experiments MCSA was detected by inhibition 
of the cytotoxic activity of an anti-MCSA serum. By lectin-affinity 
chromatography followed by gel filtration MCSA appeared to be present 
on a glycoprotein with a molecular weight of 110,000 (Siegert et 
al., 1977). On SDS gels MCSA activity was predominantly found at a 
position of 90,000 apparent molecular weight, with minor peaks at 
52,000 and 180,000-190,000 (Troy et al., 1977). The minor peaks 
(each representing less than 1 ^  of the main activity peak; Troy 
et al., 1977) were not detected by us. 
The accuracy of molecular weight estimations by gel filtration is 
limited and molecular weights estimated by different techniques 
or by different investigators with the same technique may vary to 
some extent. 
Particularly, variation in the reported molecular weights of the 
MuLV envelope precursor polyprotein should be noted in this context 
(Naso et al., 1976; Van Zaane et al., 1976). 
Therefore, we conclude that our estimate of the molecular weight 
of MCSA on fibroblasts is not in disagreement with the estimates 
of others of the molecular weight of lymphocytic MCSA, 
Since we detected MCSA-positive molecules in JLS-V9 cells and NIH— 
ЗТЭ cells infected with the YAC-derived virus as well as in NIH-
3T3 cells infected with Mo—MuLV from a different source, the 
presence of MCSA is apparently not restricted to a certain cell 
type nor is the MCSA-inducing capacity restricted to one particular 
virus isolate. (Note, that R-MuLV is also able to induce MCSA; 
-enyb' and Klein, 1976, and our results). No large differences were 
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observed in the MCSA content of the three cell lines studied (Fig. 
2). On the other hand, the expression of MCSA on the cell surface 
was highly cell-dependent: both by membrane immunofluorescence and 
by surface iodination MCSA was hardly detectable on the Mo-MuLV 
-infected NIH-3T3 cells but could readily be detected on JLS-VS/ 
Mo-MuLV cells. This difference in the surface expression of MCSA 
might be related to the different origin of 3T3 and JLS-VS cells: 
3T3 cells are of whole embryo origin (Todaro and Green, 1963), 
whereas JLS— Э cells were derived from BALB/c bone marrow [Wright 
et al., 1967). Both cell lines essentially have a fibroblastic 
appearance, however. 
Our conclusion that MCSA is related to MuLV envelope proteins is 
based on a number of observations: the messenger for MCSA has the 
same size (22S) as the mRNA coding for MuLV envelope proteins (Fig. 
3); the MCSA-positive molecule found in infected cells (р 2 ) 
comigrates on SDS gels with the envelope precursor polyprotein 
gPr82 (Figs 2, 7); p82 is labeled by glucosamine as is 
gPr82 ; in cells where gPrB2 is present as a double band on 
the gel, p82 is also double on the gel (Fig. 2, lanes a, b); and, 
finally, in oocytes p82 is processed to proteins comigrating on 
SDS gels with gp70, p15E and p12E (Fig. 3). 
The oocyte system is an excellent system for translation of eukaryo-
tic mRNAs since it is the only translation system known that is 
able to adequately perform all steps in the processing of primary 
translation products, like proteolysis and glycosylation. Remarkably, 
oocytes sometimes process proteins of which the processing is 
blocked in vivo. For instance, it is known, that in vivo processing 
of the MuLV gag precursor polyprotein occurs concomitantly with 
virus budding (Yeger et al., 1978). Clearly, Xenopus oocytes do 
not produce virus when injected with 35S mRNA from MuLV-
infected cells; yet they do process the gag precursor polyprotein, 
Pr65 9 a 9, correctly (Fig. ЗВ). Therefore, p82 , although not 
processed in the infected cell, could very well be processed in 
the oocyte to MCSA-related mature enν proteins (Fig. ЗА). 
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Apparently, processing of the MCSA-positive envelope precursor 
polyprotein is inhibited in the infected cells, since we were not 
able to detect significant amounts of processing products in these 
cells (Fig. 2, lanes d). This indicates that MCSA is not identical 
to Mo-MuLV proteins. This conclusion was substantiated by the 
results of the competition experiments. A 50- to 100-fold excess of 
unlabeled Moloney virus or (R—MuLV)gp7Ò blocked the immunoprecipi— 
tation of radioactive Mo—MuLV proteins, but did not influence the 
precipitation of MCSA (Figs 4, 5, 6). These results fully agree 
with the results obtained by others, who also showed that MCSA was 
distinct from Mo-MuLV structural proteins (cf. Introduction). 
Neither was MCSA related to the so-called FMR cell surface antigen 
that is found on cells infected with Friend, Moloney or Rauscher-
MuLV, since this antigen was shown to be an env determinant that 
is also present in virions of the FMR group (Nowinski et al., 1976). 
Since MCSA is related to MuLV env proteins but serologically dif-
ferent from the envelope proteins of Mo-MuLV, the question arises: 
are there viruses that carry MCSA deterninants? 
We performed immunoprecipitations with anti-MCSA on cells infected 
with three prototype viruses to investigate whether anti-MCSA would 
recognize any one of these viruses (Fig. 7). The results show that 
anti-MCSA recognized AKR ecotropic virus as well as (AKR)MCF-type 
virus envelope proteins. Both the envelope precursor polyproteins 
and the mature envelope proteins were recognized. 
Anti-MuLV sera raised in mice are predominantly directed at type-
specific antigenic determinants (Brown et al., 1979). However, 
although (AKR)MCF virus is an env-gene recombinant between AKR 
ecotropic virus and a xenotropic virus, the fact that anti-MCSA 
did not recognize NZB xenotropic viral proteins does not neces-
sarily mean that MCSA consists of a set of ecotropic viral env 
antigenic determinants because it is not yet known which xenotropic 
virus is the parental virus of (AKR)MCF virus, and anti-MCSA could 
very well recognize antigenic determinants of xenotropic viruses 
other than the NZB virus. 
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The anti-R-MuLV serum has a broad specificity (Fig. 7). It precipi-
tated gag and env (poly-)proteins of all three prototype viruses. 
This antiserum apparently recognizes other, probably group-specific, 
env determinants than anti-MCSA does, since its activity could be 
absorbed completely by Mo-MuLV, in contrast to the activity of the 
anti-MCSA serum that was not absorbed at all by Mo-MuLV (Figs 4, 5, 
6). 
Because anti-MCSA recognizes AKR virus envelope proteins one would 
expect Gross—MuLV -induced lymphomas to cross—react immunologically 
with Mo-VluLV -induced lymphomas. Preimmunization with irradiated 
G-MuLV -induced tumor cells did not protect against small isografts 
of Mo—MuLV —induced tumors, however (Klein and Klein, 1964). 
But, although not quite understood, G-MuLV -induced lymphomas pre-
dominantly evoke cytotoxic antibodies against the glycosylated gag 
polyproteins present on the cell surface (Snyder et al., 1977). 
Apparently they do not induce a significant env-directed immune 
response. 
In an attempt to further characterize the putative MCSA-related 
virus we tried to use monoclonal anti-MuLV antibodies that we had 
received from Dr R.C. Nowinski. We obtained prototype samples of 
six antibody classes (based on their different reactivity with a 
series of murine and non—murine viruses) (Lostrom et al., 1979). 
These antibodies were either directed against gp70 or p15E. Only 
two antibody classes did not recognize Mo-MuLV. These two classes 
did not detect the presence of another C-type virus when used in 
immunoprecipitations on lysates of the Mo—MuLV —infected cell 
lines (results not shown). Therefore, it is unlikely, that the 
putative virus resoonsible for the expression of MCSA is an N-
ecotropic virus (like the AKR virus), since this group of viruses 
is recognized by these antibody classes (Lostrom et al., 1979). 
Clearly, more work has to be done to identify the nature of the 
putative MCSA-producing virus. Competition experiments using dif-
ferent (prototype) viruses to absorb anti-MCSA antibodies, would 
be one possibility to do this. 
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How does the expression of another C-type virus gene in Mo-MuLV 
-infected cells arise? One explanation could be, that the expression 
of an endogenous virus was induced by the infection with Mo-MuLV. 
This seems rather unlikely, for that would mean that everytirrm cells 
are infected with Mo-MuLV, the same virus would be induced. More­
over, NIH-3T3 cells are known for the fact that they do not contain 
inducible viruses (Aaronson and Stephenson, 1976]. 
A more plausible explanation is that the MCSA producing virus is 
present as a pseudotype in the Mo—MuLV isolates. Although we do not 
have a direct proof for this assumption, it is consistent with our 
results as well as with all other data reported in the literature. 
1. It is known that non-clonal Mo-MuLV stocks contain a number of 
different viruses in addition to the ecotropic exogenous Moloney 
virus (Troxler et al., 1977b). Particularly, MCF-type viruses, with 
env-regions related to the env-region of (AKR)MCF-virus and to 
that of the spleen focus—forming component (SFFV) of the exogenous 
Friend and Rauscher virus strains are found (Shih et al., 197В; 
Troxler et al., 1977a; Troxler et al., 1977b). 
2. Since pB2 is expressed on the cell surface (Fig. 1) and not 
processed to mature "env-like" proteins (Fig. 2) and since no MCSA-
related env proteins are present in the Moloney virus isolate (Figs 
4, 5, 6), the putative pseudotype virus coding for MCSA would be a 
replication-defective virus depending on the helper functions 
provided by an other virus (Mo-MuLV]. The R-MuLV isolate could 
also contain the same (or a closely related) virus. 
3. The envelope precursor polyprotein of most murine leukemia 
viruses is not found on the surface of infected cells (Famulari 
and Jelalian, 1979; Van Zaane et al., 1976; Witte and Weissman, 
1976), but Famulari et al. (1979) showed that, typically, MCF-
type viruses do express their env-precursor on the cell surface. 
4. Karande et al. (1979) found that MCSA was associated with MuLV 
gag proteins on the cell surface. This could indicate the presence 
of blocked budding virus particles containing the MCSA-positive 
envelope precursor polyprotein and gag precursor polyproteins of 
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either Mo-MuLV origin or derived from the putative MCSA producing 
virus. The gag protein ρ 15 rather stably associates with viral 
envelope proteins (Van de Ven et al,, 197B). Similarly, co-chroma-
tography of MCSA and p15 was found (Karande et al., 1979; Siegert 
et al., 1977). 
5. As found by Grundner et al. (1974), immunoselection of cells that 
did no longer express MCSA led to the selection of cells producing a 
variant of Mo-MuLV that was unable to induce MCSA on indicator cells. 
If our assumption is correct, this would mean that Grundner et al. 
( 1974) have obtained a Mo-MuLV/ isolate that is not contaminated 
with the pseudotype virus responsible for MCSA expression. 
The significance of MCSA is its relation to the tumor-associated 
transplantation antigen [TATA) of Mo-MuLV -induced lymphomas (Klein 
et al., 1966). Since it is known that viral envelope proteins 
(including SFFV/MCF-type virus envelope proteins) present on the 
cell surface evoke both humoral and cellular immune responses 
(Boiocchi and Nowinski, 1979; Gillis et al., 1979; Kende et al., 
1979), MCSA might well be identical to TATA. 
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CAN 35S VIRUS-SPECIFIC RNIAs BE SPLICED IN NUCLEI OF XENOPUS LAEVIS 
OOCYTES ? 
ABSTRACT 
Purified 35S poly(A) genomic RNA of Moloney murine leukemia virus 
was injected into the nuclei of Xenopus oocytes, in order to 
establish whether this RNA could be spliced into subgenomic RNA 
synthesizing env-related proteins. By coinjection of complete 
virions and purified viral proteins the potential role of the virus 
proteins in the splicing process was investigated. Furthermore, 
poly(A)~ 35S viral RNA, decapped 35S poly(A)+ viral RNA, and 35S 
cytoplasmic and nuclear RNA from infected cells were also injected. 
In all cases only gag proteins were synthesized and no enν proteins 
could be detected. We also failed to generate functionally active 
env-mRNA by endonucleolytic fragmentation of genomic RNA with RNAse 
III. 
Our results differ in part from those of others obtained in a 
different system. Passible reasons for this apparent discrepancy 
are discussed. 
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INTRODUCTION 
The first reports on mRNAs consisting of contiguous segments that 
are coded for by widely separated portions of the genomic DNA were 
dealing with S\/-40 and adenovirus-2 [3,6,22,29). This phenomenon 
has since been reported for a large number of mRNAs of animal 
viruses and eukaryotic cellular mRNAs (1,39). Apparently, eukaryotic 
genes usually consist of sequences that are represented in the 
cytoplasmic mRNA (expressed regions or "exons"; 20), intertwined 
with regions that are lost from the mature mRNA (intragenic regions 
or "introns"; 20). 
A stretch of DNA, sometimes consisting of more than one gene f e.g. 
З -ДО, adenovirus, retrovirus), is transcribed into one large 
precursor-mRNA complementary to the complete DNA sequence (12,20, 
52). This primary transcription product can be found in the nucleus 
in the so-called heteronuclear RNA (hnRNA) fraction (12,24,33,56). 
In several steps this RNA is processed to the mature mRNA that is 
transported from the nucleus to the cytoplasm (reviewed in refer­
ences 1,12,39,52). During or immediately after synthesis one 
molecule of guanosine ("cap") is invertedly coupled to the 5' end 
of the primary transcript through a S'-S' triphosphate bond (19, 
46,56). Subsequently methyl-groups are attached to the newly 
acquired guanosine and its adjacent nucleotide and to internal 
adenosines at specific sites in the RNA molecule (48,54). 
Concomitantly, the 3' end of the RNA is often polyadenylated (33). 
The modified RNA is now trimmed in one or more steps (a process 
generally referred to as "splicing") to one or more mature mRNAs 
by excision of the sequences complementary to the introns and 
ligation of the remaining sequences (complementary to the exons) 
(20,29). Splicing offers a mechanism by which one piece of DNA could 
contain several overlapping genes: differential splicing could 
lead to more than one rrfìNA, coding for different proteins. 
The splicing phenomenon has also been observed for RNA tumor viruses. 
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The env-mñNA of the avian and mammalian leukemia viruses as well as 
the src—mRNA of the avian sarcoma virus have their 5' sequence [of 
at least 150 nucleotides in MuLV; 21,43) in common with the 35S 
genomic RNA, but lack the intervening sequences between the common 
leader and the gene for which the mHIMAs code (for references: see 
chapter 2.4.5.). So in the env-mñNA the gag and pol genes and in 
the avian src—mRNA the gag, pol and enν sequences are deleted. 
In the nucleus no MuLV-specific RNAs larger than genome size were 
detected (1B,23). The main representative of nuclear virus-specific 
RNA had a size of 35S, but small amounts of 22S (env-) mRNA were 
also found. Therefore it is guessed that the primary transcript of 
retrovirus proviral DNA, apart from modifications like capping, 
methylation and polyadenylation described above, is identical to 
the genomic RNA and that the subgenomic mRNAs are generated in the 
nucleus. Small differences in the sequences of the presumed primary 
transcription product and the genomic RNA present in the virions 
can not be excluded, however. In particular, the possible presence 
in the primary transcript of the long terminal repeats that are 
contained by the proviral DNA (cf. chapter 2.3.) should be con­
sidered in this context. Similarly, subtle differences between 
cytoplasmic virus-specific 35S mRNA and the virion RNA might exist 
(cf. chapter 2.4.3.). Such differences, undetected sofar, could 
have functional significance. 
Oocytes were shown to synthesize virus-specific tumor antigens 
and capsid proteins correctly when their nuclei were injected 
with SV-40 or polyoma DNA (30,44). Intranuclear injection of cloned 
Drosophila histone DNA also resulted in the synthesis of the correct 
protein product (13). This implies the correct splicing of at least 
part of the corresponding mRNAs, even though the majority of the 
transcripts might not be synthesized or processed accurately (26). 
Correctly spliced RNA-products were formed from cloned yeast 
tRNA r p genes in an in vitro system prepared from oocyte nuclei 
(l). It should be stressed here, however, that no successful 
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experiments have been reported on in vitro splicing of precursor-
mRNA by injection of this RNA into nuclei of oocytes and subsequent 
analysis of either the mRNA itself or the protein products. 
Assuming that the 35S RNA present in MuLV virions is identical to 
the primary viral transcription product found in infected cells, 
we investigated the ability of the oocyte nucleus to splice genomic 
MuLV RNA into subgenomic env-mRNA. Detection was indirect, namely 
by immunoprecipitation with anti-gp70 serum of virus-specific 
translation products. From an other point nf view this experiment 
could also be regarded as a test on genomic RNA being the right 
substrate for splicing. Similar experiments were performed with 35S 
cytoplasmic RNA and with nuclear RNA from infected cells. 
In parallel we used E. coli RNAse III in order to investigate whether 
functional env-mRNA might be enzymatically produced from genomic 
MuLV RNA. The idea to use RNAse III for this purpose was based on 
earlier observations of Leis et al. (29] in the ASV system and of 
Shanmugam (47) in the MuLV system which indicated that RNAse III 
is able to degrade genomic RNA into discrete subgenomic RNAs (28) 
and that an enzyme with similar properties is present in mouse 
cells (47). 
MATERIALS AND METHODS 
Materials, cells and virus. RNAse III from E. coli was obtained from 
Enzo Biochem. Inc., New York. Tobacco acid pyrophosphatase (TAP) 
came from Bethesda Research Labs. Inc., Bethesda, Md. DNAse I was 
from Worthington Biochem. Corp., Freehold, N.J. A DNAse I prepa­
ration that was purified from RNAse contaminations by UTP-agarose 
chromatography (49) was a gift of Mr C.A.G. van Eekelen. R-MuLV 
proteins ρ 10 and ρ 12 were a gift of Dr J.R. Stephenson. Mo-MuLV, 
isolated from concentrated medium of roller-bottle cultures of 
NIH-3T3/Mo-MuLV(clone 1A) cells by the method described by 
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Duesberg and Robinson (14), was a gift of Dr A.J.M. Berns. Before 
injection into oocytes the virus preparation (5 mg/ml) was quickly 
frozen (CO^aceton) and thawed (37 C) five times. All other 
materials, cells and virus are described in the corresponding 
sections of chapters 4 and 6. 
Viral RNA. Purified viral 35S RNA from clone 1A Moloney virus was 
a gift of Mr C.J.M. Saris. 
In short, RNA was liberated from the virus by treatment with 
proteinase К in the presence of SDS (0.5 %) and EDTA ( 1 глМ) and 
size-fractionated on an isokinetic sucrose gradient in 10 mM Tris-
pH 6.9, 100 mM NaCl, 1 mM EDTA and 0.2 'jt SDS. After heat-denaturation 
the 50-70S RNA fraction was poly(A)_selected by oligo(dT)-cellulose 
chromatography (5) and 35S RNA was isolated by centrifugation on 
an isokinetic sucrose gradient in low salt buffer as described in 
chapter 4. 
Cellular mRNA. The isolation of 35S mRNA from NIH-3T3(NCL5611P3)/ 
Mo-MuLV cells is described in detail in chapter 4. 
Nuclear RNA. Several methods were used to isolate high molecular 
weight nuclear RNA from NIH-3T3(NCL5611P3)/Mo-MuLV cells (see 
Results and discussion section). 
r 14 Cells were labeled for 16 h with 5 ,uCi of (2- C)thymidine to 
monitor contaminating DNA and, after preincubation for 20 min with 
0.04 /ug/ml actinomycine D (to stop the ribosomal RNA synthesis; 
37), labeled for 10 min with 100 /uCi of (5,6->l)uridine (to follow 
the fate of the hnRNA during the isolation procedure). The method 
that gave the best results (see Results and discussion section) is 
described here. 
Solutions and glassware were sterilized (cf. chapter 4) . Indicated 
pH values are at 25 C. All procedures were carried out at 0 - 2 C, 
unless stated otherwise. Cells were removed from the culture flasks 
by scraping in calcium— and magnesium—free Tyrode's solution 
containing 4 mM EDTA. The cells were washed twice with isotonic 
buffer (10 mM Tris-pH 7.2, 146 mM NaCl) and resuspended in 10 
volumes RSB ( 10 mM Tris-pH 7.0, 10 mM NaCl, 1.5 mM MgCl-). 
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Tween-40 and sodium deoxycholate were added in a concentrated 
mixture to final concentrations of 1 'jd and 0.5 ^, respectively, 
and lysates were prepared by forcing the cells through a 21 gauge 
needle (36). The nuclei were pelleted by centrifugation for 10 min 
at 1200 χ g and washed once with RSB. Then the nuclei were resus-
pended to the original lysate volume in 10 mM Tris-pH 8.2, 2 mM 
EDTA and 0.5 ^ SDS, a same volume of saturated phenol was added and 
RNA was extracted at 55 DC for 20 min (45,53). Subsequently, the 
water-phase was extracted twice with phenol/chloroform/isoamyl-
alcohol (100 : 100 : l) and once with chloroform/isoamylalcohol 
(25 : 1) at room temperature. RNA was precipitated from the water-
phase by the addition of one volume of 6 M NaAc-pH 5.2, dissolved 
in H O and alcohol-precipitated twice. 
The nuclear RNA was poly(A)-selected and size-fractionated as 
described for cellular RNA in chapter 4. 
Decapping of viral RNA. The methylated "cap" of purified 355 paly(A)+ 
viral RNA was removed by treatment with tobacco acid pyrophosphate ы· 
(TAP) (47). Conditions were identical to those indicated by the 
supplier of the enzyme. A reaction volume of 10 /ul contained: 50 
mM NaAc-pH 5.2, 10 mM 2-mercaptoethanol, 1 mM EDTA, 10 /ug of 28S 
rat lens rRNA (free of mRNA-activity; a gift of Dr F.A.M. Asselbergs), 
2 ,ug of viral RNA and 2 units TAP. The mixture was incubated for 
1 h at 37 C. The reaction was stopped by the addition of 200 /ul 
of 0.1 M NaAc-pH 5.2, 1 mM EDTA and 0.5 ^ SDS. The mixture was 
extracted once with phenol/chloroform at room temperature (35) and 
the extracted RNA was alcohol-precipitated. 
RNAse Ill-treatment of viral RNA. A reaction volume of 50 /ul 
contained (41): 20 mM Tris-pH 7.4 (at 37 0 C ) , 0.1 mM EDTA, 10 mM 
MgAc-, 0.1 mM dithioerythritol, 5 ^  sucrose, 0, 50 or 100 mM KCl, 
0.2 /ug of purified 35S poly(A)+ viral RNA and 2 units of RNAse 
III. The mixtures were incubated for 5 - 6 0 min at 37 0C. The 
reaction was stopped by the addition of 150 /ul of 0.1 M NaAc-pH 
5.2, 5 mM EDTA and 0.5 $ SDS, containing 10 /ug of 28S rat lens 
rRNA. The mixture was extracted once with phenol/chloroform (35) 
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and the extracted RNA was alcohol-precipitated. 
Injection of oocytes. Intracytoplasmic injections of oocytes were 
performed as described earlier (cf. chapter 4). Intranuclear injec­
tions were carried out by the method of Kressman et al. (25). 
Oocytes were centrifugea on a nylon sieve (mesh size O.B mm) for 
10 min at 200 - 400 χ g with their animal poles (dark hemispheres) 
facing upwards. The site of the nucleus could now be localized by 
the displacement of pigment granules, giving rise to a lighter spot 
on the oocyte surface, caused by the flotation of the nucleus 
towards the surface wall. 
RNA and proteins were injected in a volume of 15 nl per nucleus. 
Immunoprecipitation. Oocyte lysates were prepared and immunopre-
cipitations were carried out as described in chapter 4. 
RESULTS AND DISCUSSION 
Injection of genomic viral RNA into oocyte nuclei. 
Purified 35S poly(A) viral RNA was injected into the cytoplasm 
and into the nucleus of oocytes. After injection the oocytes were 
preincubated in modified Barth's medium (4) for 16 h and there-
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after labeled for 40 h with L-( S)methionine. Immunoprecipitation 
with anti-gp70 was performed on the complete lysate of 20 injected 
oocytes. On the supernatant of the first immunoprecipitation a 
second immunoprecipitation with anti-MuLV was carried out. Results 
are shown in Fig. 1. As found earlier by our group and many others, 
35S viral RNA only directed the synthesis of gag proteins (for 
references see chapter 2.4.6.). In cell-free systems only the 
precursor polyproteins are made, but oocytes are able to process 
these polyproteins adequately (lanes a', b'; cf. réf. 4 and 
chapters 3,4,5,6). In cell-free systems the gag—pol precursor 
polyprotein is made in addition, but in oocytes pol-related 
(poly)proteins can not be seen under these circumstances (4; 
chapter 4). Apparently oocyte nuclei were not able to process the 
17S 
35S viral RNA into functional 22S env-mRNA (lane a). Variation of 
the labeling conditions (starting the labeling immediately after 
injection and continuing for 16, 40 or 64 h) also did not result 
in the production of enν proteins (not shown), 
After injection of 35S viral RNA into the nucleus gag proteins were 
synthesized, although in lower amounts than after injection into the 
cytoplasm (compare lanes a' and b'). Therefore, part of the intra— 
nuclearly injected viral RNA must have entered the cytoplasm. It is 
not clear whether this was due to active transport of the viral RNA 
from the nucleus to the cytoplasm, to leakage of the injected nuclei 
or to simply a certain percentage of misses, where we had failed 
to hit the nucleus. 
Coinjection of viral proteins and genomic viral RNA into oocyte 
nuclei. 
Some viral proteins are able to interact with genomic RNA (for 
references: see chapter 2.2.). The phosphoprotein pp12 specifically 
binds to the homologous genomic RNA, whereas the basic protein ρ 10 
binds to single-stranded nucleic acids in general. A functional 
significance for these properties is not yet known. We wanted to 
consider a possible function of these proteins in the splicing 
process. Therefore, we coinjected viral 35S RNA and the proteins 
ρ 10 and ρ 12 and also genomic RNA with disrupted Mo-MuLV into 
oocyte nuclei and, as a control, into the cytoplasm. Labeling and 
i/nmunoprecipitation on samples of the lysates was performed as 
described in the previous section. Again, injection of poly(A) 
35S viral RNA, either in the nucleus or in the cytoplasm,only 
resulted in the synthesis of gag proteins (Figs 2A and 2B, lanes 
a, a
1 ) . Coinjection of pp12 did not change the results (lanes f, 
f ) . Coinjection of p10, however, completely abolished translational 
activity (lanes e, e'). The effect of ρ 10 could be prevented by the 
addition of pp12 (lanes g, g'). Finally, disrupted Mo-MuLV altered 
the translational pattern of 35S viral RNA (lanes d, d'): inde­
pendent of the site of injection of the RNA a protein with apparent 
leo 
Figure 1. Injection of genomic viral 
RNA. 
Purified 35S poly(A)+ Mo-MuLV RNA 
(l mg/ml) was injected into the nucleus 
and into the cytoplasm of Xenopus 
oocytes (15 nl per oocyte). Oocytes 
were preincubated in modified Berth's 
medium for 16 h and labeled for 40 
h with L-(^^S)methionine. Translation 
products were first immunoprecipitated 
with anti—gp70. On the supernatant 
of this inmunoprecipitation a second 
precipitation with anti-MuLV was 
carried out. Precipitates were 
analyzed by SDS-PAGE followed by 
scintillation autoradiography. 
Lanes a—d, anti—gp70; lanes a'—d', 
anti-MuLV. (a,a') RNA injected into 
the nucleus; (bjb') RIMA injected 
into the cytoplasm; (c.c') HgO injected 
into the nucleus; ( d ^ 1 ) H2O injected 
into the cytoplasm. 
Figure 2. [A + 9) (page lai). 
Injection of modified genomic RNA. Coinjection of genomic RNA and 
viral proteins. 
Mo-MuLV RNA (0.5 mg/ml) was injected into the nucleus or in the 
cytoplasm of Xenopus oocytes (15 nl per oocyte). Oocytes were 
preincubated for 16 h and labeled for 40 h with L-(35S)methionine. 
Translation products were analyzed by immunoprecipitation followed 
by SDS-PAGE and scintillation autoradiography. (A) anti-gp70; 
(В) anti-MuLV. Lanes a-g, intracytoplasmic injection; lanes a'-g', 
intranuclear injection, (a,a') 35S poly(A)+ RNA; (b,b') 35S poly 
(A) - RNA; (с,с') 35S poly(A)+ RNA treated with tobacco acid pyro-
phosphotase; (d,d') 35S poly(A)+ RNA coinjected with disrupted 
Moloney virus (2.5 mg/ml); (e,e') coinjection with 0.5 mg/ml ρ 10; 
(f,f') coinjection with 0.5 mg/ml p12, (g.g') coinjection with p10 
and ρ 12; (m) 14C—labeled molecular weight marker proteins (cf. 
chapter 4, Fig. 1.). 
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of genomic RNA and v i r a l p r o t e i n s . [Legend on page 180) . 
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molecular weight of 60,DDO, called tp6D , was synthesized that 
could be precipitated by anti-MuLV. Moreover, only after intra-
cytoplasmic injection, a second protein, with an apparent molecular 
weight of 28,000, tp28, was detected with anti-MuLV. At first sight 
(Fig. 2B, lanes d, d') it seems as if Pr65 and p30 were slightly 
modified by some component of the virus. This can not be true 
since these proteins were precipitable with anti-gp70 (Fig. 2A, 
lanes d, d']. Because this was the only situation in which env-
related proteins could be precipitated after injection of genomic 
RNA into oocytes we performed some additional experiments (Fig. 3). 
The Mo-MuLV preparation did not influence immunoprecipitation when 
added, even in a tenfold higher concentration than it was present 
in the coinjection experiment, to the lysate of oocytes injected 
with poly(A)+ 35S viral RNA only (Fig. 3, lanes a, a') or when 
injected without viral RNA (in the latter case no virus-specific 
products could be imnunoprecipitated; not shown). From Fig. 3 it 
can be seen further that tp60 and a protein of about 10,000 
apparent molecular weight, tp10 (not visible in Fig. 3), could be 
precipitated from lysates of oocytes, coinjected with viral RNA 
and Mo-MuLV, by anti-рЗО (lanes b, b'), anti-gp70 (lanes с, c') 
and anti-p15E,p12E (lanes d, d'). These proteins were also pre­
cipitable with anti-BSA (lanes e, e') and, therefore, this 
precipitation should be regarded as non-specific. Only tp28 (lane 
b) and a protein of 55,000 apparent molecular weight, tp55, (lanes 
b, b'; also weakly visible in Fig. 2A, lanes d, d') and a protein 
of 8,000 apparent molecular weight, tp8, (lanes b, b'; not seen 
in Fig. 2A, lanes d, d') seem to be precipitated specifically by 
anti-gp70. The molecular weights of these polypeptides do not 
equal those of known env—related (poly—)proteins. We have not 
studied this bizarre phenomenon any further. 
1) tp = translational ¿roduct; see chapter 5. 
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Figure 3. Influence of Mo—MuLV proteins on the translation of 
Mo-MuLV RNA in oocytes. 
Purified 35S poly(A)+ Mo-MuLV RNA was injected alone (lanes a,a') 
or coinjected with disrupted Moloney virus (lanes t^b'-eje') into 
the nucleus and into the cytoplasm of Xenopus oocytes. Oocytes 
were preincubated for 16 h and labeled for 40 h with L-(^S] 
methionine. Translation products were analyzed by immunoprecipi-
tation followed by SDS-PAGE and scintillation autoradiography. 
Lanes a-e, intracytoplasmio injection; lanes a'-e', intranuclear 
injection. Precipitation was with: (a,a1) anti-MuLV in the presence 
of Moloney virus (7.5 /jg/ml lysate] ; (^b') anti-p3Q,· (ο,ο') 
anti-gp7D; (d.d1] anti-p15E,p12E; (e.e') anti-BSA. 
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Injection of modified genomic viral RNA into oocyte nuclei. 
The scheme of nuclear mRNA processing depicted in the Introduction 
section is a generalized one and individual variations may exist, 
dependent on the mRNA studied (12,52). 
Therefore we also injected poly(A)- 35S viral RNA and decapped 
poly(A) genomic RNA into oocyte nuclei. As can be seen from Fig. 
2 (lanes b, b', с, c') these modifications did not influence 
translation qualitatively and only slightly reduced translation 
efficiency. This latter effect, if significant at all, could reflect 
the increased instability reported for mRNAs without poly(A) or 
cap (39). 
RNAse III treatment of viral RNA. 
The endoribonuclease RNAse III from E. coli has a functional role 
in the processing of ribosomal RNA precursors in bacteria (16), 
but the best characterized series of processing reactions of this 
enzyme involves the early mRNA precursor of bacteriophage T7 (15). 
RNAse III acts on native RNA by nicking unpaired nucleotide 
sequences in the vicinity of double-stranded RNA, e.g. a "hairpin 
loop" structure. Cleavage is not only dependent on structure but 
also depends on the sequence in the "hairpin loop" (42). In addition 
to these "primary cleavage sites" (17) at non-physiological low 
salt concentrations or at high enzyme : substrate ratios "secondary", 
but still highly specific sites are cleaved by RNAse III (17,34, 
42,55). Data sofar obtained suggest that the secondary cleavage 
reaction of RNAse III provides the equivalent of an RNA "restric­
tion enzyme", allowing reproducible production of specific RNA 
fragments. 
An RNAse Ill-like activity has been detected in mammalian and 
avian cells (1,47) which might be involved in the processing of 
rRNA- and mRNA-transcription units (1,12). 
Retroviral RNA has a high order of secondary structure (10,27,40). 
Therefore we treated genomic viral RNA with RNAse III in an attempt 
to generate subgenomic RNA molecules that would have the initiation 
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site for env protein synthesis exposed. Both salt conditions and 
incubation time were varied. In all cases translational activity 
was lost and no env proteins were synthesized when the HNAse Ill-
treated RNA samples were injected into the cytoplasm of oocytes. 
Accordingly the size of the treated RNA had changed from 30-35S 
to the low molecular weight range (below 7S) as measured on Poly-
acrylamide gels (courtesy of Mr C.J.M. Saris). Apparently, MuLV 
genomic RNA is not cleaved by RNAse III as specifically as was 
found with some E. coli RIMAs (17,34,42,55). We did not further test 
the enzyme at limiting enzyme : substrate ratios which might result 
in the production of larger fragments (11). 
Stacey et al. who used mild alkali—treatment (50) or limited RNAse 
TI digestion (51) to generate large fragments from Rous-associated 
virus-2 genomic RNA were not able to measure any env-mRNA activity 
of these fragments in a very sensitive system (cf. chapter 2.4.5,8). 
Genomic RNA might therefore be an inappropriate substrate for the 
endonucleolytic generation of env-mRNA (e.g. because it might lack 
the env initiation site; this does not exclude other 35S virus-
specific RNA specimens from being suitable substrates). Alterna-
tively, the env initiation site might only be produced by a process 
of splicing and not by mere degradation of larger RNAs. In contrast, 
Purchio et al. (38) were able to generate active src-mRNA from 38S 
ASV genomic RNA by RNAse T1 treatment. 
Injection of cytoplasmic 355 virus—specific RNA into oocyte nuclei. 
Not only virion RNA, also cytoplasmic virus-specific 35S RNA failed 
to be spliced into active env-mRNA in oocyte nuclei. 
Intranuclear injection of poly(A) 35S cytoplasmic RNA did not 
result in the synthesis of env proteins. As with 35S viral RNA 
only gag proteins were synthesized (results not shown). 
Injection of nuclear RNA into oocyte nuclei. 
Isolation of high molecular weight nuclear RNA is hard to achieve. 
Several criteria should be fulfilled: 1. The nuclear RNA should be 
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free of cytoplasmic RNA contaminations. To satisfy this condition 
cells should be lysed in such a way as to leave the nuclei intact 
(9). Nuclei can be further purified by mixed-detergent treatment 
and/or centrifugation through 0.88 M sucrose (7,9). 2. The nuclear 
HNA should be free of contaminating DNA. This aim can be achieved 
by DNAse treatment (7,36) or by phenol/chloroform extraction at 
55 0C ("hot phenol"; 7,31,45,53). Additionally, in high salt (3 M 
NaAc or 2 M LiCl) single-stranded RNA is precipitated but DNA 
remains dissolved (7,35). Absolute care should be taken that the 
DNAse preparation to be used is free of RNAse activity. Commercial 
DNAse I preparations, though called "RNAse-free", are still con­
taminated with RNAse (θ). They can be further purified by affinity 
chromatography on UMP-agarose (θ) or UTP-agarose (49). 
"Hot phenol" extraction in the presence of SDS inactivates ribo-
nuclease instantly (7). 3^ The nuclear RNA should remain intact. 
It is known that different cell types have different levels of 
intracellular ribonucleases (7; S. Penman and J. Darnell, personal 
communication). The major source of RNAse are the lysozomes (7) 
that fall apart by detergent lysis as well as by mechanical dis­
ruption of the cells. The most powerful RNAse-inhibitors known, 
SDS and heparin, can not be included in lysis buffers since they 
cause désintégration of the nuclei. Moreover they also inhibit 
DNAse action. 
To optimize the isolation of high molecular weight nuclear RNA 
from Mo-MuLV -infected NIH-3T3 cells we used several methods. 
The method that gave the best results is described in the Methods 
section. This method resulted in a nuclear RNA preparation that 
was still contaminated with less than 2 % of the DNA originally 
14 
present in the cells (determined by C-thymidine labeling). 
The size of hnRNA, labeled by a short ΊΗ—uridine pulse, was deter­
mined by isokinetic sucrose gradient centrifugation and ranged 
between 7 and 50S, with a broad maximum between 20 and 40S. This 
size distribution did not significantly change after poly(A)-
ІВ7 
selection of the RNA. The size of isolated unlabeled steady-state 
nuclear RNA [primarily consisting of (pre-)rRNA) ranged between 4 
and SOS with a broad maximum between 20 and 35S. No discrete peaks 
were found at 45S, 28-32S and 18S, as can be seen with Heia cell 
nuclear RNA (Зб). Our results are in line with those of Kamen et 
al. (2) who isolated nuclear RNA from polyoma virus-infected NIH-
3T3 cells. 
As total and paly(A)-selected nuclear RNA was translated in oocytes 
by intracytoplasmic or intranuclear injection no virus-specific 
polypeptides could be precipitated. These results are only seemingly 
in contrast with those of Kamen et al. (2) who detected polyoma 
virus-specific (late) protein synthesis in a wheat germ cell-free 
system with nuclear RNA that was not purified further, since it 
should be realized that late polyoma virus-specific RNA contributes 
up to 10 % of the hnRNA (2), compared to only 0.5 % for MuLV-
specific RNA ( 18), and that the four times smaller polyoma virus 
late transcripts are less prone to degradation than the 35S MuLV 
primary transcripts. Our experiments do not exclude that 
fractionated nuclear RNA would contain enough translatable material 
to detect the synthesis of virus-specific proteins. 
CONCLUSIONS 
Our negative results with genomic viral RNA as a template for 
splicing into env-mflNA in oocyte nuclei are in agreement with the 
results of Asselbergs et al. (4). These investigators used complete 
(70S and heat-denatured) viral RNA from R-MuLV isolated from the 
plasma of viremic mice. They did not detect env-mRNA activity in 
these preparations, no matter whether these were injected into the 
cytoplasm or the nucleus of the oocyte. This is in contrast with 
the finding of Stacey who detected env-rrPNA activity in the virion 
RNA of RAV-S virus (51). This activity was demonstrated by intra­
cytoplasmic injection of the RA\/-2 virion RNA into cells infected 
with an env-deletion mutant of RSV. Complementation of the deficient 
1ΘΒ 
function was detected by the release of focus-forming virus (cf. 
chapter 2.4.5,8). The discrepancy between the results of Asselbergs 
et al. and those of Stacey may be explained by the higher sensi­
tivity of the assay used by the latter author, in whose system the 
response is magnified by virus multiplication. The same explanation 
might be used for our apparent failure to generate env-mRNA from 
purified 35S viral RNA by injection into the nucleus of oocytes, 
whereas Stacey and Hanafusa were able to accomplish this splicing 
step by intranuclear injection of RM-2 35S genomic RNA into 
(env-) BH-RSV -infected cells (50). Since in this latter system 
gag and pol proteins are present, one might argue that one or more 
of these proteins are necessary for the splicing of genomic RNA. 
This could be excluded, however, (cf. chapter 2.4.5.) by the results 
of intranuclear injection of 35S RAV-2 genomic RNA into chick 
embryo fibroblasts which expressed no viral functions. In this 
case also infectious (RAV-2) viruses were synthesized (50). 
Moreover, this result completely refutes the objection raised by 
Asselbergs et al. (4) that the env—mRNA in the intranuclearly 
injected BH-RSV -infected cells might have been generated from 
integrated proviral DNA, originated from the reverse transcription 
of the genomic RA\/-2 RNA by reverse transcriptase molecules present 
in these cells. The apparent inability of Stacey et al. (50,51) 
to generate env-mRNA from genomic RA\/-2 RNA chemically or enzy-
matically in vitro also made a non-specific formation (i.e. 
without splicing) of env-mRNA in vivo very unlikely. 
Taken together all our results we conclude that the Xenopus 
oocyte nucleus is probably not a suitable system to study splicing 
of retroviral RNA, either because the sensitivity of the system 
is too low or because the oocyte nuclei are not able to handle 
the viral RNA properly to make it accessible for the splicing 
machinery (e.g. binding of essential factors to the RNA or 
attachment of the RNA to the nuclear skeleton might be required). 
Moreover, if an "RNAse Ill-like" enzyme is involved in the 
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processing of retroviral RNA in vivo at all, this enzyme should 
exhibit certainly more specificity than the E. coli enzyme did with 
this RNA. 
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SUMMARY 
This thesis deals with the expression of murine leukemia virus 
proteins. In chapter 1 our results are placed in the perspective 
of the rapidly evolving RNA tumor virus research of which chapter 
2 gives a general survey. 
Chapters 3 to 7 describe our experimental data. 
In chapter 3 it is shown that the murine leukemia virus core 
proteins are synthesized on a genome-size (35S) virus-specific 
mRNA, whereas the viral envelope proteins are made on a subgenomic 
(22S) mRNA, comprising about the 3' half of the genome. These 
results were obtained by translation of size-fractionated mRNAs 
from infected cells in oocytes of the African clawed frog Xenopus 
laevis. immunoprecipitation of translation products from lysates 
of injected oocytes with polyvalent and monospecific antisera 
directed against viral proteins, and analysis of precipitated 
products by SDS-polyacrylamide gel electrophoresis. By the same 
method it was established in chapter 4 that the viral enzyme 
reverse transcriptase is also made on genome-size mRNA. Despite of 
much effort, we were not able to confirm these results independently 
by enzymatic detection of reverse transcriptase in mRNA-injected 
oocytes. In chapter 5 it is shown that translation of 14S mRNA in 
Xenopus oocytes resulted in the synthesis of presumably cellular 
proteins that were precipitable with antisera directed against 
complete murine leukemia virus and that are encapsidated by the 
virus particles. 
Since it was known from the literature that the subgenomic mRNA 
directing the synthesis of murine leukemia virus envelope proteins 
is generated from genome-length RNA in the nucleus of infected cells 
by a splicing process, we attempted to mimic this process by 
injection of purified 35S poly(A)+ RNA, 35S decapped poly(A)+ RNA 
and 35S poly(A)_ RNA from Moloney murine leukemia virus particles 
into the nuclei of Xenopus oocytes. This is shown in chapter 7. 
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We also studied the potential influence of viral proteins on the 
splicing process. In no case, however, we were able to detect the 
synthesis of envelope proteins. Yet we observed an alteration of 
the translation pattern, induced by some viral protein(s). In order 
to investigate whether we might have offered the wrong substrate 
for splicing, we directed our efforts to cytoplasmic 35S virus-
specific mRNA and to nuclear RNA. These RNA species were equally 
inproductive in envelope protein synthesis after intranuclear 
injection into oocytes. 
Our negative results with genomic RNA contrast with the positive 
results of others obtained in a different system. Possible explana­
tions are discussed. 
Positive results were obtained by the use of the oocyte translation 
system in the identification of the \jloney cell surface antigen 
(MCSA). This antigen is induced с mouse cells by Moloney murine 
leukemia virus and is related to the Moloney virus-induced tumor-
associated transplantation antigen. We showed in chapter 6 that 
MCSA is an envelope gene product of a defective murine RNA tumor 
virus not related to the Moloney strain of murine leukemia virus. 
1Э4 
SAMENVATTING 
Het muizö-leukemievirus behoort tot de RNA tumor virussen. Verte-
genwoordigers van deze groep virussen komen voor bij zowel hogere 
als lagere gewervelde dieren. Sinds in 1970 een uniek enzym ont-
dekt werd in deze virussen, het zgn. "reverse transcriptase", dat 
in staat is het virale RNA genoom over ta schrijven in DNA, is 
over de gehele wereld een intensief onderzoek gestart naar de bouw, 
de replicatie en de gen-expressie van de RNA tumor virussen en 
natuurlijk naar de wijze waarop zij tumoren kunnen veroorzaken. 
Hoofdstuk 1 van dit proefschrift plaatst onze experimentele gege-
vens, die in de hoofdstukken 3 tot en met 7 weergegeven worden, 
in het perspectief van het zich snel ontwikkelende RNA tumor 
virus—onderzoek, waarvan hoofdstuk 2 een, noodzakelijkerwijs be-
perkt, verslag geeft. De volgende hoofdstukken betreffen alle de 
expressie van muize—leukemievirus eiwitten, zoals ook aangegeven 
door de titel van het proefschrift. In de hoofdstukken 3 tot en 
met 5 wordt aangetoond dat de verschillende virale eiwitten ge-
maakt worden op boodschapper-RNA's van verschillende grootte. 
De eiwitten van het kerndeeltje van het virus en het "reverse 
transcriptase" worden gesynthetiseerd op genoom-lengte RNA terwijl 
de virale envelop eiwitten gemaakt worden op een boodschapper-RNA 
dat maar half zo groot is. Op een nog kleiner boodschapper-RNA 
werden eiwitten gesynthetiseerd van cellulaire oorsprong die op 
de één of andere manier in het virusdeeltje terechtkomen. Deze re-
sultaten werden verkregen door het "vertalen" van boodschapper-
RNA' s die geïsoleerd waren uit geïnfecteerde cellen, in eicellen 
van de Afrikaanse klauwkikker Xenopus laevis. Deze eicellen zijn 
zo groot, dat zij met eenvoudige middelen te injecteren zijn, en 
hebben het voordeel ten opzichte van zgn. "celvrije" vertaal-
systemen dat alle cellulaire processen ongestoord kunnen blijven 
verlopen. De virus-specifieke vertaal-producten werden geïsoleerd 
door middel van specifieke antisera en geanalyseerd met behulp 
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van de gel—elektroforese techniek. 
Omdat uit de literatuur bekend was dat het RNA van subgenoom— 
grootte waarop de envelop eiwitten gesynthetiseerd worden ontstaat 
uit genoom—lengte RNA in de kem van geïnfecteerde cellen via een 
zgn. "splicing"-proces, hebben wij geprobeerd [hoofdstuk 7) of het 
mogelijk was dit proces na te bootsen door injectie van genoom-
lengte virus—specifiek RNA in de kernen van Xenopus eicellen. 
Onze pogingen bleven zonder succes. Mogelijke verklaringen hiervoor 
worden besproken. 
Wel succesvol was het gebruik van het Xenopus eicel vertaal-systeem 
bij de karakterisatie van het "Moloney Cell Surface Antigen" 
(MUSA). Dit is een cel-oppervlakte antigeen dat door Moloney muize-
leukemievirus op muize—cellen wordt geïnduceerd en dat nauw gere-
lateerd is aan het door het Moloney virus geïnduceerde tumor-
specifieke transplantatie—antigeen. 
Lange tijd is de aard van dit antigeen onbekend gebleven, maar in 
hoofdstuk б wordt aangetoond dat het hier een envelop eiwit be­
treft van een vooralsnog onbekend defectief virus dat niet gere­
lateerd is aan het Moloney virus. 
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STELLINGEN 
1. 
De hoeveelheid virus-specifiek RNA dat door middel van nucleïnezuur-
hybridisatie gedetecteerd kan worden in RNA tumor virus geïnfecteerde 
cellen, is ongeveer omgekeerd evenredig met de mate waarin dit RNA 
gepolyadenyleerd is. 
Dit proefschrift, hoofdstuk 2.4.3. 
2. 
Bij het aangeven van het mogelijke belang van virale eiwitsynthese vooraf-
gaand aan het integratieproces van RNA tumor virussen, vergeten Shurtz et 
al., dat geen de novo synthese nodig is voor de introductie in de cel van 
eiwitten die bij de infectie al binnengekomen zijn, en dat defectieve sarcoma 
virussen die geen enkel leukemie virus specifiek eiwit kunnen produceren, 
zeer wel in staat zijn als provirus in het gastheer-genoom te integreren. 
Shurtz, R., S. Dolev, M. Aboud en S. Salzberg. 1979. J. Virol. 31: 668-676. 
3. 
Het idee dat de verhoogde H-2D expressie door thymocyten van muizen 
geïnfecteerd met het "radiation leukemia virus" (RadLV) veroorzaakt zou 
worden door integratie van het virus naast het H-2D locus is een oversym-
plificatie. 
Meruelo, D. 1980. J. Immunogen. 7 : 81-90. 
4. 
De fysische associatie van RNA tumor virus eiwitten met histocompatibili-
teitsantigenen op het oppervlak van geïnfecteerde cellen is een omstreden 
zaak. Het zicht hierop wordt niet verhelderd, wanneer Azocar en Essex ter 
adstructie van de door hen gevonden evidentie vóór associatie een artikel 
van Aoki et ai. aanhalen, dat echter uitsluitend bewijs tégen het bestaan van 
deze associatie bevat. 
Azocar, J. en M. Essex. 1979. Cancer Res. 39 : 3388-3391. 
Aoki, T., E.A. Boyse, L.J. Old, E. DeHarven, U. Hämmerling en H.A. 
Wood. 1970. Proc. Natl. Acad. Sci. USA 65 : 569-576. 
5. 
Door het elektroforetisch patroon van verschillende eiwitten in natrium-
dodecylsulfaat/polyacrylamide gels ook in verschillende figuren weer te 
geven is het klaarblijkelijk mogelijk eiwitten die comigreren toch een met 
10.000 verschillend molecuulgewicht toe te kennen. 
Buetti, E. en H. Diggelman. 1980. J. Virol. 33 : 936-944. 
6. 
De H-2 restrictie van de immuunreactie bij muizen wordt niet bepaald door 
het H-2 fenotype van de thymus. 
7. 
Het door Williamson voorgestelde model voor de "major histocompatibility 
complex" (MHC) -geassocieerde herkenning van antigenen door T-lymfo-
cyten biedt geen redelijke verklaring voor het functioneren van de in het 
MHC gelocaliseerde immuunresponse genen en is daardoor, althans in deze 
vorm, niet acceptabel. 
Williamson, A.R. 1980. Nature (London) 283 : 527-532. 
8. 
De uitspraak van Present et al. dat 6-mercaptopurine bij langdurige 
toediening aan patiënten waarschijnlijk niet carcinogeen is, is slechts 
gebaseerd op de resultaten van een tweejarige observatie-periode en daarom 
voorbarig. 
Present. D.H., B.I. Korelitz. N. Wisch, J.L. Glass, D.B. Sachar en B.S. 
Pasternack. 1980. New Engl. J. Med. 302 : 981-987. 
9. 
De veelbelovende studies naar het effect van immunisatie tegen Strepto-
coccus mutans antigenen in de bestrijding van tandbederf (caries) moeten 
krachtig voortgezet worden, al verdient het kweken van betere eetgewoontes 
toch de voorkeur. 
Lehner, T., M.W. Rüssel en J. Caldwell. 1980. The Lancet 1 : 995-996. 
10. 
Het vinden van verschillen tussen de concentratieverhoudingen van andro-
steron en etiocholanolon in de urine van heterosexuelen en van homo-
sexuelen heeft gelukkig geen invloed gehad op de voortschrijdende accepta-
tie van homosexuelen in onze samenleving. 
Margolese, M.S. en O. Janiger. 1973. Br. Med. J. 3 : 207-210. 
11 
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12 
De regering dient thans actief de verspreiding van informatie over het vóór 
of tegen van kernenergie te bevorderen, om te voorkomen dat de door haar 
toegezegde, zo belangrijke maatschappelijke discussie over dit onderwerp, 
slechts "breed" in de zin van "oeverloos" zal worden 
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